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Globally, diarrhea remains a leading cause of avoidable morbidity and 
mortality in children under 5. The most pressing challenges and recommendations for 
the reduction of childhood diarrhea today are consistent with those described over the 
past decade, pointing to a need for innovation. Key challenges include insufficient 
access, production, distribution and promotion of essential commodities like ORS 
and zinc, the globally recommended treatments. Market-based solutions that engage 
the private sector and simultaneously stimulate both supply and demand of these 
commodities have been recommended as a way of increasing coverage, and 
ultimately reducing mortality.  
The ColaLife project aimed to emulate the commercial, private-sector value 
chains of fast moving consumer goods (FMCGs), like Coca-Cola, and apply similar 
principles to the development and introduction of an innovative diarrhea treatment 
kit called the Kit Yamoyo®. This dissertation explores key elements related to the 
establishment of an end-to-end value-chain for this new product in Zambia. It 
includes 1) analysis of the overall impact of the approach on uptake of ORS and zinc, 
2) determining the effect of applying human-centered design to global health product 
innovation, and 3) a detailed description of commercial general stores to inform their 
potential as informal, community-level providers of public health commodities. 
 The main data sources include cross-sectional, rural household surveys 
conducted in August of 2012 (baseline) and August of 2013 (endline), as well as 
retailer surveys conducted in March of 2013 (midline) and August of 2013 
(endline). Questionnaires were administered to 2458 and 2477 caregivers of 
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children under 5, across 4 rural districts of Zambia, at baseline and endline, 
respectively. Two districts (Kalomo and Katete) served as intervention districts, 
while the other two (Monze and Petauke) served as matched comparators. Paper #1 
uses a generalized linear model (GLM) with Poisson distribution to calculate the 
adjusted relative risk of combination therapy use in intervention districts vs. 
comparator districts at endline. Secondary analysis uses difference-in-differences 
estimation to compare ORS use (with or without zinc) in the intervention and 
comparison districts, before and after market-shaping activities. Paper #2 compares 
ORS use in children under 5 with diarrhea who either used Kit Yamoyo or standard 
one-liter sachets of ORS from rural health centers. Data drawn from the endline 
survey is analyzed using logistic regression and calculates the odds of correct 
preparation of ORS (i.e. concentration) in kit-users vs. non-users. Secondary analysis 
examines to what extent preparation of ORS in the correct concentration, or other 
factors, are associated with a change in the odds of perceiving ORS as effective.  
Paper #3 is predominantly descriptive in nature. It uses retailer survey data from 
180 interviews of general, community-level retailers across the 4 study districts, 
who commonly sell FMCGs, to explore the potential of using them as outlets for 
provision of basic public health products like ORS and zinc. Findings are grouped 
under key themes including: infrastructure, staffing, ownership and operations, 
purchasing patterns, product preferences, and level of engagement with an intervention to 
expand coverage of a newly introduced diarrhea treatment kit.  
Within the span of one-year, use of ORS and zinc combination therapy in 
children under 5 years of age with diarrhea, increased from less than 1% at baseline 
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to 46.6% across the intervention districts, while no change was seen in comparator 
districts. Difference-in-differences analysis comparing ORS use (with or without 
zinc) in the intervention and comparator districts, before and after market-shaping 
activities, found that ORS use increased significantly across intervention districts 
from 59.8% to 76.4%, while usage across comparators decreased non-significantly 
from 66.4% to 58.2%. In the intervention districts, there was a significant shift in 
point of access, from the public (originally the only point of access in rural Zambia) 
to the private sector, with introduction of the kit through community-level retailers.  
Rational use of ORS, defined as preparing and consuming ORS in the correct 
concentration, differed significantly between Kit Yamoyo users and users of 
standard one-liter ORS sachets. Kit Yamoyo, having been developed through a 
human-centered design (HCD) process resulting in smaller (200mL) ORS sachets 
and provision of a measurement vessel in the form of the kit s packaging, increased 
the odds of correctly preparing ORS by 10.93 times as compared to one-liter sachet 
users. Kit users prepared ORS in the correct concentration 93% of the time, while 
users of standard one-litre sachets prepared it in the correct concentration only 
60% of the time. Secondary analysis found that correct preparation of ORS 
significantly increased the odds of perceiving ORS as effective, along with having 
heard a message related to ORS in the previous 3 months. Caregiver s age was also 
significantly associated with perception of ORS, with the odss of perceiving ORS as 
effective decreasing with age. 
In rural Zambia there exists a largely untapped potential to leverage community-
level, general store retailers, who commonly sell fast-moving consumer goods (FMCGs) 
v 
like soap, snacks and beverages, to expand access to select public health products (PHPs) 
like ORS and zinc. On average, these types of shops are open longer than rural health 
facilities. Retailers typically purchase goods multiple times per month, from multiple 
wholesalers, providing increased opportunity for supply when compared to the public 
sector. With 87% of rural general store retailers having been asked for advice related to 
diarrhea treatment, they are well placed to help address market demand. With an average 
gross margin of 29% across other FMCGs commonly sold by these retailers, margins on 
PHPs can meet the profit needs of the retailers by following suit and remain affordable 
for the majority of people. The leading motivational factors indicated by general retailers 
for carrying a PHP were helping children and their community followed by profit. 
Following the introduction of the Kit Yamoyo, 76% of retailers were found to have it in 
stock on the day of visit, improving upon stock rates at rural health facilities. 
Implementation of a value-chain approach for over-the-counter public health 
products, like a diarrhea treatment kit, can significantly improve coverage at the 
community level. Adopting a human-centered design approach in the development of 
PHPs and other public health interventions allows for greater consideration of demand-
related factors of access, such as acceptability, and can lead to improved product 
innovation, appropriate utilization and perceived efficacy, as well as a strengthened 
value-chain.  
Evidence that standard 1-liter ORS sachets are often being prepared incorrectly 
and administered without zinc, has important implications for design and optimal product 
presentation for diarrhea treatment. In addition, it implies that one of the standard global 
indicators used to measure progress in the treatment of diarrhea globally – coverage – 
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may not be a completely accurate way of measuring progress. Measuring 
effective/rational use of treatments is vital when considering the details of 
implementation. Co-packaging of ORS with zinc and soap, smaller sachets of ORS (i.e. 
200mL), packaging that doubles as a measurement vessel, and enabling access through 
community-level general retailers (which presumes ORS and zinc have over-the-counter 
status) are features of an effective product and value-chain for diarrhea treatment that can 
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The 2013 Lancet Series on Childhood Diarrhea and Pneumonia noted that the 
most pressing challenges in the reduction of childhood deaths from diarrhea 
included insufficient access, production, distribution and promotion of key 
commodities, and that there was a need to strengthen supply systems that deliver 
essential commodities like Oral Rehydration Salts (ORS) and zinc (Gill et al., 2013). 
These challenges are consistent with those identified over the past decade (Bryce et 
al., 2005; Bhutta et al., 2010; Fischer-Walker et al., 2009), leading to increased calls 
for innovation. Market-based solutions that engage the private sector and 
simultaneously stimulate both supply and demand of these essential commodities 
have been recommended as a way of overcoming such barriers. 
1.1.1. The ColaLife Project 
 
The ColaLife project attempted to address these key gaps by piloting an 
innovative global health delivery model in Zambia. With the intention of improving 
access and effective use of ORS and zinc at the household level in rural Zambia, it 
applied a health systems lens to address gaps. More specifically, the approach 
involved emulating the value-chains of private sector, fast-moving consumer goods 
(FMCGs), like Coca-Cola, and applying similar principles to a newly developed 
diarrhea treatment kit (Figure 1.1).  The treatment kit, called Kit Yamoyo ( Kit of 
Life  in multiple local languages) was developed in conjunction with the intended 
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end-user (i.e. caregivers of children under 5) using a human-centered design 
approach. Designed for home use, the kit was innovative in that it:  
 Co-packaged low-osmolarity, orange flavored ORS (4 sachets) and zinc (1 
blister pack of ten dispersible, pediatric formulated tablets) (ORSZ);  
 Contained smaller [than the global standard] sachets of ORS (200mL vs. 
1L) more suitable for home use;  
 Included a small bar of hand-washing soap to tie in the message of 
prevention and add to the kit s attractiveness;  
 Included packaging that doubled as a measurement vessel to facilitate 
correct preparation of the ORS;  
 Integrated a graphical instructional pamphlet that doubled as the 
branding for the product; and  
 Focused on continual localization of the manufacturing of the product 
 
An end-to-end value-chain for the product was then established, which included 
tapping into the same, existing, private sector distribution channels as other FMCGs. 
These distribution channels are made up of district level wholesalers, as well as the 
community-level, general retailers who regularly procure products from them and 
operate shops across the last mile . These general stores (sometimes called grocery 
shops) make up the majority of private sector outlets in rural Zambia, with retailers 
regularly procuring products from district level wholesalers via bicycle, motorcycle, 
car, lorry, and a variety of other means. Each player in the product s value-chain 
stands to make profit, which plays a role in driving delivery and sustainability of 
that product at the community-level. The model is meant to complement (not 
replace) the diarrhea services provided through public health centers (including 
their affiliated community health workers), which tend to be the only other points of 
access for ORS and Zinc, providing choice and an additional option for caregivers at 
the community level.    
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1.1.2. Organization of the Document 
 
This dissertation aimed to evaluate key aspects of this ColaLife model , drawing 
on data from household and retailer surveys conducted across 4 rural districts. It 
starts by providing information related to key background concepts considered in 
the development and evaluation of the model (Section 1.3), including the rationale 
for the study and the approach in Zambia. Additional relevant literature review is 
provided within the Introductions of each research paper (Chapters 2, 3 and 4). The 
aims and objectives (Section 1.4) of the project and the research, more specifically, 
are then presented, including the key research questions that form the basis of this 
dissertation. Section 1.5 then presents the relevant conceptual framework and 
overall methodology used for the larger project from which the specific dissertation 
papers are derived. Chapter 2 provides an analysis of the overall impact of the 
value-chain approach on uptake of ORS and zinc combination therapy, as well as on 
ORS (with or without zinc) (Paper #1). Chapter 3 explores the role of human-
centered design in global health product innovation. More specifically, it examines 
the effect of applying HCD in the development of a diarrhea treatment kit and its 
resulting effect on rational use, and in turn, perceived effectiveness of ORS (Paper 
#2). Chapter 4 provides a detailed description of rural, community-level, general 
stores in Zambia. It explores the potential of leveraging these types of retail outlets 
to expand coverage of basic public health products that can be easily administered 
at the household level (Paper #3). Finally, Chapter 5 concludes with a discussion of 
the potential policy implications of the findings and provides a set of 
recommendations.  The affiliated tables and figures appear at the end of each 
respective chapter. Selected data collection tools and additional 
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information/analyses associated with the papers appear in appendices at the end of 
the document, after Chapter 5.  
 




Diarrhea is a leading cause of childhood morbidity and mortality (Liu et al., 
2015). It accounts for approximately 9% of all childhood deaths, making it the 
second leading infectious cause of death in children under 5 (Figure 1.2). This 
means that of the estimated 5.9M child deaths in 2015 (You D et al., 2015), 531,000 
of them were due to diarrhea.  
Estimates show that 2% of diarrhea episodes progress to severe cases, with 
approximately 72% of deaths in children under-5 taking place in the first 2 years of 
life (Fischer-Walker et al., 2013). While the incidence of diarrhea peaks between 6 
and 11 months, decreasing thereafter (Fischer-Walker et al., 2012), the proportion 
of deaths are greatest between 0 and 11 months, when the risk of disease and 
severity are at their peak (Fischer-Walker et al., 2013).   
Diarrhea is among the most common reasons for hospital admission in 
children in low- and middle-income countries (LMICs). It accounts for a large 
proportion of case visits seen at rural health centers. The greatest proportions of 
severe episodes of diarrhea occur in the South East Asian (26%) and African (26%) 
regions (Fischer-Walker et al., 2013). The highest numbers of deaths from diarrhea 
(about 50% of diarrheal deaths in 2011) occur in sub-Saharan Africa (Fischer-
Walker et al., 2013). In Zambia, where childhood mortality rates are among the 
highest in the world (World Bank, 2014), diarrhea is the third leading cause of 
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childhood mortality, after pneumonia and malaria, with malnutrition and HIV/AIDS 
serving as important contributors (WHO, 2014; Thea, 1993; Baqui, 1993; Zacharof, ; Macwan gi, .  
Although significant progress has been made in reducing diarrhea-related 
mortality, it remains a major cause of avoidable death. More than a decade has 
passed since the World Health Organization (WHO) and the United Nations Children s Fund UN)CEF  released a joint statement recommending low-osmolarity 
oral-rehydration salts (ORS) and zinc supplementation for diarrhea treatment in 
2004, yet even today, many children in the developing world are not receiving these 
life-saving interventions. Oral Rehydration Salts (ORS) after each loose stool, until 
the diarrhea stops, and zinc supplementation for 10-14 days, are safe and effective 
in both home and facility settings when properly prepared and administered. Yet, of 
those children with acute diarrhea, less than 1% receives zinc and only a third 
receives ORS globally (Gill et al., 2013). In Zambia, coverage estimates for zinc are in 
line with global figures at less than 1%, while ORS coverage has reached 62% (DHS, 
2014). 
Munos and colleagues assessed 205 developing country studies to review the 
efficacy and effectiveness of ORS and found that it reduced diarrhea specific 
mortality by 69% and rates of treatment failure by 0.2% (Munos et al., 2010). 
Fischer-Walker and colleagues reviewed 13 zinc supplementation studies from 
developing countries and concluded that zinc supplementation for diarrhea 
management was associated with a significant reduction of 46% in all-cause 
mortality and of 23% in diarrhea-related hospital admissions. Zinc treatment 
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resulted in non-significant reductions in diarrhea specific mortality of 66% and 
diarrhea prevalence by 19% (Fischer-Walker et al., 2010).  
Bhutta et al. modeled the benefits associated with three strategies (including 
the scale up of interventions for zinc and ORS, breastfeeding promotion, and case 
management of pneumonia) on the poorest quintiles through community-based 
platforms and showed that if 90% coverage were achieved for these three 
interventions, 64% of diarrhea deaths could be averted in the poorest quintiles in 
the three countries assessed (Bhutta et al., 2013). This is in line with previous 
estimates which have demonstrated that more than three quarters of diarrhea 
deaths can be prevented with full coverage and utilization of ORS and zinc (Jones et 
al., 2000).  
Oral rehydration replaces lost fluids and essential salts thereby preventing or 
treating dehydration and the risk of death. Glucose contained in ORS enables the 
intestine to more effectively absorb the fluids and salts. Low-osmolarity ORS 
reduces the need for intravenous fluids (required in the most severe cases) and 
shortens the duration of diarrheal episodes (WHO, 2001). Zinc supplementation is 
added to ORS as an adjunct therapy and has been proven to decrease the duration 
and severity of diarrheal episodes, as well as the risk of subsequent infections in the 
2-3 months following treatment (ZICG, 2000).  
According to Fischer-Walker et al. (2009) many countries have been stalled 
in the technicalities of adapting national policy for low-osmolarity ORS and zinc 
(ORS/zinc), while others struggle to find the funds for start-up activities . The 
problem is even worse in rural parts of the developing world, where for millions of 
people, ORS/zinc are often not available locally and are hard to come by, either 
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because of distance, cost, or because the supply has run out (Gill et al., 2013; Werner 
& Sanders, 1997). In addition, there was a period where a movement towards 
integrated management of childhood illnesses moved the treatment of diarrhea 
away from the community and household level to facility-based care and often-
incorrect case management (Bryce et al., 2008). With a recent increased emphasis 
on integrated community case management (iCCM)i there may be a trend towards 
greater balance.  
It has also been noted that providing ORSZ solely through public sector 
clinics has not been effective, comprehensive or sustainable in any country (Fischer-
Walker et al., 2009). Mothers and caregivers of children under 5 often face 
numerous opportunity costs associated with traveling to distant clinics, including 
taking time off work, paying for transportation, risks associated with treatment 
delay, etc. Thus, what may be needed to improve ORSZ usage in rural Zambia, and 
many other LMICs, is to make it available through the private sector at low cost. This 
could involve making the items available in local shops at the community level, or 
for distribution at the household level by community health workers. But it is 
important to keep in mind that need does not equate to demand. There are 
challenges associated with access, willingness to pay and utilization. Awareness is 
also generally an issue, particularly with regard to zinc. Mothers need to see the 
value and benefits of giving ORSZ to their children. They need to know when and 
how to use them, and where to get them. It has been suggested in recent calls for 
                                                        
i Integrated Community Case Management (iCCM) is a strategy to extend case management of 
childhood illness beyond health facilities giving more children access to lifesaving treatments. 
The iCCM package can differ by context, but typically focuses on diarrhea, pneumonia and 
malaria. 
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renewed action on ORSZ that the combined promotion of these two commodities is 
critical and may benefit from expansion to private sector markets, social marketing, 
and targeted behavioral change campaigns (Fischer-Walker et al., 2009; Bhutta et 
al., 2013). Even though there were successes in the promotion of ORS in the early 
and mid-1980s, strategies currently being used by countries, if at all, are in need of 
renewal. Combined packaging and promotion of ORS and zinc may help address 
some of these shortfalls.  
 
1.2.2. Value Chains & Delivery 
 
 The application of business principles to global health is an evolving science. 
With increasing skepticism around conventional supply-chain systems used to 
deliver medicines in developing countries, there has been increasing pressure to 
learn from the commercial private sector (Ballou-Ares, 2008; Yadav, 2010). One 
promising approach to improving access and delivery of ORS and zinc involves 
blending concepts from health systems thinking and value-chain theory.  Both 
emphasize a holistic way of viewing product/service delivery, and can help when 
attempting to analyze and address bottlenecks from both a supply and demand-side 
perspective. While value-chain thinking is commonly applied to FMCGs, it has not 
commonly been applied with regard to access to medicines, or to public health more 
generally.  
 A value-chain refers to the entire production chain from the input of raw 
materials to the output of final product consumed by the end user, with each link 
adding value to the original inputs (Dyer, 2000; Porter & Teisberg, 2006; Burns, 
2002). In a value-chain, value flows back from the end-user as product is pulled  to 
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them. This is as opposed to traditional supply-chain systems, which tend to push  
product out from the manufacturer toward the end-user. This is a key difference 
between value-chains and supply-chains – they flow in opposite directions (Feller et 
al., 2006).  
 The primary focus of value-chains is on the benefits that accrue to end users, the 
interdependent processes that generate value, and the resulting demand and flow of funds 
created (Feller et al., 2006). In this way, value-chains can be thought of as an ecosystem 
of players, processes, information and resources required to effectively deliver a 
product/service from its conception to the end user. These “end-markets” determine the 
characteristics of the final product/service, with their demands and specifications driving 
quality and standards (Lusby & Panlibuton, 2006). Thus, understanding the demands and 
trends of the end market is central to the value-chain.  
 Kim, Farmer and Porter (2013) note that the biggest obstacle facing global 
health is a failure of delivery. They note that:  
 The gritty business of actually delivering health care in developing 
countries has not attracted much academic interest, even though 
improving capacity to deliver care in these settings will save lives, 
leverage substantial and growing philanthropic support of global 
health, and increase returns on existing and new investments in both 
discovery and development of new resources. 
  
 They emphasize care delivery value-chains as a corner stone of their 
strategic framework for global health delivery, which defines core principles that 
underpin a high-value delivery system and its component parts. These include: 1) 
use of care delivery value-chains (CDVC), 2) shared delivery infrastructure, 3) 
aligning delivery with external context, and 4) leveraging the health-care delivery 
system for economic and social development (Kim et al, 2013). The ColaLife 
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approach considered all of these principles in different ways. Appendix 1 
summarizes the various ways in which the four components of the framework were 
addressed. Kim et al. note that by focusing on the design and operation of delivery 
systems, greater attention is paid to developing systems that may be brought to 
scale.  
  
1.2.3. Integrated Innovation & Health Markets 
 
The relatively new concept of integrated innovation  focuses on the 
coordinated application of scientific/technological, social and business innovation 
to develop solutions to complex challenges (Singer et al., 2010).  This approach 
emphasizes the synergies that can be achieved by harnessing all three types of 
innovation, rather than focusing on the individual benefits of each alone. It 
recognizes that public health innovations have a greater chance of achieving 
sustainability, global impact and scale, if from the outset, they are developed with 
the appropriate social and business considerations (Singer et al., 2010).   
Similarly, in their discussion of the growing interest in social entrepreneurship 
in health-markets, Bloom et al. note that the term social entrepreneurship refers to 
organizations that borrow a mix of business, charity and social movement models 
to reconfigure solutions to community problems and deliver sustainable new social 
value (Nicholls, 2006).  Both Austin et al. (2006) and Nicholls2 note that social 
entrepreneurs often work across the public, private and social sectors, which Bloom 
et al. note makes them particularly interesting in the context of marketized health 
systems (Bloom et al., 2009). 
 From a global health policy perspective, interventions that harness these 
11 
sister concepts, while applying a health market lens are currently of particular 
interest and promise. A recent report from the Center for Health Market Innovations 
(CHMI) noted that, When well-monitored and regulated, health markets can be a 
source of creative new approaches with the potential to achieve greater efficiencies, 
improved quality, and increased access to care for underserved populations 
(2011).  However, the report notes that few innovative programs are ever evaluated 
to academic standards and the evidence base for such programs is still lacking 
(CHMI, 2011).  In sharing key expert recommendations from a recent Health Market 
Symposium held in Bellagio, Peters and Bloom reiterate the need for a major effort 
by all market players to test innovative business models to improve access to safe 
and effective health services in the developing world (Peters & Bloom, 2013).   
 Bloom and colleagues  description of health markets (2009) centers around 
the supply (by providers) and demand (by consumers) of health goods and services as the basis of a market system. Building on Elliot s model (2008), they highlight the 
many stakeholders and roles involved in the health market system including: 
informal networks, the private sector, NGOs, and Government; various support 
functions (i.e. management of various inputs like drugs); as well as the rules (both 
formal and informal) that influence the system and individual behaviors.  
 Peters, Paina and Bennett (2012) observe that due to discrepancies between 
health needs and demands, the information asymmetry pervasive in the health 
sector, and the challenge for institutions to maintain/apply rules, health market 
systems require intervention to minimize/mitigate the effects of market failure 
(Arrow, 1963; Bloom et al., 2011). Given the complexity and variability related to 
organization of a health market, the design of a health market intervention often 
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relies on the characteristics of the health commodity (Bloom et al., 2009 or Peters & 
Bloom, 2013). Some are only affiliated with minimal information asymmetry, 
facilitating consumer use with little expertise and posing low risk. One of the 
differences between these and more complex health goods relates to knowledge, trust in the provider, effort, and the users  ability to pay.  For example, a relatively 
easily treatable disease like diarrhea simply involves access to a combination of 
good quality drugs (ORS and Zinc) and information, some of which is already well 
known, at least with regard to ORS (DHS, 2014). Bloom et al. suggest that these 
situations may be best left to competitive markets, and confirm that, the main 
challenges are to develop a well-defined good and/or service, establish a 
distribution system, and inform potential users of its value. One example is the 
development and widespread use of oral rehydration solution for diarrhea  (2009). 
They add that a program focused on strengthening health market systems for the 
poor needs to identify and disseminate innovations by the poor. These innovations 
are also more likely to develop closer to where the poor live. Co-production with 





Research was carried out across 4 rural districts of Southern and Eastern 
Province, Zambia (Figure 1.3). Zambia is a landlocked nation in sub-Saharan Africa 
bordered by Mozambique, Zimbabwe, Botswana and Namibia to the South, Angola to the 
West, Democratic Republic of Congo and Tanzania to the North, and Malawi to the East. 
With a gross national income (GNI) per capita of approximately $3860 (PPP, 
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International dollars) in 2014 (World Bank, 2014) Zambia has seen steady growth over 
the past decade, but has seen a weakening of the economy and a drop in the value of the 
Kwacha in 2015. Regardless, the gains experienced over the past decade have failed to 
translate into reductions in poverty. With 42% of the population living in extreme 
poverty, the absolute number of poor increased from 6M in 1991 to 7.9M in 2010, mainly 
due to population growth (World Bank, 2015). Providing basic health services and 
essential medicines to most of the population, particularly the rural poor, remains a 
challenge.  
Limited data exist with reference to private sector health providers in Zambia, let 
alone the rural retail sector. This is partially due to the fact that there is limited private 
sector health provision in the country overall. The same applies to the provision of Public 
Health Products (PHPs) like ORS and zinc. PHPs are defined as products used for 
promoting health or for the prevention, management or treatment of diseases of public 
health significance. These can typically be provided at the general retail level without the 
delivery of an associated service (Conteh & Hanson, 2003). Additional examples of PHPs 
and their characteristics are provided in Tables 1.1 and 1.2. 
In rural areas, the vast majority of access to health products and services tends to 
be limited to public sector facilities. With few exceptions, PHPs such as ORS and zinc 
can only be obtained from rural health centers or posts. Of the 1,956 health facilities in 
the country as of 2012, the government runs 81% (1590), the private sector runs 13% 
(250), and 6% (116) are faith-based facilities (Ministry of Health, 2013). These facilities 
include 307 (16%) rural health posts, 1,131(58%) rural health centers, 409 (21%) urban 
health centers, 84 (4%) district level hospitals, 19 (1%) provincial or general hospitals, 
and 6 (0.03%) large, tertiary care hospitals.  
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The Government of the Republic of Zambia’s (GRZ) access policy states that 
there should be a health facility within 5km of every household. While this is indeed the 
case for 99% of urban households, it is only the case for 50% of rural households 
(Chankova and Sulzbach, 2006). While the GRZ’s strategic plan was to increase access 
to 70% of the population by 2015, the target was not achieved. There are a number of 
difficulties to accessing healthcare in rural areas. Key barriers to physical accessibility 
were cited as: “insufficient infrastructure; inaccessibility due to geographic factors; 
sparsely distributed population in rural areas; inadequate resources for outreach (fuel, 
vehicle, bicycle, motor-bikes, boats); and poor scheduling of services leading to missed 
opportunities” (Ministry of Health, 2011). Access of the health supply chain tends to 
be limited beyond the rail line and there is poor availability to service delivery 
points (Ballou-Ares et al., 2008). One rural Zambian study found that distance was a 
significant predictor of attendance for diarrhea treatment specifically (Chatt and Robert, 
2010). 
In addition to geographic access barriers, public sector facilities face regular stock 
outs of essential medicines like ORS and zinc. Thus, despite basic medicines being made 
available at no cost to patients as of 2006 (Masiye et al., 2010), essential and life-saving 
drugs were still widely unavailable in health facilities according to a nationally 
representative Public Expenditure Tracking Survey (Picazo and Zhao, 2008). Analysis of 
recent Health Metrics and Evaluation (IHME) data (IHME, 2015) from Zambia found 
that 23% of rural health centers surveyed (n=363) reported having stock-outs of ORS 
within the previous year, while 30% reported having zinc stock outs. Nationally, 11% of 
rural health centers surveyed were stocked out of ORS on the day of visit, while 54% 
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were out of zinc. Even when zinc is available at health centers, utilization rates of less 
than 1% across the country would indicate healthcare workers rarely prescribe it.  
The supply chain for medicines to Zambian health facilities is largely dependent 
on a three-tier public sector distribution system. Products are procured by the Central 
Medical Store (CMS) and channeled down to service delivery points on a monthly basis. 
Virtually all of the public sector supply, and much of the faith-based facility supply, 
comes from international suppliers and procurement agents, and is then pushed through 
the system (Dalberg, 2008). Primary distribution of drugs and other commodities from 
Lusaka to about 120 district medical stores (DMS) and hospitals is managed by a 
parastatal called Medical Stores Limited (MSL). The secondary distribution of 
commodities from district stores to health facilities then falls under the purview of 
District Health Management Teams (DHMTs) who report to the MOH (Vledder et al., 
2015). While MSL’s trucks do a good job of getting products to the district level, 
multiple field studies conducted between 2006 and 2008 (Beers, 2007; Dalberg, 2008; 
Picazo and Zhao, 2008, Yadav, 2007) identified the key reasons for stock-outs as lying 
beyond the district level. These included secondary distribution not being carried out in a 
uniform way across the country, with many health facilities having to travel to their 
district headquarters to pick up stock themselves (Yadav, 2015). In addition, 
transportation is a significant challenge within the secondary distribution system with 
insufficient vehicles, regular breakdowns due to poor roads and high usage, and poor 
accessibility due to seasonal weather conditions. Other challenges identified included 
difficult communication between the District Central Store and health centers who 
typically rely on radio systems and personal cell phones, as well as a lack of demand data 
resulting in supply decisions not being based on actual consumption patterns.  
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Private sector supply chain channels have yet to play a significant role in the 
country’s health sector, and less is known about their structure and operations when 
compared to the public sector supply chain (Palafox et al., 2012). That said, the MOH is 
supportive of private sector initiatives and in 2009, launched phase two of the Private 
Sector Development Reform Program. This program aims to expand and accelerate 
private health sector growth (Kwesiga et al., 2010).  
As in many developing countries, access to medicines in the private sector is 
currently largely confined to urban settings and is very limited in rural areas (Goodman, 
2004; McCabe et al., 2011; Yadav et al, 2012; Cohen et al., 2010; Wafula et al., 2012). 
Much of the private sector access that does take place is through pharmacies and drug 
shops. The fact that there are less than 100 pharmacists (i.e. Bachelor of Pharmacy) in 
Zambia and only 59 pharmacies (40 of which are in Lusaka) contributes to this 
confinement. Similarly, the lack of pharmacy technicians (i.e. diploma in pharmacy) in 
the country keeps the number of drug shops low as well (Dalberg, 2008). All private 
pharmaceutical importers, wholesalers, and retail pharmacies in the country are required 
to employ a pharmacist registered with the Medical Council of Zambia (Palafox et al., 
2012). Pharmacy technicians too should be registered with the Medical Council of 
Zambia. Licenses for the manufacturing, importation, wholesale and pharmacy retail of 
medicines are issued by the Zambian Medicines Regulatory Authority (ZAMRA, 
previously the Pharmaceutical Regulatory Authority or PRA). The functions of the 
Authority as stipulated by the Medicines and Allied substances Act of 2013 includes the 
regulation and control of the manufacture, importation, storage, distribution, supply, sale 
and use of medicines and allied substances. It covers the registration of products, 
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pharmacies, health shops and agro-veterinary shops. It is also responsible for post-
marketing surveillance.  
Drug shops, registered with local governments rather than licensed by ZAMRA, 
are not required to employ a pharmacist. While they are only supposed to dispense over-
the-counter medicines, in practice, they also dispense prescription only medicines. These 
retail outlets are mostly limited to urban centers. Medicine prices and mark-ups within 
these private sector outlets are not regulated and are established by the market.  
General stores that focus mainly on the sale of FMCGs are another source of a 
limited number of over-the-counter medicines. Very little is known about these outlet 
types, and the literature on their characteristics and behaviors in Zambia is extremely 
limited. After manufacturers, importers, distributors and wholesalers, these retailers, and 
the consumers that buy from them, constitute the end of the value-chain for a number of 
FMCGs (Paper 3; Patouillard et al., 2010; Palafox et al., 2014). In contrast to the shelves 
at many clinics, the shelves of these entrepreneurs, that live and work at the community-
level, always seem to be full of products. It has been suggested, that expanding access to 
treatment for diarrhea could benefit from private sector, market-based approaches 
(Fischer-Walker et al., 2009; Gill et al., 2013).  The World Health Organization (WHO) 
and UNICEF advocate strategies to improve home-based management of diarrhea 
(UNICEF/WHO, 2009), with retailer interventions seen as one possible facilitator. ORS 
and zinc can be taken without much guidance or with simple instructions; there is 
minimal risk associated with their use (e.g. no threat of resistance); and they are 
recommended regardless of the causal agent.  Timely and appropriate treatment of 
children under-5 years of age is particularly important in preventing dehydration and 
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curtailing morbidity and mortality. Providing care through such retailers, closer to the 






1.3. Aims & Objectives 
 
1.3.1. Project Objectives  
 
The primary objective of the ColaLife trial was to increase effective use of ORSZ 
for home treatment of acute diarrhea in children under the age of 5 in rural Zambia, 
ultimately helping to reduce diarrhea-related child mortality. The logic model 
developed for the evaluation of the project (Appendix 2) helps describes the theory 
of change, including an overview of the activities, outputs, immediate and 
intermediate outcomes, as well as the primary objective and expected ultimate 
impact.  
The model is divided into three key streams of work, namely: A) the supply chain 
stream; B) the knowledge, attitudes and practice stream; and C) the knowledge 
translation stream. All three streams were to work in unison to lead to the final 
impact of contributing towards MDG 4/SDG 3.2 – a reduction in child mortality. In 
addition, the program exemplifies a key tenet of SDG 17 – strengthening the means 
of implementation and revitalizing global partnerships for achieving the goals and 
sustainable development more generally, especially with regard to providing access 
to affordable, essential medicines in developing countries (SDG 3.b). Given the 
required timelines and resources associated with effective measurement of 
mortality impact, analysis at this level was deemed to be out of scope for the 
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evaluation, and measurement therefore ended at the intermediate outcome level of 
utilization.  
Key inputs for the trial included funding [e.g. Department for International 
Development (DFID) UK, Grand Challenges Canada, Johnson & Johnson Corporate 
Citizenship Trust], program policies being established, planning conducted during 
the design phase, commodities (e.g. packaging, ORS, zinc, soap, pamphlet, etc.), 
relevant country policies (e.g. over the counter zinc status), coordination processes 
during the project, as well as the relevant human resources and expertise required 
to make the program successful.  
Key activities/processes for streams A and B included development of the Kit 
Yamoyo, including procurement of the contents, pricing, testing, and detailed co-
design with end-users. In addition, it involved operationalizing the value-chain 
developed with the relevant program partners. Closely related to this activity were 
the awareness raising, recruitment and training of retailers and wholesalers that 
made up key components of the value-chain. A final key activity was the social 
marketing campaign associated with the Kits, including the design, testing and 
delivery of information, education, and communication (IEC) materials. This took 
place at the level of the product itself (i.e. instructional pamphlet/branding) and at 
the community level (e.g. within local shops, collaboration with health centers, over 
radio, via posters, and through workshops and community drama events run by 
trained promoters). Because measurement and development of a strong evidence 
base is essential for any potential future scale-up and knowledge generation, key 
activities within stream C included implementation of the monitoring and 
evaluation (M&E) plan, execution of an open innovation process (e.g. leveraging of 
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Social Media tools) as well as the development of a sustainability strategy (e.g. 
gradual transition to private sector partner – Pharmanova). 
These activities were expected to lead to important outputs in each stream. 
Stream A outputs, which fall within the scope of this dissertation, included Kits 
meeting the needs at all levels of the value chain (i.e. mothers/caregivers, children, 
health centers, distributors, retailers); effective operation, flow and quantities 
within the supply chain to rural communities; as well as retailers and health centers 
being effectively trained in the benefits and methods associated with the Kits. For 
the retailers, this included tracking of stocks and sales, how to redeem vouchers, 
and para-skilling/training with regard to diarrhea treatment guidance. The central 
stream B output was that the social marketing campaign, as well as the IEC 
materials, were effectively developed and implemented. The effective 
implementation of a well-designed M&E plan was the key output for stream C.  
All communities targeted were located in underserved/rural areas. In terms 
of immediate outcomes, stream A was to result in improved availability of the 
contents of Kits in underserved communities. Stream B was to result in increased 
awareness of Kits and the health benefits of the contents among target audiences. 
For stream C, the immediate outcomes were to determine a sustainability strategy, 
as well as the collection and analysis of relevant data. Both streams A and B were 
expected to help lead to the intermediate outcome of improved access to the 
combination therapy of ORSZ, and then to the purpose (i.e. final outcome) of 
caregivers of children under 5 increasing use of ORSZ for household treatment of 
diarrhea.  
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Stream C s intermediate outcome is that important lessons learned are 
disseminated, the sustainability strategy implemented, and an official multi-sectoral 
partnership established for last-mile delivery and scale-up if warranted. 
1.3.2. Research Questions 
 
The current dissertation research was derived from the above framework of the 
overall project. While there are many interesting research questions to be explored 
relating to the value-chain approach undertaken, the research questions that form 
the basis for this dissertation address some of the most important questions from a 
public health perspective. The specific research questions that will be explored as 
part of this research proposal include:  
Question #1: Does emulating the commercial, private-sector value-chains of fast 
moving consumer goods (FMCGs), such as Coca-Cola, and applying lessons to the 
introduction of an innovative diarrhea treatment kit, have an effect on coverage of 
ORS and zinc at the community-level? 
Question #2: To what extent can consideration of human-centered design – 
through a focus on product-oriented, demand-related dimensions of access (e.g. 
acceptability) - lead to improved product innovation, appropriate utilization (i.e. 
rational use) and perceived efficacy of public health commodities such as Oral 
Rehydration Salts (ORS)? 
Question #3:  What are the characteristics and operations of rural, commercial, 
community-level, general retail shops that commonly specialize in the sale of fast-
moving consumer goods (FMCGs)? What insights can be drawn that may inform 
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their use as informal private providers  of public health products (PHPs)? 
1.4.     Conceptual Frameworks 
 
The ColaLife distribution system (Figure 1.4) started with Pharmanova, a 
Zambian pharmaceutical company and the key private sector partner based in 
Lusaka. They were responsible for manufacturing (e.g. ORS) and procuring (e.g. zinc, 
soap, container) Kit Yamoyo components (as of 2015, they also started 
manufacturing the zinc), assembling and storing the Kits, and then delivering the 
Kits to Medical Stores Limited (MSL), a government parastatal responsible for 
delivery of drugs in the public sector.  MSL was then responsible for storage and 
delivery of the Kits to the intervention districts (Kalomo and Katete) on a monthly 
basis. Rather than MSL delivering the Kits to a district medical storage facility (as 
with the public sector), they delivered the Kits to the Coca-Cola wholesaler located 
in the district towns.  
These independent wholesalers typically sell numerous other FMCG s, along 
with being the exclusive district-level distributors of Coca-Cola. Once the Kits were 
available from the wholesaler, they were free to be purchased by registered Kit 
Yamoyo retailers. This restriction was only in place for purposes of the trial s 
operational research and has since opened up to all retailers interested in carrying 
the product. Retailers then purchased the kits from wholesalers, and took the Kits 
back to the community level for sale in their shops, thereby opening up new points 
of treatment access for caregivers in rural Zambia. These private sector access 
points were closer to homes and provided the necessary tools for effective 
treatment of diarrhea. 
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Bigdeli et al. (2012) highlight the fact that most health systems strengthening 
interventions ignore interconnections between different system components. 
Consequently, they note that access to medicines at the population level are 
addressed mainly through fragmented often vertical approaches that focus on 
supply alone, and not wider issues of access to health services and interventions.  
Traditional access to medicines frameworks have attempted to break down the 
various dimensions and determinants relating to supply and demand of medicines 
(Table 3.1). Through their access to medicines from a health systems perspective  
framework, Bigdeli et al. build on these dimensions and determinants by proposing 
a more holistic view of both supply and demand-side factors, as well as 
consideration of several dynamic relationships between medicines and other health 
system resources. If one were to generalize Figure 1.4 (ColaLife Distribution 
Structure) and consolidate it with the elements of Table 3.1 (Access Frameworks), 
exploring the ColaLife model from a health systems perspective, the resulting 
conceptual framework would be Figure 1.5 (Access to Medicines from a Health 
Systems Perspective). While the project has been working at multiple levels within 
this framework, the key intersections relevant to this dissertation have been 
highlighted in relation to the previously identified research questions which operate 
at the key intersections of: 
 Service delivery, and individuals, households and communities – Question 
#3;  
 Market forces, innovation, and resources (particularly with a focus on the 
attributes of acceptability of medicines) – Question #2; as well as 
 The overall value-chain approach, which attacked the problem of diarrhea 
by acting at all key junctures thereby addressing multiple challenges and 
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bottlenecks within the system, but measuring the key outcome of coverage – 
Question #1.  
 
 Complementing the access to medicines frameworks and dimensions is the 
Innovation, Adoption, Diffusion Model by Rogers and Shoemaker (1971). Their 
classic model identified five key categories of characteristics for consideration with 
regard to the rate of innovation diffusion. These included: 1) perceived attributes of 
the innovation (relative advantage, compatibility, trialability, observability, and 
complexity), 2) communication channels (e.g. mass media, interpersonal, etc.), 3) 
nature of the social system (e.g. norms, degree of network interconnectedness, etc.), 
4) extent of change agents  promotion efforts, and the type of innovation-decision 
being made (e.g. optional, collective, authority). These factors were also considered 
during implementation and were active elements of the overall intervention 
evaluated in Paper #1.   
 Paper #2 focuses on the human-centered design of the product innovation at 
the heart of the overall intervention. Moultrie and colleagues (Moultrie et al, 2006) 
identify several good design  features that influence product desirability.  These 
features draw many parallels with the perceived attributes of an innovation from 
the Rogers and Shoemaker framework, and include: usability, core benefits, 
aesthetics and sensory appeal, symbolic value, and product novelty/differentiation. 
Figure 1.6 draws on these attributes as well as those from the acceptability 
dimension from various access to medicines frameworks (Frost & Reich, 2010; 
Center for Pharmaceutical Management, 2003; WHO, 2004), to establish the 
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conceptual framework for Paper #2 with the key outcome variables being 
appropriate use of ORS and its perceived efficacy.  
Variables of interest for Paper #3 were mainly identified based on market 
research frameworks and factors explored in other retailer-focused studies, both 
within healthcare and general retail sectors (Kumar, 2013; Cheungsuvadee, 2006; 
Carpenter & Moore, 2006, McCabe, 2011, Wafula et al., 2012). Key variables of 
interest explored included: demographic information related to shop owners and 
proprietors, physical aspects of the shop, sales and stocking patterns, procurement 
practices including wholesaler preferences (i.e. source of goods), product choices 
(including medicines), pricing and profits, and information relating to the customer base. 
Based on a review of the literature, understanding these elements of rural, commercial 
general retailers was considered to be a sound way of exploring their potential as 
informal private providers of PHPs from a descriptive perspective.  
 
1.5. Study Design & Data Sources 
 
The overall evaluation of the ColaLife trial used a quasi-experimental pretest-
posttest design with matched comparators. The data for the specific studies which 
make up this dissertation were derived from different components of the overall 
design. The main data sources include cross-sectional, rural household surveys 
conducted in 2012 (baseline) and 2013 (endline), as well as retailer surveys 
conducted in 2012 (midline) and 2013 (endline). Household Questionnaires were 
administered to 2458 and 2477 caregivers of children under 5, across 4 rural 
districts of Zambia, at baseline and endline, respectively. Retailer surveys were 
administered to 180 retailers across the four districts during each data collection 
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period. Two districts (Kalomo and Katete) served as intervention districts, while the 
other two (Monze and Petauke) served as matched comparators.  
Paper #1 uses logistic regression analysis to calculate the adjusted relative 
risk of combination therapy use in intervention districts vs. comparator districts at 
endline. Secondary analysis used difference-in-differences estimation to compare 
ORS use (with or without zinc) in the intervention and comparison districts, before 
and after market-shaping activities. Because zinc use was close to nil at baseline, a 
difference-in-differences analysis to test the change in combination therapy was 
deemed inappropriate.  
Paper #2 compared correct preparation of ORS for children under 5 with 
diarrhea, who either used Kit Yamoyo or standard one-liter sachets of ORS from 
rural health centers. Data drawn from the endline survey were analyzed using 
logistic regression and calculated the odds of correct preparation of ORS (i.e. 
concentration) in Kit users vs. non-users. Secondary analysis examined to what 
extent preparation of ORS in the correct concentration was associated with a change 
in the odds of perceiving ORS as effective.   
Paper #3 is predominantly descriptive in nature. It uses retailer survey data 
from 180 interviews of general, community-level retailers who commonly sell 
FMCGs, to explore the potential of using them as outlets for provision of basic public 
health products like ORS and zinc. Findings were grouped under key themes 
including: infrastructure, staffing, ownership and operations, purchasing patterns, 
product preferences, and level of engagement with an intervention to expand coverage of 
a newly introduced diarrhea treatment kit. Additional details relating to the methods of 
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FIGURE  1:3: ZAMBIA PROJECT DISTRICTS 
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FIGURE 1:5: ACCESS TO MEDICINES FROM A HEALTH SYSTEMS PERSPECTIVE 
(SOURCE: ADAPTED FROM BIGDELI ET AL., 2013) 
 
FIGURE 1:6: PRODUCT ORIENTED DEMAND-SIDE FACTORS TO ACCESS FRAMEWORK 
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Tables for Chapter 1 
 
TABLE 1.1: EXAMPLES OF PUBLIC HEALTH PRODUCTS (PHP) 
Global Health Focus PHP* 
STIs Condoms 
Malaria Antimalarial drugs * rapid diagnostic tests (RDTs) 
Malaria Mosquito nets and insecticide for re-treatment 
Family Planning Various contraceptives 
Variable Some antibiotics (e.g. Amoxicillin for Pneumonia) 
Diarrhea ORS 
Diarrhea/Pneumonia Zinc 
Helminth Infection De-worming tablets (e.g. albendazole) 
Hygiene & Sanitation Water purification devices 
 Sanitary pads 




Prevention of Deficiencies Micronutrients 
 Iodized salt 
 Vitamin A 
 Iron folate 
 Prenatal Vitamins * Positive perspective  would suggest that any products that are in practice sold as commodities, 
whether legally or not, should be considered to be PHPs (antimalarials, antibiotics, and oral 
contraceptives) 
 
TABLE 1.2: CHARACTERISTICS OF PUBLIC HEALTH PRODUCTS 
Characteristic 
Can be distributed through the private retail sector as well as through the formal 
health system. 
Have a significant private good  with significant share of benefit accruing to the 
end-user (excludable, rival and rejectable) 
Supply of many PHPs faces relatively low barriers to entry and exit, so that markets 
are contestable (e.g. do not require very specific assets; few or no sunk costs; and 
no natural monopoly issues) 
Most purchases of PHPs are discrete, time bound, and do not require an ongoing 
relationship with the retailer P(Ps have the characteristic of measurability  i.e. easy to measure with precision 
and therefore compare across products and sellers to find best deal) 
Problem of information (i.e. asymmetries between seller and consumer; level of 
knowledge of retailer, etc.) 
Problem of controlling price and ensuring affordability and purchasing power 
Based on reasons why competitive markets have tended to emerge (Berman, 2000; 
Preker & Harding, 2000; Conteh & Hanson, 2003). 
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Chapter 2 - Impact of Emulating Commercial, Private-Sector 
Value-Chains on Uptake of ORS and Zinc for Childhood Diarrhea 




Globally, diarrhea remains a leading cause of avoidable morbidity and 
mortality in children under 5. The inability to effectively access the globally 
recommended treatment – ORS and zinc – has contributed to poor coverage levels in 
most of the developing world. Weak supply-chains and low-uptake have been 
identified as priority bottlenecks.   
Market-based solutions that engage the private sector and simultaneously 
stimulate both supply and demand of these essential commodities have been 
recommended as a way of overcoming such barriers. We hypothesized that 
emulating the commercial, private-sector value chains of fast moving consumer 
goods (FMCGs), and applying lessons to the introduction of an innovative diarrhea 
treatment kit would increase coverage of ORS and zinc at the community-level. 
Through public-private partnerships between community-based retailers and 
community health workers/promoters at the micro-level, and between the Ministry 
of Health, a local pharmaceutical manufacturer (Pharmanova), SABMiller  (The 
Coca-Cola Company s bottling partner in Zambia), pi Global (packaging design firm) 
and a range of other local and international stakeholders at a macro-level, we 
emulated value-chain principals used by Coca-Cola. This included tapping into the 
same distribution channels that make FMCGs available in rural communities in 
many low and middle-income countries.  
We tested the impact of this approach on uptake of ORS and zinc in children 
under 5 suffering from diarrhea in rural Zambia.  Using a quasi-experimental 
pretest-posttest design with matched comparators, we conducted household 
surveys of 2458 and 2477 caregivers of children under 5 at baseline and endline, 
respectively. Surveys were conducted across 2 intervention districts, each with a 
matched comparator district. Use of ORS and zinc combination therapy increased 
from less than 1% at baseline to 46.6% across the intervention districts, while no 
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change was seen in the comparator districts (Pooled Risk Ratio: 39.0; 95% CI: 13.2-
115.2; p<0.001). Difference-in-differences analysis comparing ORS use (with or 
without zinc) in the intervention and comparison districts, before and after market-
shaping activities, found that pooled ORS use increased significantly across 
intervention districts from 59.8% to 76.4% (OR: 2.17; 95% CI: 1.47-3.24; p<0.001), 
while usage across comparators decreased non-significantly from 66.4% to 58.2% 
(OR: 0.71; 95%CI: 0.48-1.04; 0.08).  
 
Key Words: Value-Chain, Supply-Chain, Public-Private Partnership, Diarrhea, ORS, 





Globally, diarrhea remains one of the leading causes of avoidable morbidity 
and mortality in children under 5 (Fischer-Walker et al., 2013; Sabot et al., 2012; 
UNICEF 2009;).  It is the second leading infectious cause of childhood mortality, and 
accounts for approximately 9% of all under-5 deaths (Liu et al., 2015; UNICEF 
2012). In Zambia specifically, childhood mortality rates are among the highest in the 
world (World Bank, 2014), with diarrhea accounting for approximately 9% of 
deaths in children under-5 (WHO, 2015). This makes it the third leading cause of 
childhood mortality in the country, after pneumonia and malaria, with malnutrition 
and HIV/AIDS serving as important contributors (Thea et al., 1993; Baqui et al., 
1993; Zacharof, 2001; Macwan gi & Phiri, 2008).  
These statistics exist within the context of national policy makers and the 
global health community knowing well what is required to reduce childhood deaths 
from diarrhea (Fischer-Walker et al., 2009; Bhandari N et al., 2008; Awasthi S et al., 
2006; Hamer D et al., 1998). Oral Rehydration Salts (ORS) after each loose stool, 
39 
until the diarrhea stops, and zinc supplementation for 10-14 days, are safe and 
effective in both home and facility settings when properly prepared and 
administered. They are off-patent; can be manufactured cheaply; do not require cold 
chains; only need to be taken episodically and for relatively short durations; are 
extremely cost-effective; and with relatively low technology demands, can be 
manufactured locally provided principles of Good Manufacturing Practices are 
followed (Gill et al., 2013; Baqui et al., 2002; Yakoob et al., 2011; Mazumder et al., 
2010; Munos et al., 2010; Fischer-Walker & Black, 2010; Bhandari et al., 2008; 
Bishai et al., 2013; WHO, 2006; Fischer-Walker et al., 2009). In Zambia, they also 
both have over-the-counter status. Nonetheless, despite efforts of international 
health agencies to promote home use of these treatments, they still remain 
underutilized. Of those children with acute diarrhea, less than 1% receives zinc and 
only a third receives ORS globally (Gill et al., 2013). In Zambia, coverage estimates 
for zinc are in line with global figures at less than 1%, while ORS coverage has 
reached 62% (DHS, 2014). 
Barriers to effective access for these commodities relate both to supply and 
demand. The most pressing challenges identified in the reduction of childhood 
deaths from diarrhea include insufficient access, production, distribution and 
promotion of key commodities like ORS and Zinc (Gill et al., 2013). These challenges 
are consistent with those identified over the past decade (Bryce et al., 2005; Bhutta 
et al., 2010; Fischer-Walker et al., 2009).  In Zambia, and many other developing 
nations, the problem is compounded in rural areas, where the burden of diarrhea is 
often greatest. Here, the public sector struggles with last-mile  logistics for 
essential drugs. Delivery beyond district level warehouses to health facilities is 
40 
typically non-existent or unreliable (Yadav, 2015). Sparse populations, insufficient 
infrastructure, geographically disbursed health facilities, poor transportation 
infrastructure, inadequate resources for outreach (fuel, vehicles, etc.), and 
inaccessibility to certain areas during the rainy season are all contributing factors 
(Vledder M et al., 2015; MOH, 2011). In addition, medicine supply-chains within the 
public sector are often weakened by uncertainties in financing, long resupply 
intervals, a lack of continuous stock-out and consumption information for planning, 
and lack of incentives for supply-chain staff  (Yadav, 2015).  
Similar challenges have been reflected as top research priorities for childhood 
diarrhea. The key research theme identified as part of the Global Action Plan for 
Childhood Diarrhea, for example, was the need to substantially increase the delivery 
and use of ORS and zinc, as well as to identify those factors that supported and 
interfered with their proper use (Zipursky et al., 2013). Fischer-Walker and Black 
specify that knowledge is lacking with regard to the best delivery strategies and 
how to introduce zinc into health systems that already struggle with coverage of 
ORS (Fischer-Walker & Black, 2014).  
In rural Zambia, availability of ORS and zinc is largely limited to a reliance on 
public supply-chains. With few exceptions, access in these areas remains limited to 
often-distant health facilities alone. The Government s access policy states that there 
should be a health facility within 5km of every household. While this is indeed the 
case for 99% of urban households, it is only the case for 50% of rural households 
(Chankova and Sulzbach, 2006). Stock-outs of both ORS, and to a greater extent zinc, 
are commonplace at these rural health facilities. Analysis of recent Health Metrics 
and Evaluation (IHME) data (IHME, 2015) from Zambia found that 26% of rural 
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health facilities (RHFs) surveyed (n=432) reported having stock-outs of ORS within 
the previous year, while 32% reported having zinc stock outs. Nationally, 13% of 
RHFs surveyed were stocked out of ORS on the day of visit, while 55% were out of 
zinc. Data from the Essential Medicines Logistics Improvement Program (EMLIP) 
analyzed public sector stock for ORS and zinc in our intervention district of Kalomo 
(JSI, 2013).  They found that during our trial, ORS stock–outs varied from a high of 
78% of facilities in November 2012 to a low of 11% of facilities stocked-out in April 
2013. The period average was 35% of facilities stocked-out of ORS. With regard to 
zinc, none was supplied to Kalomo health centers from August - November 2012, or 
from April –June 2013. Even when zinc is available at health centers, negligible 
utilization rates would indicate healthcare workers rarely prescribe it.  
With only an estimated 59 retail pharmacies throughout the country 
concentrated in urban centers (40 of which are in Lusaka), and a small number of 
informal drug shops, there is very limited access to ORS or zinc through the private 
sector in rural parts of the country (Ballou Aares et al., 2008). However, the over-
the-counter (OTC) status afforded to these essential medicines in Zambia would 
allow them to be sold through private sector, community-level, general stores closer 
to the household level (Ramchandani, Paper 3).   
Few studies have been conducted to facilitate comparison of alternative 
delivery strategies for ORS and zinc uptake, and countries have few tangible 
examples around which they can build programs (Fischer-Walker, 2009). 
Regardless, the provision of low-osmolarity ORS and zinc through public sector 
clinics alone has not been an effective or lasting strategy in any country (Fischer-
Walker, 2009). Incorporating the private sector to strengthen supply chains (Gill, 
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2013; Fischer-Walker, 2009), and calls to learn from the private commercial sector 
specifically (Yadav, 2015; Ballou-Aares et al., 2008), have been suggested as 
promising ways of reaching additional segments of the population. Market-based 
solutions that simultaneously stimulate both supply and demand of these essential 
commodities, while supporting manufacturers and distributors, may help facilitate 
widespread availability (Gill et al., 2013). These ideas are central to the theory 
behind value-chains. 
While the concept of value-chains for healthcare delivery has been detailed 
elsewhere (Porter & Teisberg, 2006; Burns, 2002; Kim et al., 2013), it is worth 
discussing some of their key features here. The primary focus of value-chains is on the 
benefits that accrue to end users, the interdependent processes that generate value, and 
the resulting demand and flow of funds created (Feller et al., 2006). Value is generated 
when needs of the end user are met through provision of products or services, typically in 
the form of an exchange or transaction (Feller et al., 2006). Thus, value-chains result in 
collaborative partnerships between networked players engaged in economic 
exchange (Burns, 2002). Under this scenario, customers at the end of the value-
chain, perceiving a product as having value, pull product  to them. This generates 
both information for demand planning as well as value , which both flow back from 
the customer toward the manufacturer. This strengthens the chain and builds 
confidence of the players involved, while the product is pulled  to the end user. 
This means two things: that end users need to value the product (i.e. in a marketing 
sense); and they need to have value  in their hands to purchase the product (in an 
economic sense). In this way, effective value-chains generate profit (Feller et al., . Where cash availability is low, value  can be placed in the hands of end-users 
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through distribution of vouchers in order to stimulate, sustain and/or target the 
value-chain for particular populations. A systematic review of studies on voucher 
distribution for free or subsidized health goods found that health voucher programs 
have been successful in increasing utilization of health goods/services, targeting 
specific populations, and improving the quality of services (Meyer et al., 2011).  
Alternatively, traditional supply chain management as seen in most public 
health systems, starts with the manufacturer and pushes product  out, toward the 
end-user (Burns LR, 2002). Push systems are typically designed to work in instances 
where ordering and stock management capabilities at the lowest level of the 
distribution system are extremely weak (Yadav et al., 2011). This is a key difference 
between value-chains and supply-chains – they flow in opposite directions (Feller et 
al., 2006). Nonetheless, they represent complementary views of an extended 
enterprise with integrated business processes, which enable the flows of product in 
one direction, while value, as represented in terms of rapidly shifting tastes, 
preferences, demand, and cash-flow, moves in the opposite direction (Tan & Zailani, 
2009). In this way, the success of the supply-chain depends on the product and the 
value generated, and vice-versa (Gokhan et al., 2014). This type of systems 
perspective that uses customer, marketing and management requirements for 
product design, as well as information relating to suppliers and the value-chain as a 
whole, has the potential to transform the way we think about access to many public 
health products.  
While value-chain principles have commonly been applied to a multitude of 
commercial, fast-moving consumer goods (FMCGs), they have typically not been 
applied to access for essential public health products. FMCGs usually refer to non-
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durable products. Examples include beverages such as colas and juices, toiletries 
such as soap and toothpaste, and grocery items such as sugar and salt. From a 
consumer perspective, FMCGs are purchased frequently, are typically found to 
command high levels of brand loyalty, and are usually low-priced (Majumdar, 2004). 
They move in high volumes, command low margins, and consumers usually spend 
minimal effort in procuring them (Majumdar, 2004). Most importantly, the shelves 
of rural, community-level, commercial general stores in LMICs seem to be consistently 
full of them. We hypothesized that emulating the commercial, private-sector value-
chains of fast moving consumer goods (FMCGs), and applying lessons to the 
introduction of an innovative diarrhea treatment kit, would increase coverage of 
ORS and zinc at the community-level. Through a public-private partnership with a 
local pharmaceutical manufacturer and SAB Miller, The Coca-Cola Company s 
(TCCC) bottling partner in Zambia, and a range of local and international 
stakeholders, we emulated value-chain principals used by Coca-Cola. This included 
tapping into the same distribution channels that make FMCGs available in rural 
Zambian communities. The purpose of this study was to test the impact of this 
approach on uptake of ORS and zinc. 
Methods 
Study Design  
 
We tested our hypothesis using a quasi-experimental pretest-posttest design 
with matched comparators. The study was conducted across four, predominantly 
agrarian, rural districts of Zambia. Two districts served as intervention arms 
(Kalomo and Katete), and two served as comparators (Monze and Petauke). Each 
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intervention district had its own matched comparator (Kalomo with Monze in 
Southern Province, and Katete with Petauke in Eastern Province), giving two sets of 
intervention and comparator arms. Intervention districts were purposively selected 
based on a number of key criteria including being rural (i.e. distance from major 
centers), presence of mobile phone coverage, high diarrhea rates, logistical 
considerations (e.g. within a days drive of Lusaka), and the presence of a Coca-
Cola/SAB Miller wholesaler. Through a public-private partnership, SAB Miller 
provided a list of their key wholesalers across the country and agreed to facilitate 
introductions to those who aligned with our other selection criteria. As with Coca-
Cola, these wholesalers served as the sole district-level suppliers of the innovative 
diarrhea treatment kit introduced through the program. Thus, the intervention 
occurred at the district level in Kalomo and Katete. This helped to minimize external 
effects and cross-contamination with respect to ORS and zinc access. 
Comparators  
 
The two matched comparator districts – Monze and Petauke - did not receive 
the intervention and had status quo access to diarrhea treatment through public 
sector RHCs alone. Intervention and comparator districts were matched on a 
number of relevant criteria including being rural (i.e. distance from major centers), 
livelihoods (predominantly agrarian), language/tribe (Tonga in Southern Province; 
Chewa-Nyanja in Eastern Province), road intensity, diarrhea burden in children 
under 5, education levels, age distribution of caregivers, combination therapy 
coverage levels, and substantial consultation with local partners (e.g. UNICEF 
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Zambia, Keepers Zambia Foundation) who deemed them to be the best possible 
comparators for each respective intervention district.  
Intervention 
 
An end-to-end value chain was established in order to ensure a newly 
developed, co-packaged ORS and zinc commodity would be available via usual 
channels for FMCG, at the community level, in the two intervention districts. The 
ORS and zinc commodity was developed using a human-centered design approach 
and is covered in more detail elsewhere (Ramchandani, Paper 2). Pre-packaged as 
Kit Yamoyo®, the diarrhea treatment kit became available through independent, 
commercial, general retail shops across rural parts of the intervention districts. 
These retailers are described in more detail elsewhere (Ramchandani, Paper 3), and 
made up the final link in the value-chain before the product was sold to end-users.  
Distribution of the kit occurred via the same secondary channels that bring 
Coca-Cola and other FMCGs to outlying communities. This market eco-system 
consisted of existing networks of independent wholesalers (one per district town) 
and independent, general retailers (i.e. village shops) operating at the community-level across the last-mile  (Figure 2.1). Kits were transported from the 
pharmaceutical manufacturer in Lusaka to district level wholesalers by Medical 
Stores Limited (MSL), the same parastatal responsible for distributing drugs and other commodities to the district level for the public sector. The manufacturer s 
price, including delivery to wholesaler was 3100 Kwacha (~US 57 centsii) per kit. 
The wholesale price to retailers was 3700 Kwacha (~US 69 cents).  And the retail 
                                                        
ii At prevailing 2012-2013 exchange rate 
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price for caregivers was 5000 Kwacha (~US 93 cents). In this way, the 
manufacturer, wholesalers, and retailers all benefited from a profit incentive.  
The kit was subsidized at the top-end of the value-chain (manufacturer level) 
during the trial, but with a view to becoming commercially sustainable post-trial. A breakdown of the kit s costing during the trial, and since, is provided in Appendix 3. 
The retail price of 5000 Kwacha was established based on willingness-to-pay studies )Dinsight,  and in consultation with caregivers, and then the kit s 
value-chain was reverse engineered to ensure that a retail price at this level could 
sustain a profitable value-chain (i.e. price-minus-costing approach). 
In addition to developing a demand-driven product and engaging with the 
existing market eco-system for FMCGs, establishment of the value-chain also 
consisted of demand-generation activities. A social marketing campaign involving a 
cadre of community promoters, vouchers, radio spots, posters, liaison with RHCs 
and retailer training/para-skilling formed a core third component of the approach. 
In most cases, promoters were community health workers (CHWs) whose training 
through the Ministry of Health relating to product benefits (including those of ORS 
and zinc), as well as proper diarrhea treatment seeking behaviors more generally, 
were reinforced. Product-specific training was also provided.  
Approximately 30 promoters per intervention district ran awareness 
campaigns and demonstrations at the community-level.  Methods such as drama and 
testimonials from previous kit-users were used, usually during existing health-
related events including child health days. Content included the definition of 
diarrhea, common signs and stages of dehydration, indications for referral, benefits 
of ORS and zinc, as well as hand-washing and other preventive behaviors. While the 
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OTC product was designed to be self-sufficient, not requiring any attached service, 
retailers were also trained on similar content. Finally, radio spots (including a Kit 
Yamoyo jingle) covered similar material.  
The vouchers provided by promoters as part of the demand generation 
strategy covered the full value of the kits (figure 2.2). While they were only 
distributed during the first six months of the trial, they were redeemable 
throughout the pilot period. A total of 28,000 vouchers were distributed. Vouchers 
were used as a product launch and market preparation tool. They allowed 
caregivers to access kits at no cost from community-level retailers, and were 
implemented in order to catalyze rural market demand in a short period of time. In 
other words, they put value  in the hands of caregivers and helped create the pull  
required to trigger the value-chain. They could be exchanged for a kit by caregivers 
at the retailer level. Retailers were able to redeem the vouchers for the full value of 
the kit using their mobile phones (mobile money transfer) or by visiting the project 
office in the district town. They were required to purchase the kits from 
wholesalers. Kits were also available to caregivers for cash purchase throughout the 
study period.  
 
Trial End Point 
 
The highest-level outcome of the trial relates to coverage of ORS and zinc 
combination therapy. Coverage is defined as the proportion of children under age 
five with diarrhea in the previous two weeks who received zinc with ORS (DPWG, 
2014). Diarrhea was defined as experiencing three or more loose or watery stools 
during the previous 24 hours. Given that baseline figures for zinc use were less than 
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1%, we compared the difference in coverage proportions between each set of 
intervention and comparator arm at endline only. Use of ORS and zinc was 
operationalized based on the caregiver reporting that the child suffering from 
diarrhoea received both ORS and zinc. As defined, utilization was not necessarily 
based on effective/rational use, but any use at all. This is in line with global 
reporting standards. For example, if the child received any amount of zinc (not 
necessarily the full ten-day course), they were counted as having received zinc.  The 
end point was measured in a representative cross-sectional household survey 
conducted after program implementation. We also examined the difference in total 
ORS coverage (i.e. with or without zinc) between intervention and comparator 
districts at baseline and endline.  
Study Population, Sampling and Household Surveys 
Representative households surveys were administered to independent, 
cross-sectional samples of primary caregivers of children under-5 (the vast majority 
being mothers) from rural communities of Southern and Eastern Province, Zambia. 
Surveys were conducted at baseline in August of 2012, prior to the intervention, and 
at endline in August of 2013, after exactly one year of implementation.  
In each district, households were sampled from 12-15 rural sites. Sites were 
defined by the presence of a community-level retailer (or a cluster of retailers) at 
the center, and their 5 Km radius (A = 78.5km2). Retailers were identified during a 
pre-study survey that attempted to identify all retailers in the district 
(Ramchandani, Paper 3), as there was otherwise no accurate record of rural 
retailers or their locations. Identification of retailers was carried out in consultation 
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with key stakeholders including the District Planner in each district. This resulted in 
good geographic coverage of populated areas across the entire district (Figure 2.3), 
helping to reduce the potential for selection bias. The majority of identified retailers 
was recruited into the study, trained in product benefits and issues around diarrhea, 
and became Kit Yamoyo outlets after the baseline. Parts of the district within 10km 
of town ( urban centers ) were excluded. As a result, the baseline and endline 
samples were specifically representative of the rural population within the rural 
study districts. 
No information on the specific locations of households was available during 
the survey periods. Households were, therefore, selected using a modified random-
walk technique with probability proportional to population size within the site 
[based on Standard Enumeration Area (SEA) data from the Central Statistics Office 
(CSO)]  (Turner, 2003). A sampling interval of 3 was used to determine each 
successive household, after randomly selecting the first household along the 
perimeter of the site. Due to large distances between households in Southern 
Province, the interval was altered to 1 or 2 (where necessary). An interval of 3 was 
selected to avoid any potential clustering effects and selection bias, but was likely 
unnecessary given the large distances between some households in Southern 
Province. 
The primary caregivers selected for interview had to be at least 15 years of 
age. In those instances where there were multiple primary caregivers of children 
under-5 residing within a household, those who had a child with diarrhea in the 
previous 2 weeks were prioritized. If there were multiple caregivers that met these 
selection criteria, the caregiver sampled was selected alphabetically by first name. 
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The same sampling procedure was used in instances where the selected caregiver 
had multiple children under 5 with diarrhea in the two weeks preceding the survey.  
Only using a single reference child per household eliminated intra-household 
correlation. A two-week period was used in order to minimize recall bias and ensure 
comparability by aligning with the globally recognized indicator for coverage. 
Local enumerators from an external data collection agency, with previous 
survey experience, were trained by the project and administered all surveys 
(professionally translated) in the local language. Surveys typically took between 20 
and 60 minutes to complete, and were carried out over the course of three weeks. 
All surveys were carried out on Samsung tablets using Open Data Kit (ODK). 
Consistency checks and skips to avoid entry of erroneous data were automated in 
the electronic surveys. All data was crosschecked by trained field supervisors on a 
daily basis and then uploaded to a central server each evening. Uploaded data was 
then checked by a data specialist from the data collection agency for completeness 
and consistency, as well as coding of open-ended responses. In cases of 
inconsistency, missing responses, or other questions, the data specialist flagged 
them for discussion with supervisors and the principal investigator for any 
necessary follow-up with interviewers. Surveys measured the prevalence and 
treatment of diarrhea, demographic characteristics, as well as factors related to 
diarrhea treatment seeking by caregivers and use in children under-5. The 
questionnaire adapted and built upon the Toolkit for the Collection of Survey Data 
on the Correct Use of Pediatric Zinc as a Treatment for Diarrhea (MacDonald & 




Sample Size and Statistical Analysis 
 
The primary analysis of this study aimed to test whether emulating the 
commercial, private-sector value-chains of FMCGs like Coca-Cola, and applying 
lessons to the introduction of an innovative diarrhea treatment kit, would increase 
coverage of ORS and zinc in children under-5 with diarrhea. Secondary analysis 
looked at the effect of the intervention on total ORS coverage (with or without zinc). 
Given that there was no baseline information on zinc coverage (anecdotally it was 
known to be very low), an a priori sample size estimation was made prior to 
baseline in order to provide 80% power to detect a 20% difference in ORS use alone 
with a two-tailed alpha of 0.05. Assuming a 25% period prevalence of diarrhea 
during the high burden season (DHS, 2007; confirmed to be valid during baseline) 
and a baseline treatment level of 60% (DHS, 2007), the estimate was 548 
households with children under-5 per study arm. This was rounded up to 600 
households to account for the potential of a small design effect. Using ORS coverage 
as the basis for the sample size calculation ensured ample power for detecting a 
difference in our main outcome - combined use of ORS and zinc.  
Given that zinc coverage was <1% at baseline across all districts, evidence of the trial s success or failure was determined by the difference in ORS with zinc 
coverage between matched intervention and comparator districts at endline. The 
primary end point was calculated as the proportion of diarrhea cases within the 
previous two weeks treated with ORS plus zinc among children under-5, computed 
as a percentage for each district. The effect of the intervention is the difference in percent or delta  of ORS plus zinc treatment between each set of intervention and 
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comparator districts at endline. A pooled analysis was also conducted comparing 
coverage across both intervention districts vs. both comparator districts. We used a 
generalized linear model (GLM) with Poisson distribution to estimate relative risk of 
combined ORS and zinc use (Zou, 2004). Variances of beta coefficients are adjusted 
for within site correlation.  
In order to assess the impact of the program on total ORS coverage (with or 
without zinc), additional analysis compared pre and post-intervention levels of total 
ORS use using a difference-in-differences (DiD) analysis. Logistic regression with 
time (pre- vs. post-intervention), study arm (intervention vs. comparator) and their 
interaction was used to assess the odds ratios for total ORS use comparing 
intervention vs. comparator districts. The Wald test for the interaction term from 
this model shows whether there is a statistically significant difference between odds 
ratios in the intervention versus comparator districts (i.e. DiD analysis). A robust 
variance estimate was used to account for within-site correlation of outcomes 
(Gutierrez R & Drukker D.M., 2007).  
In addition, we present the DiD estimator for each set of intervention and 
comparator district, as well as a pooled analysis which compares outcomes across 
both intervention districts combined and both comparator districts combined. DiD 
estimation provides evidence of program effectiveness by comparing the changes in 
outcomes between baseline and endline in the intervention and comparison 
districts (Gertler et al., 2011). It can be used with quasi-experimental designs by 
analyzing independent cross-sections across time and using the change in outcomes 
for the comparison district as an appropriate counterfactual for the intervention 
district (Wooldridge JM, 2009).  This quasi-experimental setup permits isolation of 
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the effect of the overall approach by applying a DiD estimator. These estimators are 
categorized as within estimators because they rely on the assumption that any 
potential unobserved confounders are fixed with respect to time and identify impact 
based on variation in outcomes and exposure over time (Lance et al., 2014). One of 
the key advantages of the DID approach is that baseline characteristics, including 
levels of the outcome of interest, do not need to be comparable at baseline, as the 
method compares differences over time in the treatment group to those in the 
comparator (Buckley & Shang, 2003).  
Data on key social and demographic characteristics are also presented that 
show comparability of intervention and comparator districts over time (baseline vs. 
endline). All analyses were conducted using STATA version 13 (StataCorp, 2013).  
Ethical Approval and Consent 
Informed consent was obtained from all respondents prior to survey 
administration. In cases where the caregiver was under the age of majority, consent 
was sought from both the head of household and the caregiver themselves. Because 
this was a low-literacy population, the statement of consent was explained to the 
caregivers, who then provided signature (if possible) or made their mark using their 
finger and ink. Both national and district level government health administrations 
authorized the implementation of the study while community-level approval was 
obtained through local chiefs. Ethical approval for the study protocol was obtained 
from ERES Converge in Zambia, with approval for secondary analysis obtained 





A total of 2458 and 2477 households with children under age 5 were 
successfully surveyed across all four districts at baseline and endline, respectively. 
The survey verified comparability between intervention and comparator districts at 
baseline, with reference to a number of key variables related to diarrhea treatment 
including age and education of caregivers, perceived seriousness of diarrhea as a 
health concern for children under-5 at the community level, proportion of public 
sector access of ORS, household period prevalence in children under 5, and use of 
recommended treatments (Table 2.1). Almost all ORS access was from public sector 
sources in all districts. Use of zinc with ORS was less than 1% in all districts at 
baseline. While there was a statistically significant higher level of ORS use (with or 
without zinc) in Monze (62.9%) as opposed to Kalomo (48.7%) (p=0.007) prior to 
the intervention, the DiD approach used to assess the effect of the intervention on 
total ORS coverage in the second analysis accounts for this.  
Table 2.2 shows the difference between intervention and comparator 
districts at endline with regard to household prevalence of diarrhea, coverage levels 
of recommended treatments, and the proportion of caregivers who sourced ORS 
from the public sector. All other characteristics presented in Table 2.1 saw no 
significant change, except for mean distance to an ORS access point. Due to the shift 
in point of access from the public to the private sector (as demonstrated by the 
proportion of caregivers who obtained ORS from the public sector), the mean 
distance to access ORS decreased for those using Kit Yamoyo. This will be discussed 
further in a future paper.  
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With regard to point of access for ORS, there was a clear shift to the private 
sector, and specifically to use of Kit Yamoyo. The proportion of ORS users who 
obtained ORS from the public sector fell from close to 100% (Table 2.1) to 40.1% in 
Kalomo and 34.1% in Katete, while ORS continued to be sourced solely from the 
public sector in both comparator districts. This represents a significant shift from 
the public to private sector in the intervention districts of 60% in Kalomo and 56% 
in Katete. A decrease from baseline was seen in household prevalence of diarrhea 
across all districts as well, however there was no significant difference between the 
paired intervention and comparator districts.  
With regard to the primary analysis, there was a significant difference in the 
use of zinc with ORS at endline when comparing intervention and comparator 
districts. Both intervention districts saw significant increases in combination 
therapy use, to 46.9% in Kalomo and 46.3% in Katete, while utilization in 
comparator districts remained very low and similar to baseline levels (Table 2.2; 
Figure 2.4): 1.7% in Monze and 0.6% in Petauke. The unadjusted risk ratio for 
utilization of ORS with zinc comparing Kalomo to Monze was 27.0 (95% CI: 10.6-
69.1, p<0.001). The unadjusted risk ratio for utilization of ORS with zinc comparing 
Katete to Petauke was 75.2 (95% CI: 10.3-547.7, p<0.001). We also conducted a 
pooled analysis comparing intervention and comparator districts combined. The 
unadjusted risk ratio for utilization of ORS with zinc comparing the intervention 
districts to the comparators was 39.0 (95% CI: 13.2-115.2, p<0.001) (Table 2.3).  
The secondary analysis used a DiD approach to compare the change in total 
ORS use (with or without zinc) between baseline and endline in the intervention vs. 
comparison districts. Table 2.4 summarizes the difference-in-differences analysis 
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and shows the proportion of under-5 children who were given ORS in each district 
at both baseline and endline. It shows the differences between each set of matched 
intervention and comparator at pre and post periods, and provides the DiD 
estimator.   
The analysis indicates that the intervention was associated with a significant 
overall increase (i.e. from all sources) in use of ORS in the intervention district of 
Kalomo as compared to its comparator Monze, with a DID estimator of 40 
(p<0.001). Table 2.5 shows the odds of ORS use were 3.67 times higher (95% CI: 
1.77-7.61, p<0.001) in Kalomo than in Monze at endline, while they were 
significantly lower at baseline (OR=0.56, 95% CI: 0.37-0.85, p=0.006). The Wald test 
for the interaction term (time by study-arm) from this model (Table 2.5) verifies the 
significance of the estimator in table 2.4, and shows that there was a significant 
difference between the odds ratios in Kalomo vs. in Monze.  
With reference to the second intervention district and its comparator, the 
difference in differences analysis found a non-significant DiD estimator of 8.2 
(p=0.178) (Table 2.4). The odds of ORS use were not significantly different in Katete 
compared to Petauke at either baseline (OR=1.06; 95% CI: 0.74-1.52; p=0.749) nor 
at endline (OR=1.57; 95% CI: 0.78-3.15; p=0.208), with the proportion of ORS use 
staying relatively the same in Katete and dropping non-significantly in Petauke. ORS 
use was already relatively high at baseline in these districts and no major increase 
in ORS use was hypothesized, rather only a shift in point of access and toward use of 
the combination therapy.  
The overall pooled analysis comparing both intervention districts to both 
comparators shows a significant change in ORS use over time across the 
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intervention districts. Here too, the DiD estimator of 24.8 (p<0.001), is verified by 
the significance of the Wald test for the interaction term in this model (p<0.001) 
(Table 2.5).  
Within each district, the odds of ORS use comparing baseline to endline were 
only significantly greater in Kalomo post intervention (OR=4.71, 95% CI: 2.68-8.26, 
p<0.001), while the odds of use remained similar in Katete (OR=1.07, 95% CI: 0.65-
1.78, p=0.787), and decreased non-significantly in both comparators (Table 2.5).  
Programmatic data recorded approximately 26,000 Kit Yamoyo anti-diarrhea 
kits being sold by wholesalers to community-level retailers in the intervention 
districts over the one-year trial period. A breakdown of sales (voucher and cash-
based sales combined) from wholesaler to community-based retailers is provided in 




The application of business principles to global health is an evolving science. 
Our trial provides evidence that emulating the commercial, private-sector value-
chains of fast moving consumer goods (FMCGs), and applying lessons to the 
introduction of an innovative diarrhea treatment kit can result in a significant 
increase in coverage of ORS and zinc at the community-level. After a one-year study 
period, the coverage of this globally recommended combination therapy was 
several-fold higher in the intervention districts compared with the matched 
comparators at endline. The use of ORS (with or without zinc) was also found to be 
significantly higher in the intervention district of Kalomo after implementation, 
while it remained relatively stable in the intervention district of Katete, and reduced 
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non-significantly in the comparators. However, there was a significant shift in the 
source of the ORS used in the intervention districts from public to private sector.  
Additional findings reinforce and strengthen the plausibility that the 
intervention was responsible for the increase in proper treatment of childhood 
diarrhea. Use of zinc with ORS at baseline was less than 1% in both intervention and 
comparator districts. Use of this combination therapy increased significantly to 
~46% in both intervention districts relative to baseline, while coverage levels in 
both comparators remained relatively the same at negligible levels. At baseline, both 
sets of intervention and comparators were similar with reference to factors that 
may have influenced the outcome of the intervention, including caregiver age, 
education, perceived seriousness of diarrhea as a health concern for children under-
5, where they would typically access ORS, reported distance to a treatment access 
point, and period prevalence. Programmatic data also indicated that the amount of 
ORS and zinc delivered to the community level was commensurate with the 
observed effect size. This was also reflected in a shift in treatment source at endline 
(i.e. to the private sector), which corresponds to the coverage with Kit Yamoyo. 
There was no other source of zinc in the private sector throughout the trial period in 
project districts, and no other diarrhea-focused programs were active during the 
trial in any of the districts, other than the standard rural health center services. The 
latter was confirmed with District Medical Officers (DMO) in each district and 
through regular monitoring through a multi-organizational Steering Committee (i.e. 
those with interest in diarrhea treatment) chaired by the Ministry of Health.  
At its core, establishment of the value-chain for the Kit Yamoyo had three core 
pillars, including: 
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1. Development of a public health commodity, based on human-centered design 
(Ramchandani, Paper 2), concurrently with its supply-chain (i.e. 
simultaneous consideration of both supply and demand elements of access). 
 
2. Tapping into existing, local networks of private sector actors, including local 
manufacturers, district-level wholesalers and community-level, commercial, 
general retailers (Ramchandani, Paper 3) who made a profit from selling the 
product. 
 
3. Demand generation activities beyond the design of the product, including 
social marketing (radio, posters, community events, drama, testimonials, 
etc.), working with rural health centers including CHWs, training of retailers 
and reinforcement of training for promoters (i.e. often CHWs), and targeted 
distribution of vouchers (i.e. for the total value of the product). 
 
These were enabled by drawing on the best expertise and establishing 
partnerships across organizations and sectors to generate maximum value. In this 
way, the value-chain concept inherently addresses the core barriers identified for 
reducing childhood deaths from diarrhea - access, production, distribution and 
promotion  - by taking a systems approach (Gill et al., 2013).  
While the study design could not disaggregate which component of the model 
contributed the most to increased uptake, and which stand to be improved or 
removed altogether, this type of package of interventions  has a theoretical basis 
for being stronger than its component parts (Montagu D, 2002). Future research will 
attempt to disaggregate which components are necessary and which are sufficient. 
This, for example, might include comparing and contrasting the most cost-effective 
methods for generating (and sustaining) demand for a newly introduced health 
commodity into rural markets (e.g. vouchers vs. other mechanisms). However 
lending strength to previous recommendations (Gill et al., 2013), it is clear that 
simultaneous stimulation of supply and demand with coordinated marketing 
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campaigns, while supporting manufacturers and distributors, can indeed help to 
ensure widespread availability and use.  
Existing networks of private sector players (e.g. wholesalers, community-level 
retailers) can be leveraged and trained to provide access to basic health 
commodities at the community level. These secondary distribution channels, 
beyond the district towns, already exist and can help overcome distribution 
bottlenecks seen in the public sector. In the trial we contracted with Medical Stores 
Limited (MSL) on commercial terms to distribute the product to the district level. 
This function could have been fulfilled by one of many pharmaceutical distributors 
that operate between Lusaka and the district towns where the wholesalers were 
located. 
Introducing these complementary points of access to the public sector can serve 
to improve community case management of diarrhea at the household level. 
However, in order to assess progress/success in management of diarrhea, there is a 
need to go beyond ORS and zinc coverage data. Additional research is needed 
around the detailed and rational use of ORS and zinc at the household level. This 
would include factors such as whether ORS is prepared in the correct concentration 
(Ramchandani, Paper 2), whether it is consumed within the recommended 24 hour 
period, whether it is prepared with treated water, as well as the level of adherence 
to the 10-day zinc regimen. This should be considered an important part of the 
implementation and delivery science research agenda. In the same vein, other 
seemingly important elements of the model should be evaluated from a process 
perspective. With obvious implications for feasibility and sustainability, these 
include the quality of information/services provided by general, commercial 
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retailers, the role of project management/champions in catalyzing the value-chain, 
as well as consideration of enabling factors. Enabling factors that facilitated 
effectiveness of the value-chain intervention for Kit Yamoyo included such things as 
over-the-counter status of zinc, support of private-sector initiatives by national 
authorities, international recognition through awards and social media, and 
cooperation and capacity of local private sector manufacturers (especially if local 
production of products are emphasized). Gaining greater insight into the role such factors play in contributing to overall value of this type of total-market approach  
will be important for future adaptations.    
 
Limitations  
Limitations to the study are noted. For example, vouchers were distributed 
during the first half of the trial and caregivers were able to access kits at no cost 
while the value-chain was being established and fortified. Of the 26,000 kits sold, 
~21,000 were purchased with vouchers and ~5,000 with cash. Further research 
would be required to assess a market-driven approach without voucher-based 
incentives.  
Producers of FMCGs, such as Coca-Cola, commonly use vouchers and other 
promotional methods to stimulate market demand. Vouchers helped provide 
retailers with the confidence to purchase the new kits from wholesalers and bring 
them into their communities. It also allowed caregivers to try a new product without 
having to pay for it. In addition, the perceived commercial risk associated with 
entering the market for often low-cost public health products can deter potential 
manufacturers. Vouchers can effectively be used to entice new entrants by building 
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market demand and allowing the product to gain traction. Vouchers do this without 
distorting the value-chain. Rather, they strengthen it by putting value in the hands of 
the customer. This has the effect of strengthening existing distribution systems 
rather than undermining them. Public funds can be impactful in facilitating these 
types of market-shaping initiatives, as well as the associated research and 
development that is necessary, prior to transferring full ownership of the value-
chain over to the private sector for long-term sustainability. Our objective was to 
test whether emulating the value-chains of FMCGs, and applying the lessons to a 
diarrhea treatment kit would increase coverage of ORS and zinc. We were successful 
in this endeavor.  
While a cluster randomized trial would be considered the gold standard 
design for such a trial, random allocation of the districts to intervention or 
comparator was deemed to be in contention with the free market aspects of the 
value-chain we were attempting to test. As such, the selection of districts for the 
study was purposeful and therefore may not be completely representative of all 
rural areas of the country, however, as in any business transaction, the willingness, 
interest, accountability and level of engagement of the independent, private 
wholesalers all play an important role. While this has implications for external 
validity, it would inevitably be an important consideration in any potential scale-up 
scenario. In addition, with only two intervention districts and two comparator 
districts, randomly allocating the intervention would have added little statistical 
advantage and claiming true randomization would have been somewhat arbitrary. 
With an ever-expanding focus on health market interventions (i.e. inherently not 
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congruent with control), the feasibility and appropriateness of RCTs for assessing 
these types of interventions should be considered.  
Intensity of promotion differed by intervention district. In the six-month 
period from April to September of 2013, 1195 events were conducted by promoters, 
of which 68% were in Kalomo and 32% were in Katete (this programmatic output-
level data was not gathered prior to April 2013). While Katete started out stronger, 
in the long run, Kalomo field staff ended up being more effective both in terms of 
messaging and post-March 2013 sales (Appendix 4), after voucher distribution 
stopped. This may account for some of the variability in effect seen in the two 
intervention districts, particularly with regard to ORS use with or without zinc, 
which increased in Kalomo while remaining relatively constant in Katete.  
While an impact on household prevalence of diarrhea was not hypothesized 
for this one-year intervention, a drop was found across all four districts (Table 2.1 & 
2.2). Within each district, household prevalence decreased significantly from 
baseline to endline in both of the intervention districts of Kalomo (OR: 0.68, 
p=0.001) and Katete (OR: 0.69; p=0.002), as well as in Petauke (OR: 0.45; p<0.001). 
It did not decrease significantly in Monze (OR: 0.86; p=0.238). Given that drops in 
prevalence were seen in both intervention districts, as well as in comparators (the 
largest taking place in Petauke), it is unlikely that the observed difference was due 
to the intervention. Although some decrease in the intervention districts may be 
possible due to the short-term protective effect (from re-infection) conferred by 
zinc, given the drop seen across all districts, it is more likely attributable to seasonal 
shifts which can occur from one year to the next. Baseline data collection took place 
during a particularly dry August during which many communities were facing 
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drought. Studies focused on sub-Saharan Africa have demonstrated that when water 
is scarce the prevalence of diarrhoea (non-cholera) increases due to consumption of 
unsafe water and poorer hygiene practices (Bandyopadhyay et al., 2011; Fewtrell et 
al. 2005). This may be one possible explanation for the difference in household 
prevalence between August of 2012 and 2013.  
Our intervention proved feasible in multiple rural communities in two 
distinct geographic areas (Southern and Eastern Provinces) of Zambia. Given that a 
large proportion of the country is rural, we project that gains observed in our study 
could translate to subnational reductions in childhood morbidity and mortality, 
particularly if efforts are made to increase and sustain uptake. Previous research 
has also demonstrated that optimal treatment with ORS and zinc, as facilitated by 
our innovative kit design (Ramchandani, Paper 2), is associated with reductions in 
inappropriate use of antibiotics and intravenous fluids for diarrhea (Habib, 2013; 
Das, 2013; Fischer Walker et al, 2011; Borapich et al, 2010; Santosham et al, 2010). 
Estimates have shown that if the combination therapy of ORS and zinc achieved 
universal coverage, 75% of diarrheal deaths could be averted (Gill 2013, Jones 
2003), which in 2013 would have reduced overall childhood mortality by 7%. 
Implementation of a value-chain approach for over-the-counter public health 
products, like a diarrhea treatment kit, can significantly improve coverage at the 
community level. Aside from measuring the impact of a market-based intervention 
on a priority child health outcome, this study will help inform future interventions 
and policy initiatives for this priority childhood disease. Ensuring community-level 
access of ORS and zinc within multiple sectors of the health system will contribute 
to achieving universal health coverage and in reducing global childhood mortality.  
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Figures for Chapter 2 
 
 
FIGURE 2:1: THE KIT YAMOYO VALUE-CHAIN (SOURCE: COLALIFE) 
 

























FIGURE 2:3: STUDY DISTRICTS AND SITE MAPS 
 
  
FIGURE 2:4 COVERAGE OF RECOMMENDED TREATMENTS, BASELINE VS. ENDLINE, 
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Tables for Chapter 2 
 
TABLE 2.1: CHARACTERISTICS OF INTERVENTION (KALOMO & KATETE) AND 
COMPARATOR DISTRICTS (MONZE & PETAUKE, RESPECTIVELY), 2012 
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*p-values are for the unadjusted odds ratio comparing matched districts and account for within site 
correlation of outcomes for proportions and t-tests for difference in matched districts for means. 
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TABLE 2.2: COVERAGE IN INTERVENTION (KALOMO & KATETE) VS. COMPARATOR 
DISTRICTS (MONZE & PETAUKE, RESPECTIVELY) AT ENDLINE, 2013 
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TABLE 2.3: RISK RATIO FOR UTILIZING ORS WITH ZINC IN INTERVENTION (KALOMO & 
KATETE) VS. COMPARATOR DISTRICTS (MONZE & PETAUKE, RESPECTIVELY) AT 
ENDLINE, 2013 







Kalomo (intervention) vs. 
Monze  (comparator) 
(n=348) 
27.0 (10.6-69.1) 0.000 
   
Katete (intervention) vs. 
Petauke (comparator) 
(n=356) 
75.2 (10.3-547.7) 0.000 
   
Intervention vs. 
Comparator (Pooled) 
39.0 (13.2-115.2) 0.000 
aGeneralized Linear Model with Poisson distribution to estimate relative risk;  Adjused for within site 




TABLE 2.4: DIFFERENCE IN DIFFERENCES ANALYSIS FOR EFFECT OF EMULATING 
PRIVATE SECTOR VALUE-CHAINS ON UTILIZATION OF ORS (WITH OR WITHOUT ZINC), 
RURAL ZAMBIA, 2012-2013 
 Baseline Endline Difference DID p-value 
Intervention (Kalomo) 48.7 81.1 32.4   
Comparator (Monze) 62.9 54.9 -8.0   
Difference -14.2** 26.2***  40.4 0.000*** 
Intervention (Katete) 70.2 71.1 0.9   
Comparator (Petauke) 69.0 61.7 -7.3   
Difference 1.2 9.4*  8.2 0.178 
Intervention (Pooled) 59.8 76.4 16.6   
Comparator (Pooled) 66.4 58.2 -8.2   
Difference -6.6* 18.2***  24.8 0.000*** 
p-values are for the Wald test based on linear regression. 
***p <0.001, **p<0.01, *p<0.05 
 
 
TABLE 2.5: IMPACT OF EMULATING PRIVATE SECTOR VALUE-CHAINS: DIFFERENCE 
AND CHANGE IN USE OF ORS AMONG INTERVENTION AND COMPARATOR 
HOUSEHOLDS, RURAL ZAMBIA, 2012-2013 





Intervention (Kalomo) vs. Comparator (Monze) at Baseline  0.56 (0.37 – 0.85) 0.006 
Intervention (Kalomo) vs. Comparator (Monze) at Endline  3.67 (1.77-7.61) 0.000 
Intervention (Kalomo) Endline vs. Baseline  4.71 (2.68-8.26)  0.000 
Comparator (Monze) Endline vs. Baseline  0.72 (0.43-1.19) 0.200 
Time by Study-Arm Interaction 6.55 (2.96-14.49) 0.000 
   
Intervention (Katete) vs. Comparator (Petauke) at Baseline  1.06 (0.74-1.52) 0.749 
Intervention (Katete) vs. Comparator (Petauke) at Endline  1.57 (0.78-3.15) 0.208 
Intervention (Katete) Endline vs. Baseline  1.07 (0.65-1.78) 0.787 
Comparator (Petauke) Endline vs. Baseline  0.73 (0.46-1.15) 0.173 
Time by Study-Arm Interaction 1.48 (0.69-3.17) 0.317 
   
Pooled Intervention vs. Comparator at Baseline 0.75 (0.57-0.99) 0.049 
Pooled Intervention vs. Comparator at Endline 2.33 (1.36-3.98) 0.002 
Pooled Intervention (Endline vs. Baseline) 2.17 (1.47-3.24) 0.000 
Pooled Comparators (Endline vs. Baseline) 0.71 (0.48-1.04) 0.080 
Time by Study-Arm Interaction 3.09 (1.64-5.81) 0.000 
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Chapter 3 - Product Innovation and Human-Centered Design for 
Global Health Delivery: Improving Effective Use of Oral 
Rehydration Salts Through the Introduction of an Innovative 
Diarrhea Treatment Kit 
Abstract 
 
A recent focus on affordability and supply has dominated discussions of access 
to medicines. A more balanced consideration of established dimensions of access, 
including acceptability and its associated demand-related factors, may lead to 
improved global health delivery. This study aimed to explore whether greater 
consideration of human-centered design – through a focus on product-oriented, 
demand-related dimensions of access - can lead to improved product innovation, 
appropriate utilization (i.e. rational use) and perceived efficacy of public health 
commodities such as Oral Rehydration Salts (ORS). Using ColaLife s innovative 
diarrhea treatment kit - the Kit Yamoyo - as a basis, we tested whether an increased 
focus on the acceptability dimension of access and its related components could 
contribute towards increased odds of appropriate use of ORS.  
Having followed the phases of an HCD approach – Hear, Create, Deliver – 
design decisions focused on improving the acceptability and demand of the diarrhea 
treatment kit were made.   Cross-sectional data collected from household surveys of 
caregivers in rural Zambia was then used to compare ORS use in diarrhea patients 
under age 5, who either used Kit Yamoyo or standard one-liter sachets of ORS from 
rural health centers.  
With regard to preparation of ORS in the correct concentration, there was a 
significant difference between those who used the Kit Yamoyo, developed through a 
human-centered design approach, as compared to those who used standard one-
liter ORS sachets from the health center. Odds of correct ORS preparation were 
found to be 10.93 times greater (p<0.001; 95% CI: 5.74-20.78) in Kit Yamoyo users 
vs. those that used 1-liter sachets from the health center. Kit users prepared the ORS 
in the correct concentration 93% (95% CI: 0.89-0.96) of the time, while non-users 
prepared it in the correct concentration only 60% (95% CI: 0.54-0.66) of the time. 
Secondary analysis found preparation of ORS in the correct concentration to be 
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significantly associated with an increase in the odds of perceiving ORS as effective 
(OR: 1.84, 95% CI: 1.05-3.23, p<0.05), along with having heard a message related to 
ORS in the previous 3 months (OR: 3.77, 95% CI: 1.72-8.26, p=0.001). Correct 
preparation was also significantly associated with a decrease in the odds of caregiver s perceiving ORS as effective with each additional year of age (OR: 0.98, 
95% CI: 0.96-0.99, p<0.05).  
Our findings suggest that a focus on human-centered design and greater 
consideration of demand-related factors of access, such as acceptability, can lead to 
improved product innovation and appropriate utilization. This in turn, has the 
potential to lead to improvements in perceived efficacy of public health 
commodities. Our findings have implications for how ORS coverage is measured 
globally, and indicate that coverage levels cited in DHS and other large surveys may 
actually be much lower when considered from the perspective of whether the ORS 
was used correctly. This perspective considers something as being delivered  only 
once it has been used correctly, and not merely used. Related to this, our findings 
also cast some doubt on the appropriateness of one-liter sachets of ORS for home 




Access and Delivery 
 
Previous research has shown that over 60% of childhood mortality could be 
prevented with full access to existing, often low-cost solutions (Jones et al, 2003).  
Catalyzed by this revelation, and in order to address existing implementation gaps, 
the global health community has seen the recent emergence of global health 
delivery and implementation science as an area of practice and research (Kim et al, 
2013; Yamey G, 2012). This emerging discipline draws on many areas of expertise, 
combines multi-sectoral approaches, and considers the complexities involved in 
delivering health services in effective, efficient, and equitable ways towards scale.  
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Central to global health delivery is the concept of access. Common 
dimensions covered in existing access to medicines frameworks include variations 
of availability, affordability, geographic accessibility, acceptability, adoption and 
rational use (Table 3.1) (Bigdeli et al, 2012). Due consideration must be given to 
both the supply and demand side factors of access under any global health delivery 
framework. However, while demand-related factors have inherently been a core 
tenet of commercial business approaches (i.e. based on competition, shifting 
preferences and user demand), the development community has placed greater 
emphasis on perceived need , with predominant focus given to affordability and 
other supply-related dimensions of access (Jacobs et al, 2011; Yamey G, 2012). 
When it comes to research around these topics, Kim et al. note, When assessments 
of delivery do occur, they are often narrow studies of the cost-effectiveness of a 
single intervention rather than the complex set of them required to deliver value to 
patients and their families  (Kim et al, 2013). 
In many developing nations, delivery through public health services alone 
has not met the access needs of the poor. This has led to the emergence of markets 
in response to demands for services and drugs (Bloom et al., 2011). Recent 
increased attention on the role of health markets (Bennett et al., 2014) has been 
accompanied by an interest in market-based approaches to improving health 
delivery, including access to public health commodities (Bloom et al., 2011). With 
demand being a key driver of markets, this should reinvigorate consideration of 
demand-related dimensions of access such as acceptability, adoption, and rational 
use of products of global health significance.   
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Traditional access to medicines frameworks (WHO/MSH, 2000) identify two 
determinants of acceptability. The first relates to the actual characteristics of a 
product or service, while the second focuses on the attitudes and expectations of the 
user towards a particular product or service. Through a focus on design, these 
dimensions can be used to facilitate rational use of medicines including rational 
therapeutic choices and improved use of medicines by the consumer. These factors 
play an important role in the widespread adoption of the product by end-users and 
markets more generally. This can be further understood when examining similar 
principals covered in human-centered design.  
 
Access and Human-Centered Design 
 
IDEO, the leading San Francisco based innovation and design firm, defines 
human-centered design as innovation inspired by people . They describe it as a 
process and set of methods used to create new solutions including products, 
services, spaces and systems (IDEO, 2011). Design Thinking incorporates end-user 
insights and rapid prototyping to move beyond assumptions. It is inherently 
optimistic, collaborative, empathetic, experimental and experiential, addressing the needs of the product s consumer and its enabling infrastructure (Brown & Wyatt, 
2010). According to IDEO, key phases in the process include: 
 
 Hear – understand needs, desires, aspirations, barriers and constraints of 
target end-users using qualitative methods; synthesize patterns/themes 
 Create –recognize existing knowledge; identify opportunities for innovation; 
brainstorm solutions with the end user s desirability filter in mind; 
participatory co-design & prototyping; gather feedback 
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 Deliver – identify capabilities required to deliver; create financial model for 
sustainability; plan pilot and measure impact 
 
While design thinking has traditionally been employed in the business sector, it 
has clear applications in improving access to global health solutions. Indeed, it is 
increasingly being employed in the area of social innovation and its principles have 
been touched on in the literature relating to access at the bottom of the pyramid 
(BoP) (Prahalad, 2005; Rahman et al., 2014). Prahalad, for example, stressed the 
need to partner with the poor to innovate and achieve sustainable win-win 
scenarios where the poor are actively engaged . This co-creation is an essential 
element of human-centered design and crucial to understanding and creating user-
demand.  
Solutions that emerge through human-centered design processes, result from a 
framework consisting of three lenses: desirability, feasibility, and viability (IDEO, 
2011). As with more traditional access frameworks familiar to public health 
practitioners, these lenses reflect both supply and demand related dimensions, with 
desirability being central to demand. Desirability refers simply to what people want. 
Product desirability, more specifically is defined as the level of desire to consume 
the product if price is not a consideration  (Garbarino et al, 2003). Based on 
literature review and case studies, Moultrie and colleagues (Moultrie et al, 2006) 
identify several good design  features that influence product desirability. Linking 
these to the desirability lens of human-centered design and the acceptability 
dimension of Access to Medicines Frameworks, product desirability can be thought 
of as a function of:  
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 Usability – ease of use; ability to be maintained/cleaned; clarity of the 
interface (cognitive usability); physical usability (size, shape). 
 Core benefits - underlying need for the product; degree of functionality; 
availability of alternative solutions & perceived value/utility.  
 Aesthetics and sensory appeal – visual novelty, colors, taste, graphics, 
material. 
 Symbolic value - pride of ownership; status; emotional response evoked. 
 Visual clarity – clear brand identity; clear purpose; consistent with expected 
values (e.g. caring, responsible, tough, fun, etc.). 
 Product novelty & differentiation – differentiation of aforementioned factors 
when compared to similar products that are available; relative advantage 
 
Using ColaLife s innovative diarrhea treatment kit - the Kit Yamoyo - as a basis, 
we tested whether addressing demand-oriented factors on the supply-side could 
contribute towards increased rational use of ORS on the demand-side. In this way, 
this study aimed to explore whether greater consideration of human-centered 
design – through a focus on product-oriented, demand-related dimensions of access 
- can lead to improved product innovation, appropriate utilization and perceived 
efficacy of public health commodities such as Oral Rehydration Salts (ORS).  
The remainder of the introduction presents insights from the first phase of the (CD process i.e. (ear . The Methods section then presents the product-
development process from the Create  phase (i.e. presented as the Intervention) as 
well as how impact on rational use and perceived ORS-effectiveness was measured 
using cross-sectional household surveys i.e. part of the Deliver  phase of (CD . This 
is followed by the results of the study which focus on the impact of the kit on 
82 
rational use and perceived efficacy of ORS. While the decisions relating to the design of the diarrhea treatment kit could also be considered results , they are 
incorporated into the Methods section as part of the Intervention description. This decision was made due in part to the design choices being integral to the Create  
phase of HCD, and their centrality to the intervention (i.e. the kit), hypothesized to 
improve rational use and perceived efficacy of ORS. This decision also helped to 
facilitate greater clarity and flow.  
 
The Need For Improving Access To Diarrhea Treatment 
 
Globally, diarrhea is the second leading infectious cause of childhood 
mortality (Liu et al, 2015), with approximately 600,000 children under age 5 losing 
their lives to this largely preventable disease each year (UNICEF, 2013). These 
deaths occur within the context of the global health community being fully aware of 
the treatment needed to successfully manage the vast majority of uncomplicated 
diarrhea cases. Low-osmolarity Oral Rehydration Salts (ORS) and Zinc 
supplementation for 10-14 days are safe and effective in both home and facility 
settings when properly prepared and administered (Awasthi S, 2006; Bhandari N et 
al, 2008). Together, these medicines make up the globally recommended treatment 
for diarrhoea, which has been in place for more than 10 years (WHO/UNICEF, 
2004). ORS has been shown to remedy more than 90% of dehydration from 
diarrhea (Claeson M et al., 1990). Low-osmolarity ORS more specifically, has been 
shown to reduce stool output, vomiting, as well as the need for unscheduled 
intravenous treatment (Hahn S et al., 2002). In a review of 205 studies, use of ORS 
was found to have reduced diarrhea specific mortality by 69% and rates of 
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treatment failure by 0.2% (Munos MK et al., 2010).  
Zinc supplementation as an adjunct therapy, has been shown to decrease the 
severity and duration of diarrhea, as well as provide subsequent protection from 
recurrence in the 2-3 months following treatment (Bhutta ZA, et al, 2000; Strand TA, 
et al., 2002; Chandyo RK et al. 2002; Lazzerini M et al., 2008). A review of 13 studies 
exploring zinc supplementation for diarrhea found that zinc administration was 
associated with a 46% significant reduction in all cause mortality and a 23% 
reduction in diarrhea-related hospital admissions (Fischer-Walker CL et al., 2010). 
Taken together, ORS and zinc can reduce both morbidity and mortality 
(Fischer-Walker et al., 2009; Fischer-Walker et al., 2010; Munos et al., 2010; 
Bhandari et al., 2008; Fischer-Walker et al., 2011; Baqui et al., 2002; Bhutta et al., 
2013). Estimates have shown that more than 75% of all diarrhea deaths could be 
averted with full coverage and utilization of zinc and ORS (Jones G et al., 2003). 
Nonetheless, of those children with acute diarrhea, less than 1% receives zinc and 
only a third receive ORS globally (Gill 2013; UNICEF, 2012). A 2015 report on 
Scaling Up Life-Saving Commodities for Women, Children, and Newborns identified 
low demand and effective use by caregivers as key barriers to improving access to 
ORS and zinc (Kade et al., 2015). 
With reference to effective use, while coverage estimates of ORS and zinc are 
typically derived from reported levels of usage from household surveys (e.g. DHS, 
MICS, etc.), they do not provide an indication of whether the medicines are actually 
being prepared or administered correctly (i.e. rational use). Global estimates find 
that up to 50% of medicines are used incorrectly by patients (WHO, 2004). With 
reference to ORS more specifically, few published studies have explored whether it 
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is prepared correctly at the household level. The majority of studies that do exist 
were conducted in the early 90s and prior.  
Barros et al. found that 44% of caregivers used less than 800ml of water (i.e. 
56% used a sufficient amount) when preparing a sachet that should have been 
diluted in 1 liter of water (Barros et al., 1991). Only 69% of ORS users in that study 
used the entire sachet. One study in Nigeria reported that only 62% of users at the 
household level correctly described how to prepare ORS (Charyeva et al., 2015). 
Another unpublished study from Haiti found that only 40% of ORS users were able 
to correctly describe how to prepare it (Ward, 1985). A final study from Indonesia 
demonstrated that 59-69% of caregivers who administered ORS to their children 
under-2 were able to correctly prepare it (Pulungish, 1992). Caregivers have 
regularly noted a lack of confidence in administering ORS without health provider 
consultation, often rooted in uncertainty around preparation and etiology of 
diarrhea (Blum et al., 2011).  
Inaccuracies in home-mixing of solutions can lead to electrolyte imbalances 
like hypernatremia (Fayad et al., 1992). According to Nalin et al., failure to ensure 
correct solution preparation, concentration, and appropriate drinking volumes can 
lead to electrolyte imbalance, whatever the formulation  (Nalin et al., 2004). This 
incorrect dilution can result in either high or low concentrations of sodium and 
glucose, which in turn, decrease the effectiveness of oral rehydration therapy for the 
treatment of dehydration of acute diarrhea (Pulungsih, 1992; Snyder, 1992).  
In supporting a recommendation to prioritize use of ORS over home-
prepared sugar-salt-solution (SSS), Bhutta et al. (2013) note that due to variability 
in the quality and concentrations of ingredients, and risks of electrolyte 
85 
abnormalities in children with severe diarrhoea, the majority of SSS programs have 
been abandoned. They also cite the fact that many children still have three episodes 
of diarrhea per year, and that this should stress the need for treatments of proven 
effectiveness rather than solutions prepared  haphazardly  at home. While the 
proportion of solutions prepared correctly using ORS is certainly greater than with 
SSS (Barros, 1991), there is a need to ensure it is consistently prepared correctly, as 
this too has an influence on demand. While there is evidence that inaccuracies in 
home-preparation of ORS can be reversed with proper education and health 
promotion (Fayad et al., 1992), a more fail-safe strategy would be to also ensure 
inclusion of the tools necessary for proper health behavior (i.e. correct dilution). 
With this in mind, it is also worth understanding the history behind the 
development of ORS.  
 
History of ORS 
ORS, or the discovery of sodium-glucose transport more specifically (the 
basis for the development of ORS), has been hailed as the most important medical 
advancement of the 20th century (Lancet, 1978). While seeking out a therapy that 
could be applied in the field, far away from hospitals and intravenous treatment, 
scientists conducted much of the early research around ORS within the context of 
cholera epidemics in the late 1960s and early 70s. However, it was only in the late 
1970s that cholera ceased being the primary target for rehydration research. In 
1978, the WHO recognized that in non-epidemic seasons, cholera only accounted for 
less than 5-10% of all acute diarrheas in cholera endemic areas (WHO, 1978). That same year, the Advisory Group for the W(O s Control of Diarrheal Diseases (CDD) 
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program met in Geneva to study tactics that could be leveraged in the global fight 
against diarrhea. By the time the CDD program was fully operational in 1980, the 
standard formula for ORS had already been determined at the 1978 meeting based 
on the research available at that time (WHO, 1999).  
The investigators behind those studies believed that the oral solution should 
consist of one universal form and quantity to facilitate use by untrained villagers 
and health care workers under very basic conditions. They therefore decided on an 
arbitrary amount, one litre, and hoped for success  (Ruxin, 1994). In terms of the 
original formulation of ORS, in order to address implementation challenges and 
develop a single formulation and packaging for global use in both cholera and non-
cholera situations, the WHO struck a compromise between the ideal solutions for 
cholera and non-cholera-related diarrhea (Nalin et al., 2004). Aside from the switch 
to low-osmolarity ORS in 2004, it is largely this legacy that has shaped guidelines 
around the non-formulaic aspects (e.g. packaging and quantity) of ORS 
manufacturing to this day, with one-liter sachets being the norm. Understandably, 
the focus at that time was on the primacy of the pharmacodynamics behind ORS. 
The original development of ORS was, therefore, based largely on medical need with 
less consideration being given to demand-related factors of the consumer. This was 
made clear when speaking to caregivers of children under-5 in rural Zambia during the (ear  phase of the human-centered design approach.  
 
Human-Centered Design in Practice: Key Themes from the HCD Hear  Phase Prior to implementation, a key component of the (CD hear  phase involved a 
series of eight focus group discussions with caregivers of children under-5 in rural 
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Zambia. The specific methodology followed has been captured in more detail 
elsewhere (Pratt et al., 2012). In short, 82 caregivers from remote rural areas of 
Katete and Kalomo districts participated in consumer consultations. Focus groups 
ranged in size from 9 to 12 participants. Qualitative information was gathered to 
understand challenges faced by caregivers with regard to appropriately treating 
diarrhea in children under 5. In addition, feedback was solicited on an early 
prototype of the co-packaged diarrhea treatment kit (DTK) under development for 
the project.  
Key themes emerging from the focus group discussions are discussed further 
in the methods section and included:  
1. Challenges with preparing the standard-issue 1L sachet of ORS from the 
health centers at the household level; 
2. Taste of the ORS obtained from the health centers;  
3. Preferences relating to branding and kit components; 
4. Willingness to pay (WTP) for a commercially available ORS and zinc product;  
5. Long distances to public sector treatment access points; and 
6. Regular stock-outs at public sector rural health centers  
 
This paper focuses on the demand-driven themes that helped inform product 
innovation (1-3), while a parallel paper addresses supply-oriented themes 5 and 6. 
Cost effectiveness and WTP (4) will be discussed in a future paper. In this way, other key components of the deliver  phase are covered elsewhere Ramchandani, Paper 
1). By addressing these supply and demand related themes, our intervention 
recognized the need for a multi-pronged systems approach; one that acknowledges 
the complexity of health markets by placing value on optimization of product and 
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supply chain design decisions simultaneously. This approach – referred to as Design 
for Supply Chain (DFSC) – builds on the principle that the success of the supply-
chain depends on the product and vice-versa. While the literature shows that 
modeling smaller supply chain sub-problems has been the norm, it also shows that 
handling these sub-problems separately leads to suboptimal solutions due to a high 
degree of interdependency (Gokhan et al., 2014). DFSC uses customer, marketing 
and management requirements for product design, as well as information relating 
to suppliers and the value-chain as a whole. In industry, this approach has been 
shown to maximize profit, and also helps reduce the iterations a product design 
team would go through in order to achieve a successful design, thereby reducing 
time-to-market (Gokhan et al., 2014).  
Building on insights from the hear  phase of the HCD process, this study sought 
to explore whether greater consideration of human-centered design and product-
oriented, demand-related dimensions of access could lead to improved product 
innovation, appropriate utilization and perceived efficacy of public health 




The Kit Yamoyo® diarrhea treatment kit (Figure 3.1) was developed using a 
human-centered design approach that closely considered product-oriented, 
demand-related dimensions of access. In short, it sought to deliver what caregivers 
want not what we perceive they need. This innovative DTK formed the basis of the 
intervention in this study. Building on themes from focus group discussions 
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conducted during the hear phase , as well as existing knowledge found in academic 
literature, the kit and its various design considerations are elaborated upon below. 
While the resulting outcomes of this study (i.e. rational use and perceived 
effectiveness) relate directly to the first set of desirability considerations below, we 
also present the other responsive design features incorporated based the 
desirability lens of HCD. How the Kit was introduced at the community level and its 
effect on overall uptake of ORS and zinc is the subject of separate studies 
(Ramchandani, Paper 1; Ramchandani, Paper 3). 
 
Usability, Core Benefits and the Challenge of the One-Liter ORS Sachet 
Two key challenges associated with the standard issue one-liter ORS sachets 
from health centers  (e.g. Government of the Republic of Zambia – GRZ), for home 
treatment of diarrhea, were highlighted during the focus group discussions. First, 
caregivers had no standard way of measuring a liter of water. Different household 
containers were typically used, ranging from beer bottles to teacups to local 
beverage containers. This creates the risk of preparing a solution that is either too 
concentrated or too diluted. To address this challenge, we developed the diarrhea 
treatment kit such that the packaging/container that held the components doubled 
as a measurement vessel to facilitate proper preparation, mixing and drinking of the 
ORS.  
The second challenge relates to the quantity of ORS prepared with a 1-Liter 
sachet. A Liter of ORS solution is much more than the average 400ml of ORS a child 
under-5 typically consumes in a day (Fontaine, 2012; Touchette et al., 1990; Barros 
et al., 1991). While perhaps appropriate for health facility settings, a 1L sachet is 
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inappropriate for home use as, on average, more solution will be discarded after 
24hrs (~600 mL) than will be consumed by the child (~400 mL). The problem is 
often amplified in rural settings where accessing water and making it safe for 
drinking is a challenge. The burden of collecting household water supply, for 
example, often falls to women and young girls who may walk up to 6km per day in 
search of water, spending as much as eight hours collecting it (Interagency Task 
Force on Gender and Water, 2005). This in turn, can prevent them from 
participating in income-generating activities or attending school. In such 
circumstances, preparing more ORS solution than is necessary is misaligned with 
household-level realities. Additionally, once ORS is prepared, WHO guidelines 
(WHO, 2006) dictate that the solution should be discarded within 24 hours due to 
increased risk of contamination (Black R et al., 1981; Mathur & Reddy, 1983; 
Nagarajan et al., 1990; Adhikari et al., 1989; Shields et al., 1981).  This, in 
conjunction with previous findings that demonstrate caregivers do not like mixing 
large quantities of ORS because they do not like to throwaway the unused portions 
(Sukkary-Stolba, S, 1990), indicate that provision of a 1L sachet for household use 
may promote incorrect or even risky health behavior.  
Typical co-pack formats currently on the market include two 1-liter ORS 
sachets, with some 500mL sachets being introduced. Health centers usually 
prescribe one or two 1-liter sachets. Thus, if directions are followed and prepared 
ORS is consumed within 24 hours, most patients only receive enough sachets for 
one or two days. Yet, on average, mild episodes last 4.3 days while severe episodes 
last 8.4 days (Lamberti et al., 2012). Stanton et al. found that home-based treatment 
under such scenarios was inadequate in terms of administered quantity for both 
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rehydration and maintenance therapy of diarrhoea (Stanton et al., 1987). These 
factors suggest that multiple smaller sachets of ORS would be more appropriate for 
home use.  This is partially reflected in UN)CEF s recent addition of ml sachets to 
their supply list (UNICEF, 2015).  
With these considerations in mind, the trial version of the Kit Yamoyo was 
developed to contain eight 4.12g sachets of low-osmolarity ORS that each made up 
200ml of solution. Our team worked with a local pharmaceutical company already 
manufacturing a one-liter sachet approved by the Zambian Medicines Regulatory 
Authority (ZAMRA), previously the Pharmaceutical Regulatory Authority (PRA), and 
worked with them to get approval to produce the smaller sachets. The kit packaging 
was marked with a 200ml measurement line to facilitate proper preparation of each 
mini-sachet .  
 
Co-Packaging 
 Existing evidence suggests that the co-packaging of products, such as ORS 
and zinc, can influence the perceived value of a product (Meza, 2015). Gill et al. 
(2013) note that, co-branding or co-packaging of zinc with ORS could be another 
way to couple the use of the interventions, and would be relevant to public and 
private sector outlets.  Chopra et al. (2013) highlight that production and marketing 
of flavored ORS or co-packaging of ORS and zinc in collaboration with private sector 
companies can substantially increase purchase and use of these interventions.  
Co-packaging zinc with ORS may also have the added advantage of increasing 
uptake and perception of ORS effectiveness, which is often considered not to be a 
treatment per se, but only for rehydration , thereby limiting its use (Ellis et al, 
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2007). Multiple studies have found that that provision of zinc can not only increase 
uptake of ORS, but also decrease unnecessary use of antibiotics (Bhandari et al, 
2008; Baqui et al, 2002), which are often thought of as being the strongest medicine 
for diarrhea (Zwisler et al, 2013). This is also the case, because zinc itself, is often 
perceived as a medicine. Since caregivers often consider ORS to be insufficient on its 
own, and often believe an additional treatment should be combined with ORS to 
cure diarrhea (Ellis et al, 2007), co-packaging should help with acceptability at the 
community level. 
Caregivers in our focus group discussions liked having multiple products in 
one package (ORS, zinc, soap), perceiving the kit to have greater value as a result. In 
addition, the ability to see through the packaging and identify the components 
inside was also highly regarded. Nonetheless, most caregivers did not know what 
the zinc was, simply identifying them as pills . Most caregivers recognized the ORS 
as such, even though they were in smaller sachets. The addition of soap to the DTK 
seemed to make the kit more attractive, although not all caregivers linked it to hand-
washing specifically. Previous analysis has suggested that provision of soap is more 
effective than education alone (Waddington et al., 2009), and that risk reductions 
for diarrhea of 48% can be achieved by hand-washing with soap (Cairncross et al, 
2010). The soap in the kit was added to add to the attractiveness and perceived 
value of the kit, and link the messages of prevention and treatment, by promoting 
hand-washing. The kit packaging included a lid that doubled as a soap dish and 
separated the soap from the medicinal contents of the kit in line with requirements 
set forth by the Zambian Medicines Regulatory Authority (ZAMRA). It is for these 
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reasons that the Kit Yamoyo co-packages low-osmolarity ORS, zinc, and a small bar 
of hand soap.  
 
Aesthetics and Sensory Appeal, Symbolic Value, and Visual Clarity 
Taste 
The flavor of the ORS from rural health centers was another factor 
mentioned during formative work with regard to acceptability of ORS by children. 
GRZ branded ORS from rural health centers is not flavored. Research from Kenya 
(Blum et al., 2011), Yemen (USAID, 1986), India (Bentley, 1988), and Bangladesh 
(Baker J et al., 1986) has shown that children tend not to like the taste of unflavored 
ORS. Although acceptability of a medicine can have multivariate and complex 
causes, an acceptable taste is critical (Matsui, 2007). While this has been seen as a 
competitive advantage in the private sector, leading to development of flavored and 
colored ORS, concerns that flavoring and coloring of ORS may cause over-
consumption led the WHO to conduct a safety/efficacy study in Egypt and an 
acceptability study in the Philippines (Madkour, 1997; Saniel et al., 1997 as cited in 
WHO, 2006). Findings from these studies showed neither an advantage nor 
disadvantage for the flavored and colored ORS when compared to the standard ORS 
with regard to safety, acceptability and correct use  (WHO, 2006). This, along with 
the aim of making an essential drug available at a lower price in the public health 
system, led UNICEF and WHO to recommend that governments should use the ORS 
composition that contains only the four basic ingredients needed to effectively treat 
dehydration due to diarrhea (WHO, 2006).  
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In the Saniel et al. paper (1997), however, acceptability was not determined 
through a measure of preference, but by the amounts of ORS consumed at home by 
children with diarrhea. While reactions to the flavored vs. un-flavored ORS did not 
differ statistically between groups, it is important to note that the relative 
acceptability of ORS given to mothers in the context of a consultation at a clinic 
would likely differ from an over-the-counter market transaction where caregivers 
were purchasing ORS in the private sector. The authors acknowledge that in such a 
scenario, flavored ORS could be more attractive than standard ORS, but that this 
possibility was not tested in their study.  The ORS in the Kit Yamoyo is orange 
flavored and also creates an orange colored solution. Previous analysis has shown 
that the color of the liquid itself may influence perceived effectiveness and 
acceptability (Sukkary-Stolba, 1990). 
Similarly, masking the metallic taste of zinc has been cited as an important 
factor in product development (Lazzerini & Ronfani, 2013).  Adherence to the entire 
10-14 day treatment remains a challenge in programs globally. Other design 
considerations included the need for tablets to be dispersible and scored if 20mg 
(for 10mg use in children under 6 months) (Froes, 2001). A study of the 
acceptability of and adherence to dispersible zinc tablets found that a formulation 
that took taste, cost and feasibility into consideration was acceptable to children 
under 5 (Nasrin et al., 2005). Over ninety percent of caregivers in that study 
perceived the tablets were equally or even more acceptable to their children than 
other medicines. Zinc contained within the Kit Yamoyo comes in a blister pack of 10 
pediatric formulated, dispersible, 20mg zinc sulfate tablets. Each tablet is scored 
down the middle to facilitate use in children less than 6 months of age and had a 
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sweet coating to mask the naturally metallic taste. During the study, zinc was 
commercially procured for use in the kits and branded as PedZinc®, but is currently 
being manufactured locally, along with the 200mL ORS, and branded as NovaZinc®.  
 
Branding 
Using brand orientation as a strategy can influence adoption in bottom of the 
pyramid markets (BoP) of developing and emerging economies (Rahman et al., 
2013). Prahalad (2005) stressed that the BoP markets are eager to adopt 
innovations, and are indeed, brand conscious. Others have demonstrated that 
consumers at the BoP have strong preferences for branded products and purchase 
them when affordable because they are perceived as providing backing, confidence and quality D Andrea, .  
During our focus group discussions, caregivers were asked to provide 
feedback and suggestions on images, colors, and product name. With reference to 
images, caregivers were presented with options including cartoon lions, a smiling 
mother holding her child, and various logos including a sad face morphing into a 
happy face. By far, the most popular image was that of a caring mother holding her 
smiling child. This literal image was preferred over more abstract logos, yet was 
reminiscent of the very successful project logo of a seated mother feeding her small 
child from an ORS campaign in Egypt during the 1980s (figure 2) (Hirschhorn, 
1985).  
While images are critical to branding strategy (Dichter, 1985), so too is color, 
which is recognized as an effective means of creating and sustaining brand in customers  minds Madden et al., 2000). Various colors were tested with regard to 
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the branding of the Kit Yamoyo. Color has been recognized as an important 
marketing cue with both psychological and sociocultural associations that influence 
consumer perceptions and consumption behavior (Aslam, 2005; Grossman & 
Wisenblit, 1999). Orange and red fared well throughout the consultations with 
potential consumers. This also extended to the orange color of the ORS itself. These 
factors are likely to be particularly relevant in relation to children under 5, 
especially when considered from a competitive advantage perspective in the private 
sector. The final branding for the product included a red and white color scheme 
with a high quality, realistic photograph of a loving mother looking down at her 
smiling, healthy child. 
The name of a product can greatly influence its acceptability as well. Brand 
name is a commonly used extrinsic cue to infer perceptions about quality, and can 
embody a combination of information about a product (Richardson et al., 1994). 
While a brand name needs to be localized within the context of global health, a 
strong brand name can help control quality perceptions of the product even when 
its price is discounted (Della Bitta et al., 1981). This may be important in scenarios 
where vouchers or other subsidy mechanisms are used to reach various high-risk 
segments of the population (e.g. poorest of the poor). Dawar et al. (1994) showed 
that brand name and price discounts can explain up to 85% of the variation in 
perceived value of a product. ORS related research from Egypt demonstrated that 
caregivers preferred simple names that conveyed a warm feeling or described the 
purpose of the solution (Hirschhorn, 1985). The selected brand name in the Egypt 
campaign was Mahloul Moalgett et Gaffaff,  meaning solution for treating 
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dehydration,  but was referred to as the solution . In Nepal, packaged ORS are 
called Jeevan Jal  which translates to life fluid  (Sukkary-Stolba,1990).  
Our work tested a number of names including Tip Top Tummy , Top Tum , 
Happy and Strong , and Kit Yamoyo . Caregivers were also asked to consider 
variations of these names and suggest their own (e.g. Top Tum , Box Yamoyo , 
local translations of Happy and Strong  and other positive words relating to child 
health). Kit Yamoyo was by far the most popular brand name option, with the vast 
majority of caregivers preferring it over the others. Given previous experience, this 
makes sense. Kit Yamoyo translates to Kit of Life  or Life Giving Kit  in the local 
Nyanja, and plays well into a common local name for ORS, Manzi Yamoyo  or 
Water of Life . Kit Yamoyo anti-diarrhea kit  was printed in block letters at the 
center of the leaflet, with the final o  in Kit Yamoyo resembling a happy face. The 
recommended retail price (K5.00 = USD $1) was printed on the top right corner of 
the leaflet. Together, the image, colors and name worked in concert to establish a 
strong brand identity.  
The branding of the product was printed on the back of the Information, 
Education and Communication (IEC) materials, which helped reduce materials and 
cost. While the IEC pamphlet had written instructions in two local languages and in 
English, it focused on the use of simple, clear info-graphics, given that 25% of the 
adult population in rural Zambia cannot read (DHS, 2007). As opposed to being 
imprinted on the packaging, the branding and IEC pamphlet was simply an insert 
that could be easily adapted to meet different needs (i.e. public sector use, 
localization in another country, etc.). The kit was then heat sealed with all of the 
contents and branding/IEC pamphlet lying under a tamper proof, micro-porous, 
98 
transparent film. The packaging for the kit was originally designed to fit in between 
the empty spaces in crated bottles of Coca-Cola to facilitate easier transport to the 
community-level by rural retailers who may be transporting Coca-Cola as well, 




The study was conducted across four, predominantly agrarian, rural districts 
in Southern and Eastern Provinces (two districts in each) of Zambia. Two districts 
served as intervention arms (Kalomo and Katete), and each intervention district had 
its own matched comparator. Kalomo was matched with Monze in Southern 
Province, and Katete was matched with Petauke in Eastern Province, giving two sets 
of intervention and comparator arms. Intervention and comparator districts were 
matched on a number of relevant criteria including rurality, age distribution of 
caregivers, education of caregivers, diarrhea burden, and access to treatment 
(Ramchandani R, Paper 1).  
A value-chain for the Kit Yamoyo was established in the two intervention 
districts (Ramchandani R, Paper 1), making the Kit available through general, 
community-level retail shops. No kits were made available in the comparator 
districts. The only alternative source of ORS across rural communities in the 
intervention and comparator districts was at the facility level through rural health 
centers. Prior to our intervention, as in most countries around the world, all 
available ORS in Zambia came in sachets that make up one-liter of solution. This is 
the standard size of sachets provided at the health center level. In addition, the GRZ 
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branded ORS is not flavored, not co-packaged (and rarely co-prescribed with zinc), 
and mothers typically receive two sachets pending on available stock. 
 
Study Design & Statistical Analysis 
This study aimed to test whether the application of a new diarrhea treatment 
kit (Kit Yamoyo), developed using human-centered design, could improve rational 
use of the product, when compared to standard, one-liter sachets of ORS found in 
health centers. Whether that was associated with an improvement in perceived 
efficacy of ORS was also explored. The outcome for the primary analysis was 
rational use of ORS, defined as preparing the ORS in the correct concentration. This 
definition is based on one of the core determinants of rational use as defined by the 
WHO, specifically, improved use of medicines (i.e. ORS) by consumers (Table 3.1). 
The outcome of the secondary analysis was the perception of effectiveness of ORS. It 
was hypothesized that a higher proportion of those using the Kit Yamoyo would 
prepare the solution correctly, and that this would be associated with an increase in 
perceiving ORS as effective diarrhoea treatment.  
For the primary analysis, cross-sectional data gathered through household 
surveys in each district at endline formed the basis for the analysis. Each district 
was comprised of 12-15 sites, which provided good geographic coverage of the 
entire district. Focusing on the sample of children under 5 who had diarrhea in the 
two weeks preceding our survey and used ORS, we compared Kit Yamoyo users 
from the intervention districts, with non-users (i.e. 1L health center sachet users), in 
terms of whether or not ORS was prepared in the correct concentration. In order to 
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increase power, the sample of non-users was drawn from those using 1-liter ORS 
sachets in both the intervention and comparator districts.  
Intervention district data and comparator district data were pooled after 
confirming similar outcomes within each arm, respectively. To assess the 
association between kit use and correct ORS preparation, we used a logistic 
regression analysis and calculated odds ratio of correct ORS preparation among kit 
users vs. one-liter sachet users. A robust variance estimate was used to account for 
within-site correlation of outcomes (Gutierrez R & Drukker D.M., 2007). 
Confounding diagnostics found that age of the respondent and having heard a 
message relating to ORS in the previous 3 months were significantly associated with 
the main predictor of Kit Yamoyo use and were included in the model. We 
controlled for confounders by calculating adjusted odds ratio using a multivariable 
logistic regression model.  
Given that preparation of ORS in the incorrect concentration can influence its 
efficacy, we also tested whether preparing ORS in the correct concentration, or 
other factors related to the introduction of the product (developed through human-
centered design), might influence the perception of ORS effectiveness. Perceived 
efficacy of a product is an important determinant of its utilization and adherence 
(Ilyuk V. et al., 2014; Berg et al., 1993). This certainly seems to be the case with ORS 
(Blum et al., 2011; Zwisler et al., 2013; Grace, 1998; Kumar et al., 1985; Muninjaya et 
al., 1991). In addition, Rees and colleagues showed that over 40% of patients switch 
brands and choose alternative medications for any specified condition due to 
perceptions of poor efficacy (2006). Perceptions around efficacy are therefore 




To determine perceived efficacy of ORS, the questionnaire used for the 
household surveys asked caregivers whether they thought ORS was an effective 
medicine for the treatment of diarrhea. Confounding diagnostics found that zinc use, 
exposure to ORS-related messaging in the previous 3 months, and age of the 
caregiver were significantly associated with the main predictor of preparing ORS in 
the correct concentration. These covariates were therefore included in the model.  
In order to test the association between perceived effectiveness of ORS and 
its preparation in the correct concentration, we used a logistic regression analysis to 
calculate the odds ratio of perceived ORS effectiveness among those who prepared 
the ORS in the correct concentration versus those who did not. In line with the 
primary analysis, only those caregivers who had a child with diarrhea in the two 
weeks preceding the survey and used ORS at endline were included in the analysis. 
A robust variance estimate was used to account for within-site correlation of 
outcomes, while controlling for potential confounders by calculating adjusted odds 
ratios using a multivariable logistic regression model. All analyses were conducted 
using STATA version 13 (StataCorp, 2013). 
 
Sample Size 
The main outcome indicator for this study was correct preparation of ORS 
among children under 5 with diarrhea in the 2 weeks preceding the survey. 
Diarrhea was defined as experiencing three or more loose or watery stools in the 
previous 24 hours. An a priori sample size estimation was made prior to baseline in 
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order to provide 80% power to detect a 30% difference in correct ORS preparation 
with a two-tailed alpha of 0.05. Assumptions for the calculation were based on 
previous evidence and included: 60% of caregivers being able to correctly prepare 
ORS (Charyeva et al, 2015; Bunjamin et al, 1990; Ismail and Nazir, 1990; Ward, 
1985; Pulungish, 1992), 60% of children with diarrhea receiving ORS (DHS, 2007), 
and a 25% period prevalence for diarrhea amongst children under 5 (DHS, 2007 and 
confirmed to be valid during baseline). This resulted in a sample size estimation of 
420 children under age 5 in each of the intervention and comparator groups. Given 
that the sample size used was based on a parent study (Ramchandani R, Paper 1) 
with more than 600 households with children under 5 per group, the sample size 
achieved was well within the required estimate for this study. 
 
Study Instruments & Sampling 
Household surveys were administered to independent cross-sectional 
samples of caregivers of children under 5 in two intervention districts, Kalomo and 
Katete, and their matched comparator districts, Monze and Petauke, respectively. 
Data collection took place prior to the intervention in August of 2012 (baseline), and 
after exactly one year of intervention, in August of 2013 (endline). Households in 
each district were sampled from 12-15 sites/clusters, resulting in good geographic 
coverage of populated areas across each district. Areas within 10km of the district 
town ( urban center ) were excluded in order to ensure the sample was 
representative of rural populations in Southern and Eastern province.  
No information on the specific locations of households was available during 
the survey periods. Households were, therefore, selected using a modified random-
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walk technique (Turner, 2003) with probability proportional to population size 
within each site. Cluster/Site population size was determined based on Standard 
Enumeration Area (SEA) data from the Central Statistics Office (CSO, 2010). After 
randomly selecting a first household along the perimeter of the site, a sampling 
interval of 3 was used to determine each successive household. Due to large 
distances between households in Southern Province, the interval was altered to 1 or 
2 (where necessary). An interval of 3 was initially selected to avoid any potential 
clustering effects and selection bias, but was likely unnecessary in Southern 
Province given the large distances between most households. If a caregiver of a child 
under 5 resided in the household but was not available, interviewers attempted to 
return to the household when logistically feasible.  
In each household, the primary caregiver (the vast majority being mothers) 
of a child under 5 with diarrhea in the two weeks preceding the survey was 
prioritized for interview. In cases where no child under 5 in the household had 
diarrhea, the primary caregiver of a child under 5 without diarrhea in the previous 
two weeks was interviewed. They were asked to recall the last time their child had 
diarrhea (if ever) and about related treatment seeking behavior and knowledge. In 
instances where multiple caregivers of children under 5 with diarrhea in the 
previous two weeks existed, the caregiver was selected alphabetically by first name. 
The same procedure was used in instances where the selected caregiver had 
multiple children under 5 with diarrhea in the two weeks preceding the survey.  
Only using a single reference child per household eliminated intra-household 
correlation. Caregivers had to be at least 15 years of age. A two-week period for 
identification of diarrhea cases was used in order to minimize recall bias. Only the 
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sub-sample of caregivers with children under 5 with diarrhea in the two weeks 
preceding the survey were used for the primary analysis in this study. Both, this 
sub-sample, and the larger sample of caregivers who had children with or without 
diarrhea in the two weeks prior to the survey, were used as a basis for the 
secondary analysis.  
Caregivers were asked questions pertaining to how they prepared the ORS 
solution including the specific ORS product used, its source, the amount of the 
sachet used during a single preparation, as well as the amount of water used.  
Correct ORS preparation was defined as preparing the solution in the correct 
concentration. The reported amount of water used was cross-referenced with 
reported information on the container used to measure the water, as well as where 
it was filled to. Interviewers were trained in advance on standard measurements 
(200ml, 500ml, 1 cup, 1 Liter, etc.), as well as common containers (and their 
associated measurements) found at the rural household level. In cases where the 
container used to measure the water was available, interviewers asked for visual 
verification.  
 Accurate concentration preparation was determined by cross-tabulating the 
amount of salts used with the amount of water used. In order to maximize 
confidence with regard to the accuracy of the prepared ORS solution concentration, 
analysis only focused on those caregivers who used the entire sachet of ORS. Those 
who used only part of a sachet were not included in the analysis (n=68) as there was 
no reliable mechanism for assessing how much ORS powder they had used.  
Local enumerators from an external data collection agency, with previous 
experience conducting household surveys in rural communities, were trained by the 
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project and administered all surveys (professionally translated and back-translated) 
in the local language. Surveys were pre-tested in the field by these same 
enumerators. Surveys typically took between 20 and 60 minutes to complete 
depending on the responses and whether the Kit Yamoyo had been used. All surveys 
were carried out on Samsung tablets using Open Data Kit (ODK) software, and were 
completed within the month of August over the span of three weeks. Consistency 
checks and skips to avoid entry of erroneous data were automated in the electronic 
surveys. All data was crosschecked by trained field supervisors on a daily basis and 
then uploaded to a central server each evening. Uploaded data was then checked by 
a data specialist from the data collection agency for completeness and consistency, 
as well as coding of open-ended responses. In case of inconsistency, missing 
responses, or other questions, the data specialist flagged them for discussion with 




Informed consent was obtained from all respondents prior to survey 
administration. In cases where the caregiver was under the age of majority, consent 
was sought from both the head of household and the caregiver themselves. Because 
this was a low-literacy population, the statement of consent was explained to the 
caregivers, who then provided signature (if possible) or made their mark using their 
finger and ink. Both national and district level government health administrations 
authorized the implementation of the study while community-level approval was 
obtained through local chiefs. Ethical approval for the study protocol was obtained 
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from ERES Converge in Zambia, with approval for secondary analysis obtained 




A total of 2477 households with at least one child under age 5 were 
successfully surveyed across all four rural districts at endline. With regard to the 
primary analysis, household prevalence of diarrhea in children under 5 during the 
two weeks preceding the survey was 28.4% (n=704). Of those children with 
diarrhoea, 67.4% (n=475) used ORS across the intervention and comparator 
districts. We compared those who used the Kit Yamoyo (n=174) vs. those who used 
standard 1-liter sachets (n=233) with regard to preparing the ORS in the correct 
concentration. Those users who did not prepare the entire sachet or did not know 
how much water or sachet-contents were used were excluded from the analysis (n = 
68). In order to get more power from our sample of 1-liter sachet users, we included 
those who used ORS in the comparator areas as well, all of whom used standard 1-
liter sachets. Preparing ORS in the correct concentration was deemed to be accurate 
within 25ml.  
We found that only 60% (95% CI: 0.54-0.66) of 1-liter sachet users prepared 
ORS in the correct concentration when preparing the ORS at home. Of those who 
used the Kit Yamoyo, with the packaging acting as a measurement vessel, 93% (95% 
CI: 0.89-0.96) prepared the ORS solution in the correct concentration. Unadjusted 
odds ratio of correct preparation comparing the Kit Yamoyo users versus one-liter 
sachet users was 10.7 (95% CI: 5.44-20.97, p <0.001). After adjusting for age and 
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exposure to ORS messaging during the previous 3 months, odds of correct ORS 
preparation were found to be 10.93 (95% CI: 5.74-20.78, p<0.001) times greater in 
Kit Yamoyo users vs. those who used 1-Liter sachets from health centers (Table 3.2).  
Secondary analysis compared caregiver perceptions of ORS effectiveness at 
endline based on those who prepared ORS in the correct concentration (n=104) 
versus those who did not (n=303) (Table 3.3). Eighty-Seven percent (95%CI: 0.83-
0.92) of those who did not prepare the ORS in the correct concentration perceived 
ORS to be effective. Of those who prepared the ORS in the correct concentration, 
93% (95%CI: 0.89-0.96) did. Unadjusted odds ratio of perceived ORS effectiveness 
comparing those who prepared ORS in the correct concentration versus those who 
did not was 2.36 (95% CI: 1.24-4.50, p<0.01). We hypothesized other likely factors 
related to the introduction of the kit that may influence the perceived effectiveness 
of ORS. These included the improved preparation of ORS, the combination therapy 
with zinc, and/or exposure to ORS messaging, with the first two factors being 
directly related to the human-centered design of the kit. After adjusting for these 
independent variables that we found to be strongly associated with the outcome, 
odds of perceiving ORS as effective were 1.84 (95% CI: 1.05-3.23, p<0.05) times 
greater in those who prepared the ORS in the correct concentration vs. those that 
did not. The age of the caregiver (OR: 0.98, 95% CI: 0.96-0.99, p<0.05) as well as 
whether the caregiver had heard a message relating to ORS within the previous 3 
months (OR: 3.77, 95% CI: 1.72-8.26, p=0.001) were also found to be significant 
predictors of perceived ORS effectiveness. Of the 100% of Kit Yamoyo users that 
said they would use ORS the next time their child had diarrhoea (n=173), 99% (95% 





A recent analysis of market shaping possibilities for ORS and zinc noted that: 
 
The inefficiencies of the ORS and zinc market have been described as an 
example of a life-saving treatment stuck in an uptake trap , wherein a 
combination of demand- and supply-side inefficiencies work in a mutually 
reinforcing manner to stifle market growth.  (USAID, 2014; pg. 27) 
 
Our study demonstrates that greater consideration of human-centered design – 
through a focus on product-oriented, demand-related dimensions of access – can 
help overcome some of these barriers by facilitating appropriate use and improved 
user perception of effectiveness. These factors play an important role in increasing 
adoption (Ramchandani R., Paper 1) and ultimately, improved access. Development 
of an innovative diarrhea treatment kit - the Kit Yamoyo - was localized to address 
consumer preferences, private sector activity and other utilization bottlenecks by 
working with end-users and focusing on product desirability. The Kit Yamoyo 
design was based on what caregivers said they wanted. This is in contrast to many 
health products which are designed on the basis of what providers think is needed. 
With a focus on optimizing usability, core benefits, aesthetics and sensory 
appeal, symbolic value, and product novelty and differentiation, we were able to 
improve product innovation, appropriate utilization (i.e. rational use) and thereby, 
perceived efficacy of ORS. Leveraging kit packaging to serve as a measurement 
vessel and reducing the size of ORS sachets to produce 200ml of ORS solution, for 
example, were direct results of taking a human-centered design approach. It 
standardized the preparation process and led to improved rational use by enabling 
ORS to be mixed in the correct concentration. This empowers caregivers by 
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removing uncertainty, enabling correct health behavior, and giving them more 
confidence in the ability to effectively treat their children at home. Castano (2014) 
notes that a process of care that is highly standardized and highly separable from 
the health facility level provides tremendous potential for business model 
innovation – one in which a patients expectations and preferences are understood.  
Positive health behaviors facilitated by a human-centered designed product 
were also associated with an improvement in perceived effectiveness of ORS for the 
treatment of diarrhea. Specifically, the preparation of ORS in the correct 
concentration, as discussed above, as well as the combination use with zinc (i.e. co-
packaging) were found to be positively associated with the outcome. This was in 
addition to exposure to ORS-related messaging in the previous 3 months, another 
feature of the overall intervention. As well as delivering the above benefits, the 
human-centered design approach is fully compatible with the use of existing private 
sector distribution systems for delivery to remote communities. Private sector 
distribution systems depend on there being a viable value chain in place. Products 
that have a high value in the eye of the consumer but are also affordable and 
profitable for those who sell them along the distribution chain are associated with a 
robust value chain. A human-centered designed product will have a higher 
perceived value than a product designed without the participation of customers. 
This is reflected in the increased utilization of ORS and zinc by children under 5 with 
diarrhea from less than 1% at baseline to 46% at endline across the intervention 
districts, while no change was seen in comparator districts (Ramchandani R, Paper 
1). In this way, a private sector co-packaged ORS and zinc product based on human-
centered design seems to be acceptable at all levels (Ministry, Zambian Medicines 
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Regulatory Authority, health facilities, NGOs, manufacturer, wholesalers, retailers, 
caregivers). Appropriate stakeholder development and establishment of multi-
sectoral partnerships, along with appropriate social marketing and awareness 
campaigns were essential complements.  
With regard to messaging, a recent study by Wilson and colleagues (Wilson S, 
2013) noted that one of the clearest differentiators between nations that have 
successfully scaled-up ORS versus those that have not was the choice to promote a 
clear, unambiguous message about the treatment of choice. In this way, linking ORS 
and zinc-related messaging with specific products, such as Kit Yamoyo, may also 
improve uptake and awareness of these essential health commodities. In addition, 
studies in Nigeria and Kenya have indicated that when knowledge and perceived 
efficacy are in place, caregivers request specific, appropriate treatments (Brieger, W 
et al, 2004).  
This paper also suggests that something cannot be considered delivered, 
until it is prepared, administered, and used correctly by the end user. The global 
indicator used to assess our progress in diarrhea treatment – i.e. coverage – is 
defined as the proportion of children with diarrhea in the 2 weeks preceding a 
household survey who received ORS (DPWG, 2013). This is based on reported 
administration of ORS by the caregiver being interviewed. However, our research 
shows that 40% of caregivers who reported giving ORS to their children prepared it 
in the incorrect concentration. This has negative consequences with regard to the 
efficacy of ORS and was likely a conservative estimate given that our analysis only 
focused on those caregivers who used the entire sachet of ORS. Those who did not 
prepare the entire sachet are more likely to have prepared a solution of incorrect 
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concentration (i.e. the proportion of users who prepared the solution incorrectly is 
likely higher).  This has important implications for global health research and policy, 
given that coverage figures from the DHS, MICS and other routine data collection 
that are using the current indicator of ORS coverage, likely overestimate the actual 
rational use . 
This begs the question of whether the global community should be assessing 
coverage based on the effective use of ORS, rather than reported use alone. There is 
a need for greater confidence in whether the solution is being prepared correctly. 
However, as with the current coverage indicator, a practical approach under routine 
data collection would likely require the indicator to be based on reported  rather 
than observed  evidence. Products developed through human-centered design that 
can help facilitate correct treatment and health behavior may help provide greater 
confidence in such reported data.  
With poor adherence to the 10-14 day zinc regimen being the norm (Nasrin, 
2005), similar thinking and further study will be required with reference to effective 
use of zinc. Future research should focus on how a human-centered design approach 
might play a role in improving adherence as well as dosage (children under 6 
months of age require dosage of half a 20mg tablet, while those older than 6 months 
require the entire 20mg tablet).  
Fischer-Walker and colleagues (2009) have noted that cooperation from 
private sector manufacturers has helped facilitate uptake of ORS and zinc, 
particularly in countries that place emphasis on locally produced products. 
Correspondingly, with a focus on reducing costs, building local capacity, as well as 
drawing on findings from our research, new kit formats that maintain the key 
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functions and human-centered design features have been developed for future 
phases of implementation.  
The original kit packaging that was designed to fit in the empty spaces 
between crated bottles of Coca-Cola was found not to be a key enabler of access. 
Only a small percentage of retailers used the nesting function to transport kits back 
to their communities 4-8%). In most cases retailers purchased the kits in bulk and 
simply used the box they came in to transport them (e.g. on the back of their 
bicycles). In addition, not all retailers purchased Coca-Cola (~50% carried it always 
or sometimes - Ramchandani R., Paper 3) at the same time as they were purchasing 
Kits. This freed the project up from the awkward (yet unique and identifiable), 
shape of the original Kit, manufactured in the United Kingdom, and allowed for a re-
focusing on simpler, lower-cost options. These new formats are manufactured 
almost 100% locally, and along with incorporation of other lessons from the trial 
(Appendix 5), have resulted in reduced production costs. With a resulting increase 
in local orders, including from the public sector, NGOs, and large commercial 
retailers, this will further translate to price reductions. New formats include a flexi-
pack and a screw-top jar (Figure 3.4). Continued research around cost-effectiveness 
and optimal packaging configuration for effective diarrhea treatment should 
continue to be a priority.  
 
Limitations 
While this study used reported information, it could have been strengthened 
by actually observing preparation to verify the accuracy of reported solution 
preparation. However, these studies are logistically more difficult and costly to run 
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at the household level. A two-week recall period likely helped mitigate against 
inaccurate reporting.  In addition, while there may have been some ambiguity 
associated with the size of the container used to prepare the ORS solution, it should 
be noted that interviewers were well trained in describing the containers used 
when a specific volume was not clear. They also asked for visual confirmation of the 
containers where available. Training the interviewers in advance so that they had 
familiarity with a standard cup size, standard liter, as well as common containers 
found in rural households, helped to ensure a higher degree of confidence in 
assessments of correct concentration.  
While the secondary analysis accounted for important factors hypothesized 
to influence perceived efficacy, there are likely other factors that would have a 
significant effect on perception of ORS effectiveness. These may include such factors 
as caregivers holding a curative theory expectation (i.e. anti-motility, reduced stool 
output, etc.) versus a re-hydration theory expectation (Coreil & Genece, 1988; 
Hudelson, 1993); whether ORS was recommended to them by a trusted healthcare 
provider; whether caregivers paid for the ORS and if so, how much (Baker et al., 
1985); the acceptability of the product as discussed in this paper (taste, color, 
branding, etc.); the opinions and perceptions of friends and family; or prior 
experience with ORS. This last factor is likely to be associated with the age of the 
caregiver, which in this study was found to be inversely associated with perceived 
efficacy (i.e. for each additional year, the odds of a caregiver perceiving ORS as 
effective decreased by 2%). Understanding the reasons behind how this long-term 
experience might influence perceived efficacy vs. more short-term experience, as 
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well as expansion of the model to account for other potential factors likely warrants 
further research.  
The study implies that having recently prepared ORS in the correct 
concentration may affect its perceived efficacy. While the aim of the secondary 
analysis was simply to explore the association between correct preparation and 
perceived efficacy, evidence exists to support the notion that a single, positive, 
recent experience may influence how patients perceive the effectiveness of a 
pharmaceutical product. In their discussion of efficacy expectations and evidence of 
consumer biases and heuristics in pharmaceutical marketing, Ilyuk and colleagues 
(2014) cite the important role of the availability heuristic. Closely related is the 
concept of attitude accessibility. The first concept refers to the tendency to judge 
something (e.g. the probability of perceiving something as efficacious) in terms of 
how easy it is to recall examples of it (Tversky & Kahneman, 1973). The second 
concept refers to the strength of the association between a product and an 
evaluation of it, typically measured by the speed with which people can access the 
evaluation from memory (Fazio, 1995). In both instances, the more readily 
information is activated in memory, the greater impact it will have on subsequent 
judgments (Song & Schwarz, 2009). More recent experiences tend to be recalled 
more easily (Deese and Kaufman, 1957), and thus it stands to reason that a recent 
positive experience with the Kit could influence its perceived efficacy. However, as 
previously noted, memory activation and recall of particular experiences (e.g. 
treating diarrhoea in children) is likely to differ between older mothers, who 
perhaps have more experience in treating childhood diarrhoea versus younger 
mothers.  
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Finally, by excluding those who did not prepare the entire sachet of ORS from 
our primary analysis, it is likely that our estimate of incorrect preparation of ORS 
was conservative. While this approach may underestimate the proportion of 1L 
sachet-users preparing the solution incorrectly, the decision was made to try and 
maximize the accuracy with which we determined the concentration of the 
prepared ORS solution. Presenting a conservative figure with a higher degree of 
confidence was deemed to be more powerful than the alternative.  
 
Conclusion From ORS  humble beginnings as a treatment in cholera camps; to a revised 
formula, and the addition of zinc to the global recommendation; to an increased 
focus on expanding coverage and delivering impact at the community and 
population level; our study positions itself in a progressive line of evidence from the 
efficacy of ORS and zinc at the individual level to their community-level utilization. 
Situated at the intersection of global health innovation, health markets, multi-
sectoral partnerships, human-centered design, and global health delivery, it is one 
few studies to empirically link human-centered design and improved treatment 
practices in a global health context. It shows the effectiveness of giving greater 
consideration to demand-related factors at the base of the pyramid, and how this 
plays into improved delivery and rational use. We believe that our findings have 
important implications from both a policy perspective, with reference to how we 
measure success in combatting diarrhea, as well as a product configuration 
perspective with regard to ORS and zinc.  
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FIGURE  3:3: KIT YAMOYO DIARRHEA TREATMENT KITS IN CRATE OF COCA-COLA 
 
 
FIGURE  3:4: NEW FORMATS OF KIT YAMOYO – FLEXI-PACK (LEFT) AND SCREW-TOP 
(RIGHT) 
118 
Tables for Chapter 3 









Availability   Medicines  supply—type and 
quantity  
 Medicines  demand—type and 
quantity  
 
 Affordability  Prices of drug products and services  
 User s income and ability to pay  
 Acceptability  Characteristics of products and 
services  
 User s attitudes, expectations of 
products and services 
 Accessibility  Medicines  supply location 
 User location 
WHO (2004) Rational Use  Rational therapeutic choices 
 )mproved medicines  use by 
consumers 
 Affordable Prices  Medicines  pricing policies 
 Sustainable Financing  Resource mobilization 
 Pooling 
 Reduction of out-of-pocket 
expenditures 
 Reliable health and 
supply systems 
 Medicines procurement and supply 
 Regulation 
 Human resources 
Frost and Reich 
(2010) 





 Affordability  Government affordability 
 Non-governmental agency 
affordability 
 End-user affordability 
 Adoption  Global adoption 
 National adoption 
 Provider adoption 
 End-user adoption and appropriate 
use 





TABLE 3.2: SAMPLE CHARACTERISTICS 
Characteristi
c 
Kit Users (N=174) 1L Sachet Users (N=233) 










































*Sample is based on those ORS users who prepared the entire contents of either the Kit or the standard 1L 
sachets 
 




 Unadjusted, Simple Logistic 
models  
Multivariable logistic regression 
model 
Characteristic Odds Ratio 
(95% CI) 
p-value Odds Ratio 
(95% CI) 
p-value 
 Kit Yamoyo vs. 
1L ORS sachet 
from RHC 






0.98 (0.96-0.99) 0.007 0.98  (0.97-1.00) 0.089 
Heard message 
relating to ORS 
in previous 3 
months vs. not 
1.48 (1.07-2.06) 0.019 0.84 (0.54-1.32) 0.456 
*Based on those who prepared the entire contents of the sachet 
Adjusted for within site correlation using robust variance estimate 
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 Unadjusted, Simple Logistic models  Adjusted Multivariable logistic 
regression model 
Characteristic Odds Ratio 
(95% CI) 








2.36 (1.24-4.50) 0.009 1.84 (1.05-3.23) 0.033 
Zinc Use vs. No 
Zinc Use 
2.62 (1.13-6.06) 0.024 1.31 (0.57-2.99) 0.521 
Heard message 
relating to ORS 
in previous 3 
months vs. not 






0.97 (0.95-0.99) 0.003 0.98 (0.96-0.99) 0.039 
*Based on those who prepared the entire contents of the sachet 
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Chapter 4 - Serving the Underserved: A Description of Rural, 
Commercial General Stores as Community-Level Providers of 




With growing interest in the potential of market-based solutions to expand 
coverage of public health goods and services in low- and middle-income countries, 
there has been a particular interest in the role of private sector retailers. In some 
countries, commercial retailers commonly selling fast-moving consumer goods 
(FMCGs) like soap, snacks and beverages may be a particularly effective channel for 
improving access to certain public health products (PHPs) at the community level. 
These retailers operate general shops that are often ubiquitous in rural 
communities, yet little research has gathered information on their characteristics 
and operations – an essential first step in assessing their potential as informal 
providers . With calls to improve our understanding of the various types of 
providers of health commodities across contexts and settings, this exploratory study 
aimed to describe some of the features of this retailer type, in rural Zambia, that 
may have implications for improving access to PHPs. 
A cross-sectional retailer survey was carried out across four rural districts of 
Zambia – two in Southern Province, and two in Eastern Province. General store 
retailers (n=180) were administered a structured questionnaire that gathered 
information on infrastructure, staffing, ownership and operations, purchasing 
patterns, product preferences, and level of engagement with an intervention to 
expand coverage of a newly introduced diarrhea treatment kit.  
Findings provide deeper insight into the operations and characteristics of 
rural, community-level, commercial retailers. For example, general retailers were 
open an average of 12 hours, longer than most rural health facilities. Retailers 
typically purchased goods multiple times per month, from multiple wholesalers, 
providing increased opportunity for (re)supply of PHPs. The leading motivating 
factors indicated by retailers for carrying a public health product were helping 
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children and their community, as well as profit. Average gross margins on other 
common FMCGs carried by general retailers was 29%, likely applicable to the 
introduction of PHPs through this channel. Eight-seven percent of retailers noted 
that they had previously been asked for advice on diarrhea treatment. Following the 
introduction of a new diarrhea treatment kit, 76% of retailers were found to have it 
in stock on the day of visit, a stock rate that improves upon rural health facilities.  
In rural Zambia there exists a largely untapped potential to leverage general 
retailers to expand access to important PHPs. Already transporting a variety of 
FMCGs from central-district to community-level, these retailers may, with the right 
balance of incentives, serve as effective points of access for basic PHPs such as ORS 
and zinc.   
 






Despite significant progress in addressing childhood mortality, 5.9M children under 
the age of 5 still die each year (WHO, 2015). The majority of these deaths, and associated 
morbidity, can be prevented with effective and affordable interventions that prevent or 
treat the most common causes of illness (PMNCH, 2011; Kade, 2015). Diarrhea for 
example is the second leading infectious cause of childhood mortality (Liu et al., 2015) 
and the majority of cases can be effectively managed with oral rehydration salts and zinc 
(Fischer-Walker et al., 2009). Its effective treatment is a priority for integrated 
community case management of childhood illnesses (ICCM), and a national priority for 
Ministries of Health when it comes to decreasing childhood morbidity and mortality. 
Nonetheless, in most low- and middle-income settings, interventions are still not reaching 
the children that need them. Of those children with acute diarrhea, less than 1% receives 
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zinc and only a third receives ORS globally (Gill et al., 2013). Thus, there is widespread 
consensus that improving access and coverage of effective interventions should be a key 
focus of health policies and associated programs (PMNCH, 2014).  
Given that a large proportion of access to health products and services takes place 
in the private sector in low- and middle-income countries (LMICs) (Hanson & Berman, 
1998; Waters et al., 2003), there has been a growing interest in the role of private 
providers and health-related markets in meeting this objective (Bennett et al., 1997; 
Bennett et al., 2014). The spread of these markets are perceived by some to respond to 
weaknesses within the public sector, including under-funding, low motivation and 
number of healthcare workers, rundown infrastructure, poor governance and inefficient 
supply chain (Coovadia H. et al, 2009; Macfarlane S. et al, 2000). It has been argued that 
private providers can sometimes deliver services that are more accessible, affordable and 
responsive to the needs and preferences of patients (Smith et al., 2001).  
The retail sector accounts for a large proportion of private sector provision in 
LMICs, particularly for health products (Goodman et al., 2009). This is due in large part 
to retailers often being more geographically accessible, being open for longer hours, 
providing quicker service, having more reliable drug stock and being perceived as 
relatively courteous and approachable (Williams and Jones, 2004). Medicine retailers 
vary in type and include pharmacies and drug shops, patent medicine vendors, market 
vendors, itinerant hawkers, and general stores (Goodman, 2004). These retailer types 
range from formal registered pharmacies, to informal private providers (IPPs), to general 
retailers that may only sell a small number of medicines alongside other goods (Wafula & 
Goodman, 2010). IPPs have been referred to variously as patent medicine vendors 
(PMVs), as well as chemical, drug and medicine sellers (Brieger et al., 2004). They can 
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be found operating out of drug shops, general stores, kiosks, and markets stalls, and also 
operate as itinerant hawkers (Goodman et al., 2007). Shah and colleagues (2010) define 
IPPs as:  
Those who provide allopathic medical treatment or services to the public, but 
have not received formal training in allopathic medicine. These providers operate 
in a market for health services, and provide alternative sources of health care to 
the government’s public health providers or to non-state providers who have 
formal qualifications, such as in the for-profit or NGO sectors. 
 
Goodman notes that very few studies tend to categorize retailers by type of shop 
(Goodman, 2004). In addition, omission of retailers’ main product orientation (i.e. what 
they specifically focus on selling) also makes distinctions difficult. While IPPs generally 
refer to those retailers “unqualified” to provide health care services, they predominantly 
focus on the sale of medicines (although in practice, even medicine sellers often sell other 
commodities simultaneously) (Brieger et al., 2004; Cross & MacGregor, 2010). The 
literature often groups these informal retail providers together with more general retailers 
who operate at the fringe of the medical marketplace. Perhaps the most informal type of 
‘provider’, these general, commercial retailers typically have no formal training in health 
and generally focus on selling a variety of fast-moving consumer goods (FMCGs) 
alongside, perhaps, a few medicines (e.g. antipyretics). FMCGs usually refer to non-
durable products such as beverages (e.g. colas and juices), toiletries (e.g. soap and 
toothpaste), and grocery items (e.g. sugar and salt), and may include items such as talk 
time. As with IPPs, these general retailers also operate out of outlets including grocery 
stores, general stores, kantemba, and kiosks.  
These retailers generally fall within the informal or microenterprise category. 
Although the terms “informal” and “microenterprise” vary from country to country, in 
Zambia, they are defined as: 
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 Informal - total investments (excluding land and buildings) under 50M 
Zambian Kwacha, less than 10 employees and not being registered with the 
Registrar of Companies; and  
 
 Microenterprise - total investments under 80M Zambian Kwacha, annual 
turnover not exceeding 150M Zambian Kwacha, and being registered with the 
Registrar of Companies (note: USD $1 = ~ 5000 ZMKiii).  
 
Most informal and microenterprises in Zambia have less than 5 employees (GRZ, 
2008). After agriculture, retailer-and-wholesaler trade account for the second largest 
sector in which informal and microenterprises operate (Conway, 2010).  
In sub-Saharan Africa, the number of formal pharmacies is very limited 
(Goodman, 2007), particularly in rural areas. IPPs tend to be more common in both rural 
and urban areas of East and West Africa [e.g. Tanzania (Goodman et al, 2004), Uganda 
(Awor, 2012), Ghana (Ansah, 2015), Nigeria (Oshiname & Brieger, 1992), Cameroon 
(van der Geest, 1987)]. However, in some countries such as Zambia, Malawi and 
Mozambique, neither of these retailer types is common, particularly in rural areas. As in 
many developing countries, access to medicines in Zambia’s private sector is largely 
confined to pharmacies and drug shops in urban settings (Goodman, 2004; McCabe et al., 
2011; Yadav et al, 2012; Cohen et al., 2010; Wafula et al., 2012). The fact that there are 
less than 100 pharmacists (i.e. Bachelor of Pharmacy) in Zambia and only 59 pharmacies 
(40 of which are in Lusaka) contributes to this confinement. Similarly, the lack of 
pharmacy technicians (i.e. diploma in pharmacy) in the country also keeps the number of 
drug shops low (Dalberg, 2008).  
All private pharmaceutical importers, wholesalers, and retail pharmacies in the 
country are required to employ a pharmacist registered with the Medical Council of 
                                                        
iii ZMK is now the outdated Zambian currency. New Zambian currency is ZMW (USD $1 = 5 ZMW). Conversion rate as of 
August 2013 (end of trial).  
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Zambia (Palafox et al., 2012). Licenses for the manufacturing, importation, wholesale 
and pharmacy retail of medicines are issued by the Zambian Medicines Regulatory 
Authority (ZAMRA, previously the Pharmaceutical Regulatory Authority or PRA). The 
functions of the Authority as stipulated by the Medicines and Allied substances Act of 
2013 include the regulation and control of the manufacture, importation, storage, 
distribution, supply, sale and use of medicines and allied substances. It covers the 
registration of products, pharmacies, health shops and agro-veterinary shops. It is also 
responsible for post-marketing surveillance.  
Drug shops, registered with local governments rather than licensed by ZAMRA, 
are not required to employ a pharmacist. While they are only supposed to dispense over-
the-counter medicines, in practice, some also dispense prescription only medicines. These 
retail outlets are mostly limited to urban centers. Medicine prices and mark-ups within 
these private sector outlets are not regulated and are established by the market. General 
stores that focus mainly on the sale of FMCGs are another source of a limited number of 
over-the-counter medicines. Very little is known about these outlet types, and the 
literature on their characteristics and behaviors in Zambia is extremely limited. These 
outlets fall within the aforementioned informal microenterprise category.  
In rural Zambia, access to health care products and services is thus largely limited 
to public sector facilities. Here, a number of physical barriers to access are cited 
including: “insufficient infrastructure; inaccessibility due to geographic factors; sparsely 
distributed populations in rural areas; inadequate resources for outreach (fuel, vehicles, 
etc.); and poor scheduling of services leading to missed opportunities” (Ministry of 
Health, 2010). One rural Zambian study found that distance was a significant predictor of 
attendance for diarrhea treatment specifically (Chatt & Robert, 2010). In addition to 
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geographic access barriers, public sector facilities face regular stock outs of essential 
medicines like ORS and zinc. Thus, despite basic medicines being made available at no 
cost to patients as of 2006 (Masiye et al., 2010), essential and life-saving drugs were still 
widely unavailable in health facilities (Picazo and Zhao, 2008). 
In these places, the commercial private sector, and micro-enterprises like general 
retailers who focus on the sale of FMCGs more specifically, may provide a suitable outlet 
for expanding access and coverage to public health products (PHPs) at the community 
level. For the purposes of this analysis, PHPs are defined as products used for promoting 
health or for the prevention, management or treatment of diseases of public health 
significance. These can typically be provided at the general retail level without the 
delivery of an associated service (Conteh & Hanson, 2003). Examples of PHPs include, 
but are not limited to: mosquito nets, water purification tablets, condoms, micronutrient 
supplements (e.g. Sprinkles, Vitamin A, etc.), soap, and certain over-the-counter (OTC) 
medicines like ORS and zinc for diarrhoea.iv 
Operating out of fixed premises, these shops are ubiquitous in rural areas around 
the world and run on a for-profit basis. This has the added benefit of contributing towards 
local livelihoods. However, when it comes to understanding the potential of these 
retailers to provide PHPs, very little is known about them, particularly from a global 
health perspective. Few studies have attempted to address this gap and there is a need to 
expand geographic coverage of existing studies in order to cover a wider range of 
settings, capture potential variations, as well as different types of medicine sellers 
(Goodman et al., 2007). 
                                                        
iv Zinc now has over-the-counter status in most countries, but is still “in progress” or not yet secured in others; as of 
2013, of the 10 countries with the highest burden of child deaths from diarrhea: India, Nigeria, Pakistan, Kenya, 
Bangladesh and China have achieved OTC status; DRC and Uganda are “in progress”; and Ethiopia and Niger have not 
yet secured OTC status. Zinc is OTC in Zambia. (Unger CC, et al. Arch Dis Child 2013;0:1–6.) 
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Understanding the nature of various private providers is an important first step in 
the design of appropriate and effective strategies to increase coverage. In this study, we 
address this issue by exploring the potential suitability of general, commercial retailers 
for carrying PHPs, such as over-the-counter ORS and zinc, in Zambia. Taking a 
descriptive lens, this paper explores the infrastructure, staffing, ownership and operations, 
purchasing patterns and product preferences associated with these retail shops, as well as 
their level of engagement with an intervention to expand coverage of an innovative 
diarrhea treatment kit. It thereby attempts to shed light on the potential of these outlets to 
expand access to appropriate PHPs, particularly in rural areas.  
It has been suggested that expanding access to treatment for diarrhea could benefit 
from private sector, market-based approaches (Fischer-Walker et al., 2009; Gill et al., 
2013).  The World Health Organization (WHO) and UNICEF advocate strategies to 
improve home-based management of diarrhea (UNICEF/WHO, 2009), with retailer 
interventions seen as one possible facilitator. ORS and zinc can be taken without much 
guidance or with simple instructions; there is minimal risk associated with their use (e.g. 
no threat of resistance); and they are recommended regardless of the causal agent.  
Timely and appropriate treatment of children under-5 years of age is particularly 
important in preventing dehydration and curtailing morbidity and mortality. Providing 
care through such retailers, closer to the household level, may be one way of addressing 
this.  
In order to better understand the provider landscape in Zambia, Appendix 6 
outlines the sources of pharmaceuticals at all levels of the health system, including both 
public and private outlets. The general retailer types that are the subject of this paper are 
highlighted in green. They included independent general stores, kiosks, and kantemba 
136 
commonly found across the “last-mile” in rural Zambia and who focus on the sale of 





This exploratory study was conducted in four rural districts of Zambia – Kalomo 
and Monze in Southern Province, and Katete and Petauke in Eastern Province. The 
districts are 200-480km from Lusaka with few paved roads outside of the district towns. 
As in most of rural Zambia, access to health care products and services is predominantly 
through public sector health facilities. However, only 50% of rural households have a 
health facility within 5km (Chankova and Sulzbach, 2006).  
The four districts were purposively selected as representative of a typical rural 
setting in Zambia, with high burden of diarrhea in children under-5, limited access and 
unreliable effective use of ORS and zinc, and presence of community-level general stores 
spread throughout the districts. Further district selection criteria associated with the larger 
study are outlined elsewhere (Ramchandani, Paper 1). 
Data were collected as part of a larger study focused on determining the effect of 
emulating commercial, private sector value-chains on uptake of ORS and Zinc (in the 
form of a newly introduced diarrhea treatment kit – Kit Yamoyo®) for childhood 
diarrhea (Ramchandani R., Paper 1). Information gathered from this general retailer study 





Retailer Survey  
Data were gathered across all four districts using retailer surveys. A structured 
questionnaire was administered to proprietors (shop owners in most cases) of 
community-level, commercial, general retail outlets commonly found throughout rural 
Zambia. Surveys were administered by trained, local enumerators in face-to-face 
interviews with the retailer. Enumerators were recruited through an external data 
collection agency. All enumerators had previous survey experience. They were trained by 
the project over the course of one week and administered all surveys in the local language 
(professionally translated and back-translated). Surveys typically took between 40 and 60 
minutes to complete. Fieldwork was carried out over the span of three weeks. All surveys 
were carried out on Samsung tablets using Open Data Kit (ODK) software. 
The retail outlet survey used a questionnaire with both closed and open-ended 
questions. Surveys collected data relating to the proprietor of the shops as well as the 
respondent (usually one and the same); physical aspects of the shop; purchasing, sales 
and stocking patterns; wholesaler preferences; products carried (including medicines); 
pricing and profits; and information relating to the customer base. Variables of interest 
were identified based on project interests, market research frameworks and factors 
explored in other retailer-focused studies, both within the healthcare and general retail 
sector (Kumar, 2013; Cheungsuvadee, 2006; Carpenter & Moore, 2006, McCabe, 2011, 
Wafula et al., 2012). Table 4.1 provides the conceptual framework used to select 
descriptive factors in assessing the potential of rural retailers to serve as private providers 
of PHPs.  
While the vast majority of the analysis draws on cross-sectional data gathered 
during the midline of the larger study in March of 2013, information relating to the 
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experience of retailers with regard to selling Kit Yamoyo was also gathered at endline 
(2013). Therefore, in order to highlight the level of retailer engagement and motivating 
factors for becoming a Kit Yamoyo retailer, some results also draw on the endline survey 
conducted in August of 2013. The latter analysis draws only on data gathered in the two 
districts that received the intervention as part of the larger study (Kalomo and Katete). 
Midline data were used for the majority of analyses, as the dataset was more 
complete and some of the questions were refined in the midline questionnaire based on 
lessons from the baseline. Given the variables of interest for this study, there was limited 
concern with regard to potential bias associated with using midline data rather than 
baseline data. In the cases of analyses where the larger intervention may have influenced 
the variables of interest (e.g. diarrhea treatments carried) the analysis was adjusted 
appropriately and is addressed within the results section. GPS coordinates for the shops 
were also gathered and used for outlet mapping. This resulted in an open source, 
interactive Google map that has been published separately and shows the locations and 
basic information pertaining to selected shopsv.  
 
Sampling  
A recognized challenge when trying to construct a sampling frame of retailers 
within districts is that the number and locations of informal retailers are often not known 
(Conteh & Hanson, 2003). Formally, once a company is officially registered, the business 
is supposed to submit a copy of the company certificate to the licensing officer at the 
local (district-level) council. Discussions with district council officials, however, revealed 
that records of registered shops were typically incomplete or outdated. This is supported 
                                                        
v http://www.colalife.org/2013/05/13/a-virtual-tour-of-the-kit-yamoyo-retailers/ 
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by findings from the Zambia Business Survey (Conway, 2010), which found that only 
5% of firms in the informal, micro and small enterprises (MSME) universe reported 
having municipal licenses, only 3% reported being commercially registered, and only 2% 
reported having a tax identification number from the Zambia Revenue Authority (GRZ, 
2008). Informal and microenterprises typically do not comply with licensing 
requirements, particularly if they are located in areas designated as disadvantaged 
(UNCTAD, 1998).  
Because of this lack of insight into the population or universe of retailers, we first 
conducted a pre-study census, or inventory of general retailer shops. In order to identify 
as many rural general shops as possible within each district, each district-level, centrally 
located wholesaler that was participating in the larger study was first approached to 
identify retailers that purchased from them. However, these types of records were 
typically not kept, and they were able to offer little insight into the numbers or locations 
of their clientele. Identification of shops was thus done in coordination with key 
stakeholders including the District Planner from each district who physically 
accompanied the research team, resulting in a sampling frame of between 55 and 65 
retailers per district.  Based on discussions with district council officials, the sampling 
frames for each district were perceived to be relatively close to the actual total population 
of rural, community-level retailers within them.  
Once retailers were located, their coordinates were recorded using GPS and then 
mapped using GIS software. In many communities, groups of retailers were clustered 
together in one particular area (i.e. a “shopping center”). Using GIS software, we were 
able to group retailers into 12-15 clusters/sites per district, with one or more retailers 
forming the center of each site and providing good geographic coverage of rural areas 
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within the entire district. These sites helped form the basis for the sampling strategy used 
as part of the larger related study (Ramchandani, Paper 1, Figure 2.3). Parts of the district 
close to or within town (“urban center”) were not part of the “census” of shops and were 
excluded so as to maintain focus on rural parts of the districts only. All sites were at least 
10km from the district town.  
 
Sample Size 
Based on the market needs of the larger intervention, budgetary and project 
considerations, and the clustering of shops within certain communities, a random sample 
of 45 shops per district was targeted for interview with retailers from all clusters being 
represented. In order to verify the adequacy of this sample size for estimating population 
parameters of interest, we used a post-hoc calculation for estimating the sample size 
required for a descriptive study based on a proportion (Hulley et al., 2013). Very little 
data is available on general retailers in Zambia, particularly with regard to access of 
public health products, thus it was difficult to find appropriate reference indicators to 
assess expected proportion. Reason for not stocking ORS or zinc was one of our 
outcomes of interest. Thus, the estimated proportion used as a basis for our calculation 
was drawn from a 2008 outlet survey conducted by the Clinton Health Access Initiative 
in Zambia, which found that 44% of general retail outlets cited regulatory issues as being 
the reason for not stocking antimalarial products (CHAI, 2008). Based on a 95% 
confidence level and precision of 0.18 (CI width), the desirable sample size for the study 




Data Management, Quality and Analysis 
Consistency checks and skips to avoid entry of erroneous data were automated in 
the electronic surveys. Where applicable, some responses were verified by observing 
sales receipts and other records volunteered by providers. All data was crosschecked by 
trained field supervisors on a daily basis and then uploaded to a central server each 
evening. Uploaded data was then checked by a data specialist from the data collection 
agency for completeness and consistency, as well as coding of open-ended responses. In 
cases of inconsistency, missing responses, or other questions, the data specialist flagged 
them for discussion with supervisors and the principal investigator for any necessary 
follow-up with interviewers. All analyses were conducted using STATA version 13 
(StataCorp, 2013). Unless there were significant differences between districts on 
particular variables, presented results are based on pooled data across the four districts 
(except for variables relating to participation by retailers in the larger intervention, which 
is limited to data from the intervention districts).   
 
Ethical Approval and Consent 
Ethical approval for the study protocol was obtained from ERES Converge in 
Zambia, with approval for secondary analysis obtained through Johns Hopkins School of 
Public Health Institutional Review Board. Informed consent was obtained from all 
respondents prior to survey administration. Shop owners were prompted about the 
surveys during recruitment and training stages, and advised to inform and authorize their 
employees to cooperate with project researchers during data collection. Owners were also 
assured that the study was not connected with the tax or drug regulatory authorities, and 
that data collected would be confidential. Both national and district level government 
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health administrations authorized the implementation of the study while community-level 
approval was obtained through local chiefs.  
Results 
 
Rural Health Markets in Zambia 
A total of 180 retailers were interviewed in March of 2013 – 41 in Katete, 54 in 
Petauke, 38 in Kalomo, and 47 in Monze. All of the households sampled across the four 
districts as part of the larger study (Ramchandani, Paper 1) had some form of general 
retail store within 5km. It is not unreasonable to suggest that this is representative of rural 
communities throughout the country. These shops typically operated along or close to the 
main dirt road running through the center of villages. Smaller villages might only have 
one shop, while larger villages could have a cluster of up to 10 shops forming a 
community hub. Aside from rotational markets that pop-up at certain intervals in some 
larger communities (out of scope for this study), these are generally the only places 
community members can purchase goods on the open market without having to go to the 
main district town.  
Surveyed shops were asked to define what type of shop they were with reference 
to what they sold. Shops most commonly identified themselves as grocery stores (94%). 
The second most common identifier used was clothing store (31%) and the third most 
common was general store (18%). Very few shops identified themselves as having 
anything to do with medicines or drugs, with only 1 or 2 identifying as such in each 
district (3% overall). Retailers were able to identify themselves as more than one type of 
shop. Other less common descriptors included hardware store (9%), tavern/pub (3%), and 




The majority of shops were individual, freestanding buildings (Figure 4.1-4.3). 
Most (82%) had one room while 14% had two, and only 4% reported having 3 or more. 
92% of the shops had floors made of cement while the remainder had exposed earth. The 
roofs of all but one shop were made of metal sheets.  
Almost all retailers stored their entire inventory within the shop itself. Sixty-three 
percent of them kept the inventory solely on the shelves in the shop where the items were 
displayed for customers, while 34% noted using the shelves as well as some other area 
within the shop for storage. Only 6 retailers (3%) noted storing goods in a separate 
building.  
 
General Store Owners, Staff, and Operations 
The majority of retailers  (Figure 4.4-4.6) interviewed were the shop owners 
themselves (68%) or family members of the owner (29%). Only 3% of respondents were 
unrelated employees. Few shops had more than 3 people who worked in them, with most 
shops having only one (26%) or two (59%) workers, and a few having three (12%). The 
businesses were predominantly male owned (83%), with only 17% of owners being 
female.  Overall, 67% of respondents were male and 33% were female. The average age 
of respondents, including owners, was 34.9 years old, while it was 27.9 years old if 
owners were excluded. The average age of shop owners alone was 38.4 years old. Ages 
of the respondents ranged from 14 to 83 with a median age of 33.  
Retailers, including both owners and staff, generally had the same levels of 
education. Among retailers, there was no significant difference between males and 
females (p=0.715) with regard to having higher than primary education. Analysis from a 
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related study (Ramchandani R., Paper 1) shows that this was not the case within the 
caregiver population, where there was a significant difference between males and females 
with regard to education levels, with males being more likely to have higher than primary 
education compared to females (OR=2.5; p<0.001). Nonetheless, when compared to the 
general population of caregivers, retailers’ levels of education were significantly higher 
even after controlling for gender. 29% of retailers had higher than primary education 
(above grade 9), while only 7% of caregivers did (OR =3.4; p<0.001). As with the 
general population of caregivers (Ramchandani R, Paper 1), education levels of retailers 
were correspondingly higher in Southern Province districts than in Eastern Province 
districts.  
Opening and closing times were collected from each shop in order to calculate the 
mean and median hours of operation. Both the mean and median were the same, with 
shops being open an average of 12 hours per day. Sixty-one percent of shops were open 
for at least 12 hours, with the minimum amount of time being 5 hours and the maximum 
being 17 hours. Most shops opened on the hour at 6am (34%), 7am (28%) or 8 am (20%), 
and closed on the hour at 8pm (31%), 7pm (20%) or 6pm (19%). The vast majority of 
shops were open year-round, with only a few (8%) being closed during certain periods of 
the year. The majority of these seasonally closing shops (87%) were concentrated in 
Petauke with the most likely months of closure being December or January. 
Most shops had been running for relatively short periods of time. Sixty-three 
percent of shops had been in operation for less than 5 years, with 18% running for less 
than a year. The average length of times shops had been in operation was 5 years, with 
only 20% of shops having been in operation for 10 or more years. The longest reported 
time a shop had been running was 30 years.  
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Only 38% of retailers reported maintaining any kind of records for the store. Of 
those that kept records, content included the quantity of goods purchased (66%), 
wholesaler prices for goods (69%), inventory and stock levels (54%), goods sold (49%), 
retail/sales price (44%), and to a lesser degree profits (16%), credit (6%), and other types 
of information (10%).  
 
Purchasing Patterns 
Most retailers purchased goods from multiple wholesalers. 19% reported 
purchasing goods from two wholesalers, 28% from three, 27% from four, 8% from five, 
and 9% from more than five. 2% of respondents were not involved in the purchasing of 
goods, so were unfamiliar with the total number of wholesalers frequented. Only 7% of 
retailers purchased exclusively from one wholesaler.  
Almost all general retailers reported purchasing goods from wholesalers within 
their own district. Depending on proximity, some retailers also purchased goods from 
other districts. Out of all retailers across the four rural districts, 18% also reported 
purchasing from Lusaka. Table 4.1 shows the proportion of retailers from each project 
district that reported purchasing goods from wholesalers by location.  
Overall, project retailers travelled a reported mean distance of 46km to get to a 
wholesaler, and a median distance of 35km (IQR=5-230). The distance to wholesaler 
varied by district, with means, medians and inter-quartile ranges shown in Table 4.2. 
Most retailers visited wholesalers in order to purchase goods multiple times per month. 
29% of retailers visited twice a month, 13% visited three times a month, 27% went four 
times a month, and 19% made the trip to purchase goods more than four times a month. 
Only 12% of retailers reported visiting just once a month.  
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Modes of transport to purchase goods from wholesalers also varied, with the 
majority of retailers employing public modes of transport (62%). Table 4.3 shows the 
various modes employed and the proportion of retailers using that mode as their most 
common form of travel to the wholesaler and for transporting goods. 
As the final link in the rural market value-chain for getting products to the 
community, we wanted to understand retailer opinion on their choice of product supplier. 
Retailers were therefore asked why they preferred to use particular wholesalers. The price 
of goods was the most common reason cited for selecting a particular wholesaler, with 
86% of retailers identifying it as a key factor. The selection of goods available, 
specifically having all the items required by retailers, was the second most common 
reason cited, with 65% of retailers citing it as a key factor. 44% of retailers also identified 
friendly staff as an important factor, making this the third most common reason cited for 
selecting a particular wholesaler. Other reasons cited were less frequent, but included the 
quality of goods, having a credit facility available, transportation related factors such as 
available routing and lower fees, the security of the shop, as well as regularly offering 
discounts and promotions.  
Retailers spent an average of 1.16M Kwacha (ZMK5000 = $1USD at time of 
study) during their last wholesaler purchase. However, after removing the top 10% of 
retailers (by expenditure), who all purchased goods valued at over ZMK 3M, the mean 
expenditure reduced to ZMK 713,377, with a median expenditure of ZMK 500,000. 
Expenditures were confirmed by observing the retailer’s receipt where available (23%). 
Figure 4.8 shows the proportion of retailers within our sample and their expenditures 
during their most recent wholesaler purchase. The top graph includes the expenditure of 
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all retailers who knew what they spent, while the bottom graph removes the top 10% of 
retailers and groups the remaining retailer expenditure into 20 bins.  
Expenditure relating to transportation varied by the mode of transportation used.  
Some of the retailers who used public transport incurred charges for transporting goods 
(i.e. luggage fee based on volume or weight), while others only had to pay for their 
individual fare. Overall, most incurred a charge for both (67%), while 25% incurred no 
expenses relating to transportation. Those using private transportation reported 
expenditures mainly relating to fuel charges. Overall, 74% of retailers in our sample said 
they incurred some form of expense related to transportation. The majority of retailers 
who did not incur costs for transporting goods (n=45) used bicycles (73%).  
The average cost of transporting goods for those using public transport was ZMK 
37,782, with a median expenditure of ZMK 25,000. The mean expenditure for those 
using private transport was ZMK 172,916, with a median expenditure of ZMK 90,000. 
Higher expenditures for those transporting goods in private vehicles were mainly 
associated with fuel charges (e.g. to Lusaka). The individual round-trip fare for those 
taking public transport averaged ZMK 35,532, with a median of ZMK 30,000. The most 
common individual round-trip fares paid by retailers taking public transport were ZMK 
20,000 (25%), ZMK 30,000 (25%), and ZMK 40,000 (10%).   
 
Goods & Services 
An understanding of the fast-moving consumer goods most commonly purchased 
and sold by rural retailers can help provide insights and lessons for public health 
commodities, not least of which are the margins that are made and expected by retailers.  
Table 4.4 summarizes the top ten most common FMCGs reported by rural general stores 
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based on our sample. The majority of leading brands were local, and on average, retailers 
made a gross margin of 29%.  
Interestingly, with regard to Coca-Cola, a product perceived to be ubiquitous in 
rural retail shops, only 49% of retailers claimed to always (28%) or only sometimes 
(21%) carry Coca-Cola. 51% claimed to never carry Coca-Cola. Although Cola was a top 
FMCG, Coca-Cola was not mentioned as a common brand.  
The most important factors considered by retailers when selecting what goods to 
purchase included customer demand for specific items and profit margins. 94% of 
retailers cited the former and 67% the latter. Other factors cited, but to a much smaller 
degree, included the quality of goods as well as having the available capital for 
purchasing goods.  
In the same way some retailers valued wholesalers that provided credit services, 
they also recognized the value of providing such services to their customers. 79% of 




Not counting the diarrhea treatment kit introduced as part of the larger study, 53% 
of retailers said they purchased some type of medicine during their last wholesale 
purchase. Table 4.5 provides a summary of the types of reported medicines purchased 
and the proportion of retailers that purchased them. Aside from basic analgesics 
appropriate for general sale, other medicines were not a common purchase during the 
most recent wholesaler visit. While medicines not appropriate for general sale were 
purchased by a small number of retailers, cases were isolated.  
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Retailers were also asked whether they were selling products for the treatment of 
diarrhea more specifically. Again, after controlling for the Kit Yamoyo diarrhea 
treatment kit, thirty percent of retailers claimed to sell at least one type of diarrhea 
treatment. Retailers reported selling products for the treatment of diarrhea including 
Panado (7%), Flagyl (21%), Stomache (7%), Indocid (6%) and magnesium (1%). None 
of these medicines are recommended for the treatment of acute diarrhea.  
Of those retailers who claimed to not carry any treatment for diarrhoea, the top 
reasons provided for not doing so, based on open-ended questioning, included the 
perception of not being allowed to sell medicines (24%), not knowing what product to 
sell (23%), not having enough capital (17%), not feeling comfortable selling medicines 
(11%), rural health centers already providing treatment (18%), and products not being 
easily available (9%).  
It was clear to retailers, however, that diarrhea was an important health issue for 
children under 5 within their community. When asked to identify the key health issues for 
children under 5, based on open-ended questioning, malaria (89%), diarrhea (83%) and 
coughing (69%) were the top responses provided. Eighty-seven percent of retailers noted 
that they had previously been asked for advice on diarrhea treatment. 
To better understand the sophistication of processes in place at rural retail shops, 
we explored whether retailers had procedures in place to ensure that the earliest items to 
expire were sold first. This is particularly important for products such as medicines and 
other perishables. Only 46% of retailers claimed to have processes in place to monitor 
expiration dates and ensure that those goods to expire first would also be sold first. 54% 




Retailers reported having more female customers than male customers. Overall 
59% of retailers reported that women frequented their stores more often than men, while 
29% reported no difference and 12% reported having more male customers.  
With regard to daily patronage, retailers were asked how many customers visited 
their shop during the previous day. On average, shops reported having 31 customers per 
day with a median of 20 customers per day. The reported number of visits ranged from 0 
to 160 customers per day.  
 
Retailer Participation in Provision of Public Health Product (PHP)  
Within the context of the larger related study, retailers within two of the districts 
(i.e. intervention districts) adopted the Kit Yamoyo diarrhea treatment kit as one of their 
products, becoming outlets for ORS and zinc. The endline survey gathered information 
relating to their experience. Some of the relevant findings are presented here.  
At endline, a total of 77 retailers were surveyed across the intervention districts 
(36 in Katete, 41 in Kalomo). All of these retail shops had someone attend the training 
workshops conducted by the project. In the majority of cases - 76% in Kalomo and 97% 
in Katete - the owner of the shop attended the training. If not the owner, the person was 
typically a family member who also worked in the shop. Those attending the training 
were trained to pass along the information/lessons to other employees within the shop, 
and provided with materials to facilitate proper messaging. It was envisioned that this 
training would then cascade down to caregivers and clients of these retailers when they 
were purchasing Kit Yamoyo.  
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Retailers were trained on topics that were both general (relating to prevention and 
treatment of diarrhoea) and product specific. All retailers were provided with training 
materials (in a mostly pictorial calendar-type format). They were encouraged to keep the 
materials on hand in their shop so they could relay key health messages to customers, 
including the benefits of the product and when to go to the clinic. While the OTC product 
was designed to be self-sufficient and not require any attached service, the impact of 
training and quality of retailer-customer interaction will be an area of future research.  
We sought to identify the key motivating factors for involvement in the sale of the 
diarrhea treatment kit. 90% of retailers identified helping children and their community 
as the number one reason for being involved. Profit was the second most common 
response, with 60% of retailers identifying it as a key motivating force. Retailers were 
also asked what they liked most about selling the kits, with the same responses leading. 
62% of retailers in the intervention districts said helping children and the community, 
while good profit was noted by 30% of retailers.  
The vast majority (86%) of retailers did not dislike anything about selling the kit. 
Of the few retailers that specified something they disliked (n=11), there was a common 
theme relating to the system in place for the distribution and redemption of vouchers, 
which were used by the larger intervention to catalyze demand and facilitate access by 
the poor. Despite any potential challenges faced by retailers, 100% of retailers in the 
intervention districts planned to continue selling the kit, even after vouchers had been 
removed from the system. In addition, when asked if they would be interested in 
participating in a future pilot where they, as retailers, may act as channel distributors for 
public sector medicines to community level health centers or CHWs, 94% of them said 
yes. The 6% that said “no” ranged in age from 58 to 83 and cited being “too old” as their 
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reason for not being interested. Age was found to be a significant predictor of interest in 
participation, with older retailers being less likely to want to participate in the potential 
new access to medicines program (OR = 0.86; P<0.01).   
Retailers were encouraged to keep a constant stock of kits by project field staff. 
On the day of the survey, 76% of retailers in the intervention districts had kits in stock. 
With reference to stock-out duration within the previous month, 49% of retailers reported 
never being stocked out, 69% reported never being stocked out for more than a week, 
80% reported never being stocked out for more than 2 weeks, and 8% reported being 
stocked out for the entire month. Overall, the average monthly stock-out duration across 
all retailers in the interventions districts was 7 days.  
 
Discussion 
This descriptive study adds important information to the global knowledge base 
around rural, commercial, private-sector, general retailers operating in markets at “the 
base of the pyramid” (Prahlad, 2005). With reference to rural Zambian retailers more 
specifically, it brings to bear previously undocumented analysis that may help inform 
market-driven public health programming within and outside of the country. While there 
are other factors that can be assessed, the selected features focused on during this 
situational analysis facilitate a deeper understanding of how these retailers operate, and 
are aligned with previous studies exploring private sector retailers operating within health 
systems.  
In addition to larger related studies (Ramchandani, Paper 1 & 2), this paper 
indicates that the introduction of a diarrhea treatment kit through general retailers is 
indeed feasible and can improve access. Longer-term follow-up studies with other 
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products may be useful. It also provides key insights into the characteristics and 
operations of these retailers, an essential first step in maximizing their value and 
effectiveness as potential channels for PHPs. Reasons for prioritizing our understanding 
of these types of providers and the markets they operate in are essential to effective, 
efficient, and ethical operations – whether in the global health context, or otherwise.  
Key reasons for enhancing our understanding of these retailers in global health 
include the fact that PHPs are typically directed at important public health issues (Conteh 
and Hanson, 2003); the potential exists for expanding coverage of PHPs, particularly 
amongst the poor (Ramchandani R., Paper 1); this retailer-type (general retailers) are 
typically more ubiquitous than pharmacies or drug shops; private providers are generally 
an important, if not untapped (as in Zambia) source of PHPs; understanding them is a 
prerequisite for more effective interventions, better regulation and consumer protection 
(Bloom and Standing, 2008; Peters & Muraleedharan, 2008; Ball, 2011); and there exists 
a potential for freeing up capacity and resources within the public sector (e.g. task 
shifting) (Ichoku et al., 2013). In addition, understanding these retailers is essential to 
building a systematic appreciation of these markets in order to support collaboration 
between key actors and build institutional arrangements that could incentivize better 
performance (Bloom et al., 2011). Stakeholders with interest in these results may consist 
of Government (both local and national), development agencies, NGOs, social innovators 
and corporations with interest in emerging markets.  
Almost all shops (94%) identified themselves as grocery stores, in addition to 
other identifiers. Grocery stores generally sell products that are in the FMCGs category. 
These types of products attract the repeated and frequent patronage of customers resulting 
in regular contact between shopkeepers and community members. This, in turn, has the 
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potential advantage of exposing customers to new products, as well as being able to share 
information on a regular basis. This can be enhanced in the presence of promotional 
materials, information from the retailer as well as community-level promotion via 
promoters and radio (Borapich et al., 2010). This is particularly relevant in setting where 
word of mouth plays a strong role in building brands, far more so than in urban areas 
(Kapur M et al., 2014). Thus, the type of shop may have an indirect influence on 
awareness, access and use of the commodity.  
Due to density or clustering of shops in most villages, it is likely possible to gain 
penetration/coverage within a particular area even if only one shop carries the product. 
Given that most shops carry the same types of products, even one shop carrying a 
particular item within these community hubs may incite competition in the market 
leading to more intensive distribution. Also, given that these hubs are generally the only 
places to purchase goods at the community level, and are regularly visited by community 
members, they would likely serve as good locations for social marketing and health 
promotion activities.  
The majority of retail shops in rural Zambia were relatively basic, one-room, 
brick-and-mortar buildings with cement or dirt floors and metal sheet roofs. Generally 
speaking, these outlets were not equipped to carry large products and storage was mostly 
limited to the floor or shelves within the shop. This has implications for the types of 
products such retailers can carry, limiting them to smaller, more manageable items. This 
conclusion is further supported by the fact that the majority of retailers used either public 
transport or bicycles when acquiring goods from wholesalers, limiting their carrying 
capacity for transporting goods back to the community-level for sale. It is important to 
note that the physical space used for storage of goods in such shops is in line with the 
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type of storage conditions one would find for basic non-prescription, non cold-chain 
requiring medicines in most rural health centers. 
Interventions involving training of retailers need to consider how lessons and 
skills are passed along to other retailers within the shop. Above average levels of 
education, having only one or two other retailers per shop, and most retailers being 
family members are factors that will likely facilitate trained retailers being able to pass 
along training. Training topics gleaned from this research that would be worth covering 
include, but are not limited to: record keeping, inventory management (e.g. expiration, 
safe storage and transport, etc.), and of course product-specific benefits (for retailers and 
users).     
The relatively long work hours of rural general store retailers are well above the 
national average of 8 hours per day within the formal employment sector (CSO, 2008). 
They also compare well with the operating hours of rural health centers, which according 
to our analysis of recent IHME data from Zambia (IHME, 2015) is an average of 10 
hours per day, although some remain open longer, at least in theory. Holding other 
factors constant, these longer hours may be associated with improved access to diarrhea 
treatment, however this analysis was out of scope for the current study.  
While closures during certain months of the year were rare, the most common 
months of closure being December and January makes sense given that these months 
align well with the peak of the rainy season (Dec-Feb) or what is sometimes called the 
“hungry season” in Zambia (Jan-March). This is when factors such as a long dry season 
and a lack of irrigation infrastructure, which result in only one harvest per year, combine 
with families that rely on subsistence agriculture and a rural economy that is largely 
agrarian. Harvest income must cover household needs for the subsequent 10-12 months, 
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but often runs out in the months leading up to the next harvest. Lower levels of 
disposable income characterize this period (Fink, 2014). If people are buying less during 
this period, it follows that retailers would be less inclined, and perhaps in less of a 
position themselves, to purchase goods from wholesalers for sale at the community level. 
In addition, travel may become more difficult during the heaviest periods of rainfall as 
road conditions worsen.  
While almost all retailers purchased goods from wholesalers within their own 
districts, a significant proportion of retailers from all districts also purchased goods from 
Lusaka. This indicates that it may also be beneficial to establish a market for the product 
within major urban centers, particularly within the context of any scale-up strategy. 
In this way, the product may be cascaded into more rural districts, while interventions can 
focus efforts more centrally. This could be an effective approach in helping shape the 
national market by providing an access hub for all districts, thereby contributing to 
longer-term sustainability by providing an anchor supply. 
The fact that retailers purchase from multiple wholesalers also has implications 
for improving availability of PHPs. Rather than having only one location where 
medicines can be collected by terminal outlets (as is sometimes the case for rural health 
centers that have to collect stock from the district warehouse themselves), private sector 
provision through multiple wholesalers for certain PHPs could facilitate wider 
availability at the community level.  
The frequency of visits made by community-level retailers to wholesalers is also 
relevant. With 88% of retailers visiting a wholesaler two or more times per month, the 
opportunity for regular re-stocking of goods, including PHPs, improves upon the public 
sector delivery schedule. Delivery to rural health centers only takes place once or twice a 
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month, pending on the storage capacity of the facility, in standardized quantities 
(Vledder, 2015).  
Tapping into multiple retailers within a particular geography, who make the trip 
from communities to district centers on a regular basis, could substantially increase the 
opportunity for improving availability. This type of atomized distribution, which are 
channel arrangements that bring products as proximate to customers as possible – usually 
through small or individual distributors – has been shown to enhance new product 
adoption in rural markets (Nakata C. & Weidner K., 2012). This type of parallel private 
sector channel distribution, could complement the traditional three-tier drug distribution 
system in Zambia (where the central warehouse supplies district warehouses, who in turn 
send supplies to the health facilities). Further comparisons to the public sector relating to 
various aspects of distribution would be useful. 
Furthermore, these existing distribution channels could go beyond simply 
complementing the public sector, and in fact help address weaknesses in public sector 
provision by providing an alternative supply-chain mechanism. General retailers, already 
transporting goods in small quantities between district centers and the community/village 
level could be incentivized to act as agents for storage, collection and transport of public 
sector drugs/kits. While the larger medical supply needs of health centers will likely 
require ongoing strengthening of public sector supply-chain logistics, utilizing private-
sector micro-distribution networks to deliver medicines/kits – particularly basic, OTC, 
non-cold chain PHPs – to heath centers, health posts and community health workers may 
be one way of addressing sub-district/sub-HC supply-chain bottlenecks. Such a model 
could dovetail well with country primary health and integrated community case 
management (iCCM) services.  
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By leveraging these existing networks of retailers, as well as the wholesalers that 
supply them, interventions can avoid large investments in establishing parallel supply 
chain systems and community-level outlets which are likely to prove difficult to sustain. 
Given the potential improvements in effective access and utilization, this could represent 
an extremely cost-effective use of resources and should be studied further. Indeed, studies 
that have explored cost effectiveness around the use of private pharmacies specifically, 
both within and outside of Africa, have found this to be the case (Goodman et al., 2007).  
Retailers identified a number of factors that contributed toward wholesaler 
preference. These findings would indicate that helping to establish the lowest possible 
wholesale price (while simultaneously ensuring wholesalers make an acceptable margin), 
selecting wholesalers that carry a variety of other products commonly carried by rural 
general stores [i.e. a one stop shop rather than specialized (e.g. pharmaceutical) 
wholesalers], and good customer service, should be considered when targeting 
wholesalers to carry a particular PHP. In Zambia general wholesalers are able to 
obtain a license from ZAMRA to deal in over the counter (General Sales) items, 
which are required to be marked as such. Addressing the above factors may help 
facilitate adoption of PHPs by general retailers.  
General retailers carried a limited variety of medicines alongside a wider range of 
fast-moving consumer goods. Similar types of products were carried across the entire 
sample of retailers. With almost 60% of retailers already carrying some type of basic 
medicine, it would not be a huge leap to carry other types of basic over-the-counter 
PHPs. This concept is bolstered by the fact that advice relating to health concerns is 
sought from general retailers, with most retailers having been queried for advice on 
diarrhea treatment. 
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Primary drivers of deciding what products to stock included demand and profit 
margins, also supported by previous research (Palafox B, et al., 2014). In this way, 
retailers use local demand to drive supply of commodities according to need. Their 
stocking patterns might even be a way of predicting seasonal needs and disease patterns, 
a potential area for further investigation.  
With regard to selling diarrhea treatment specifically, it was interesting to note 
that lack of demand was not a reason cited by retailers for not carrying a diarrhea 
treatment product. Rather, other factors were noted suggesting that training/sensitization 
activities should take place to introduce new PHPs in order to help familiarize retailers 
with the product; build their confidence by equipping them with basic knowledge around 
the product, its management and the health concerns it addresses; as well as explain 
aspects relating to affordability, profit incentives, where to purchase the product, and any 
complementarity to public sector provision. These sensitization activities would help 
address some of the common concerns expressed by general retailers with regard to 
supplying medicines. 
Despite wholesalers within district towns carrying products from multinationals, 
local brands featured more prominently among the top selling FMCGs (e.g. Havana Cola 
vs. Coca-Cola). While there may be a variety of contributing factors (e.g. greater 
familiarity, lower cost, higher margins, greater demand, etc.), further study should 
explore whether local PHPs fare better than imported products when this comparison is 
feasible and this type of competition is present. Across the range of products carried, the 
average gross margin was 29%. Extrapolating to the introduction of PHPs, one might 
suggest establishing a price point that allows for similar gross margins as other FMCGs, 
as these levels are acceptable to general retailers. These retailers also seem to have the 
160 
capital required to purchase a variety of goods for which there is demand at the 
community level. The Kit Yamoyo diarrhea treatment kit was sold to retailers for ZMK 
3700 and to consumers for ZMK 5000, allowing for a 35% margin (Ramchandani R., 
Paper 1).  
As previously noted in the literature with reference to medicine sellers (Goodman 
& Brieger, 2007), our research found that rural, general store retailers are also interested 
and willing to participate in programs relating to health. This was particularly the case 
where helping children and their communities was concerned, as well as where there was 
a profit incentive. These were both highlighted as key motivators for participation in the 
intervention and selling of the Kit Yamoyo diarrhea treatment kit. While profit is 
important, ensuring that retailers understand the benefits to their communities, and 
imparting a sense of civic responsibility, would likely appeal to these retailers during any 
kind of recruitment/training process. Finding the right balance between these motivating 
factors would be an important part of any attempt in garnering their interest in solutions 
that help shape the market for PHPs.    
To better understand the effectiveness of providing PHPs, including ORS and 
zinc, through these types of general retailers, continued research is required. This is 
particularly the case where integration into the entire value-chain for these commodities 
is concerned. One priority is to compare the quality of advice/services provided by such 
retailers to those provided by health workers within public-sector facilities. Future studies 
should use mystery shoppers to assess the quality of interactions with customers as well 
as the effect of training on provision of health-related information and advice. 
 Although some treatments, such as ORS and zinc, can be easily administered at 
the household level, a greater understanding of the differences between provision through 
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general retailers and the formal health system will be important. In addition, comparing 
effective household utilization of PHPs based on provision through the public sector vs. 
the private sector will be important. Certainly, the degree of complexity of the PHP will 
determine which strategies are appropriate for what product. Complexity can range from 
a simple product (ORS and zinc, condoms, mosquito nets, etc.) through to products that 
may require more complex services (STI diagnosis and treatment), on to essential 
healthcare packages delivered by qualified health professionals. The nature of the product 
and associated service (along with prevailing regulations) determine the appropriate 
provider/channel to deliver that PHP (Smith et al., 2001).  
New Zambian legislation under the Medicines and Allied Substances Act (GRZ, 
2013) permitting the establishment of low-level “health shops”, similar to those found in 
Tanzania (Ndomondo-Sigonda, et al., 2003), will introduce a new dynamic in the private 
health markets used by the poor in Zambia. Research around their reach, ability to 
legitimize potential expanding roles of general retailers, and effect on access will be 
necessary.  
Finally, and more generally, while attempts have been made to develop a 
typology for the various types of private sector providers and the healthcare products 
and/or services they offer (Hanson & Berman, 1998), a standard, up-to-date, global 
taxonomy seems to be lacking. This includes a lack of consistent or systematic 
descriptions and definitions of private providers across countries and in the literature 
(Berman & Rose, 1996). With growing interest in the role of health markets, developing 
such a standard will be of importance. This research, and attempting to better understand 




Our findings were based on one of the more common methodologies used to 
study private sector supply of public health commodities (Conteh & Hanson, 2003). 
While retailer surveys are susceptible to various forms of bias, supplementing our 
research with data form household surveys (Ramchandani, Paper 1 & 2) allowed us to 
triangulate key variables, and enhance reliability and validity of our data. Being able to 
compare results at baseline, midline and endline periods also facilitated this. This was 
one of the factors that helped give confidence in using midline results to present the 
situational analysis rather than baseline. Nonetheless, as the findings in this paper are, for 
the most part, based on the midline retailer survey alone, it is worth discussing some of 
the potential limitations of the study.  
The key challenge with such surveys is that gathered information is largely 
dependent on reporting by the retailer. Thus, various forms of bias may have threatened 
reliability and validity, including recall bias and social desirability bias. While attempts 
were made to verify retailer expenditures during their last wholesaler visit by observing 
receipts, for example, only 23% of retailers provided them. Biases may also result due to 
sensitivities around specific topics associated with perceived loss of livelihood. For 
example, if a retailer is involved in the sale of medicines not approved for over-the-
counter provision, they may be less forthcoming with information. Future studies would 
want to incorporate direct observation of in-stock medicines rather than relying only on 
reported information. A closely related limitation within this study was that, aside from 
diarrhoea treatments, data on medicines were only collected in the context of what was 
purchased during the last wholesaler visit. Data was not gathered on all medicines in 
stock at the time of visit, which may have provided a more complete picture of what 
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types of medicines can be found at general retail outlets.  
The analysis relating to diarrhea treatments carried by retailers controlled for the 
introduced diarrhea treatment kit. However, because intervention district retailers were 
trained on the product, including the benefits of ORS and zinc, it is possible that this may 
have influenced their purchasing patterns with regard to other diarrhea treatments they 
may otherwise not have purchased.  
Finally, with structured surveys mostly quantitative in nature, there can be a risk 
of over-simplification leading to a lack of breadth and depth. Thus, in addition to using a 
mixture of methods to triangulate and verify data (including more qualitative 
approaches), we also attempted to mitigate these potential threats through substantial 
informal observation of and interaction with retailers. Many of the reported findings in 
this paper are also congruent with formal research that took place in parallel 
(Ramchandani, Paper 1 and 2).  
 
Conclusions 
In rural Zambia, there is great promise, and a largely untapped potential, in 
leveraging commercial, private sector, community-level, general store retailers to expand 
access to important public health products. Already transporting a variety of FMCGs 
from central-district to community-level, these retailers may, with the right balance of 
incentives (profit and social), serve as effective complementary points of access [to rural 
health centers] for basic products of public health significance, such as ORS and zinc.  
Tapping these underused, existing distribution channels may be a way to improve 
delivery of PHPs to the community level.  
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Figures for Chapter 4 
 
 





FIGURE 4.2: SHOP EXTERIOR 
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FIGURE 4.4: GENERAL STORE RETAILER 
  
FIGURE 4.5: GENERAL STORE RETAILER 
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FIGURE 4.6: GENERAL STORE RETAILER 
 
FIGURE 4.7: GENERAL STORE RETAILER 
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FIGURE 4.8: EXPENDITURE DURING LAST WHOLESALER VISIT 





Tables for Chapter 4 
 
TABLE 4.1: EXPLORATORY DESCRIPTIVE FACTORS CONSIDERED IN ASSESSING THE 
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Note: relevance/application of these factors is explored further in discussion section. 
TABLE 4.2: PROPORTION OF RETAILERS PURCHASING GOODS FROM WHOLESALERS 
BY DISTRICT 





















92.11    31.58    31.58 
Monze 
(n=47) 
 97.87     2.12  14.89 
Katete 
(n=41) 
  97.56   21.95  2.44 7.32 
Petauke 
(n=54) 






TABLE 4.3: REPORTED DISTANCE TRAVELED BY RETAILERS TO WHOLESALER (KM) 
 
District 
Mean Median IQR 
Kalomo 62 46 30-86 
Monze 47 35 18-50 
Katete 38 34 20-50 
Petauke 37 25 5-56 




TABLE 4.4: MODES OF TRANSPORT USED BY RURAL RETAILERS TO TRANSPORT 
GOODS FROM DISTRICT LEVEL WHOLESALERS 
Mode of Transport Used by Retailers Proportion of Retailers (%) (n=180) 
Public Mode  
Public Van/Bus 29% 
Public Truck 21% 
Public Car 12% 
TOTAL PUBLIC 62% 
Private Mode  
Bicycle 24% 
Private Van/Bus 6% 
Private Car 4% 
Motorcycle 2% 




















per Unit Gross Margin 





Roical*, Ole, Julie, 
Mama's, Amanita, Soja, 
Champion, Ambuya, 




Boom, Washa, Bullet, 
Xtra 















Boom, Romeo, Chapa, 
Geza, Yebo 200g and 500g 
4500 (500g) 
3000-3500 (200g) 5000 1500-2000 30-40% 
5 Biscuits Chicco, Petit, Spinners 125-150g 430-1500 500 & 2000 70 & 500 14%-25% 
6 Cola/Soda 
Havanna, King, Thirsty 
Pop, Mirinda 425mL 1500-2150 3000 1000 33% 
7 Talk Time MTN, Airtel, Cellz  NA variable 
1000-2000 
(most common) 200 20% 
8 
Fruit Flavoured 
Drinks Tangy, Best 350mL 1000-1500 2000-2500 1000 40%-50% 
9 Corn Snack Carnival Jiggies 22g 200-400 500 100-200 25-33% 
10 Batteries Tiger Head 12 batteries 1000-1200 1250-1500 250-300 20% 
 
*Brand names in bold signify most common brands mentioned of that particular FMCG 
+ Almost all shops would typically carry each of these products 
^ During the trial, the approximate conversion rate from kwacha to dollar was ZMK 5000 = USD 1
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TABLE 4.6: REPORTED MEDICINES PURCHASED BY RURAL GENERAL SHOPS DURING 
LAST WHOLESALER VISIT  
Brand  Medicine Type Method of Sale Proportion (%) of 
Retailers who 
purchased during 






General Sale 47% 
Cafemol Analgesic-antipyretic 
 
General Sale3 38% 
Chestcof Syrup Cough 
Syrup/Expectorant 






Flagyl1  Antibiotic 
(antimicrobial?) 
Prescription Only 3% 
Mr. Power2 Analgesic-antipyretic 
 
General Sale  3% 












Go Coff  Cough Syrup Pharmacy 
Medicine 
1% 
Safeplan Oral Contraceptive Prescription 
Only5 
0.6% 
Fansidar Antimalarial (SP) Pharmacy 
Medicine 
0.6% 
Stop Cold Sedating antihistamine – 














NA NA 43% 
 
1Eastern Province Only 
2Katete only 
3General sale medicine (GS) – are medicines which may be sold or supplied to the public without a 
prescription or the supervision of a registered pharmacist 
4Pharmacy medicines (P) - are medicines which are not to be sold or supplied to the public except by or 
under the supervision of the pharmacist or as may be prescribed by an authorized prescriber 
5Prescription Only Medicines (POM) - are medicines which may be supplied or dispensed only under a 
prescription issued by an authorized prescriber e.g. all medicines in injectable form 
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Chapter 5 : Recommendations Based on Findings 
 
This dissertation examined various aspects of emulating commercial, private-
sector value-chains of fast-moving consumer goods, such as Coca-Cola, to improve 
access to ORS and zinc in rural Zambia. Paper #1 analyzed the overall impact of the 
systems approach (i.e. addressing both supply and demand related challenges) on uptake 
of ORS and zinc. Paper #2 explored the application of human-centered design on product 
development and rational/effective use. Additional analysis aimed to better understand 
the relationship between rational/effective use and perceived efficacy of ORS. Paper #3 
provided a detailed description of rural, commercial, general stores in order to inform the 
potential of using these outlets as informal, private sector providers of basic public health 
commodities at the community level. A summary of key findings and their implications 
for public health are highlighted below as a set of recommendations.  
By applying similar principles to the development and introduction of an 
innovative diarrhea treatment kit, the ColaLife project was able to increase coverage of 
ORS and zinc combination therapy at the community-level in rural Zambia. Increasing 
coverage of ORS and zinc combination therapy is a commonly used proxy for reducing 
diarrhea-related morbidity and mortality in children under-5 (Fischer-Walker & Black, 
2010).  
A value-chain approach for improving access to over-the-counter public health 
products, like a diarrhea treatment kit, is the equivalent of applying a health systems 
approach to public health challenges. It attacks the problem from a variety of 
perspectives, requires a multi-sectoral approach, and considers issues relating to both 
supply and demand. Adopting such a lens can significantly improve coverage at the 
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community level and should be considered when aiming to improve access and coverage 
of public health commodities. Not all commodities would lend themselves to such an 
approach, however those that fall into the PHP category, should be considered. While this 
approach has been taken in certain countries where private sector access is the norm, very 
little public health literature addresses the concept in detail, and it should be considered 
in countries such as Zambia, where such access is limited.  
Adopting a human-centered design approach in the development of PHPs and 
other public health interventions allows for greater consideration of demand-related 
factors of access, such as acceptability, and can lead to improved product innovation, 
appropriate utilization and perceived efficacy, as well as a strengthened value-chain. 
Paper #2 revealed the benefits of adopting a human-centered design approach and 
looking beyond the access domain of price/cost alone.  
Evidence that standard 1-liter ORS sachets are often being prepared incorrectly at 
the household level (i.e. in the wrong concentration) and administered without zinc, has 
important implications for design and optimal product presentation, as well as 
appropriateness of setting. While compatible health center utilization (i.e. preparing for 
multiple patients, HCW preparing, etc.), 1L sachets are not ideal for household level use. 
In addition, our findings imply that one of the standard global indicators used to measure 
achievement in the treatment of diarrhea – coverage – may not be an accurate way of 
measuring progress. Global coverage figures cited for ORS, gathered through large-scale 
surveys such as DHS and MICS, likely overestimate use when considered from the 
perspective of whether the ORS is in fact prepared correctly. 
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Measuring effective/rational use of treatments is vital if considering the details of 
implementation. A medicine cannot be considered delivered until it is accessed and 
utilized in the correct way. Providing the design features necessary for caregivers to 
prepare the solution correctly would give the global health community more confidence 
in such coverage estimates, while simultaneously addressing barriers of access related to 
acceptability. This research demonstrated that co-packaging of ORS with zinc and soap, 
smaller sachets of ORS (i.e. 200mL), packaging that doubles as a measurement vessel, 
and enabling access through community-level general retailers (which presumes ORS and 
zinc have over-the-counter status) are features of an effective diarrhea product and its 
value-chain that can help enable greater access, including appropriate use, at the 
household level.  
While there has been a significant amount of research focused on private sector 
providers, and even informal private providers, very little literature exists on the potential 
of using general retailers for the supply of PHPs. These retailers are often ubiquitous at 
the community-level in rural communities around the world. Paper #3 provides a number 
of relevant insights that would suggest these retailers can be leveraged to improve access 
and coverage of important public health interventions such as ORS and zinc. This 
dissertation recommends consideration of these retail outlets as perhaps the most 
informal of the ‘informal private provider’ category. Indeed, by narrowing or using too 
rigid of a definition of competency, that remains within a biomedical paradigm, may limit 
potential positive contributions of such retailers with the potential to significantly expand 
coverage of life saving products. 
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The policy-level interest in such an approach, particularly in the area of product 
design, is reflected in the broad recognition the project has received from the global 
health community and beyond. In 2013, PATH, the Government of Norway, the UN 
Foundation and the MDG Health Alliance featured the original format Kit Yamoyo (i.e. 
‘The Aidpod’) as one of the Top 10 Breakthrough Innovations in Maternal and Child 
Health (PATH, 2013) at the Every Woman, Every Child event during the UN General 
Assembly. It was also featured as a Best Buy in Global Health (PSI, 2013) by partners 
including PATH, PSI, DEVEX and Merck for Mothers in Washington, DC that same 
year. In addition, part of the research that makes up the current dissertation received a 
Grand Challenges Rising Stars in Global Health Award. Also in 2013, the Kit was 
awarded the Product Design of the Year Award by the Design Museum in London, as 
well as the DuPont Packaging Innovation Award (Diamond level and ‘Food Security’ 
awards) in Wilmington. The Kit was also recognized at the Observer Ethical Awards in 
the ‘Products and Services’ category. Other accolades have included FastCompany’s 
Innovation by Design Award (Social Good category, 2013), the Financial Times - 
International Finance Corporation Transformational Business Award in Health (2014), 
the GSK – Save the Children Healthcare Innovation Award (2015) and the 2015 UK 
Packaging Awards for the new format flexi-pack Kit (2015). More recently, the global 
Diarrhea and Pneumonia Working Group featured key lessons learned from our work in 
Zambia as part of a high-level policy document.  
Perhaps one of the most practical policy impacts has been the procurement of co-
packaged kits (branded as Government of the Republic of Zambia product) by the 
Ministry of Health, for distribution through the public sector. This is part of the resulting 
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national scale-up process (Kit Yamoyo Transition to Scale - KYTS) which is taking place 
under the global Scaling-Up Nutrition movement, as well as with funding from UK Aid. 
Zambia is one of the few African nations to have adopted a co-packaged product for 
distribution through public sector facilities. While this will be done on a trial basis at first 
in the fourteen most underserved districts, it is hoped that procurement by the MOH will 
expand to other parts of the country in the long-term.  
Future research should continue to explore aspects of establishing and refining 
value-chains for public health products. This may include testing the quality of 
interactions with general retailers (i.e. dispensing practices of PHPs, referral practices, 
knowledge/advice shared with customers, engagement/involvement under new legislation 
for drug shops) who have received training in provision of a PHP (e.g. through the use of 
secret shoppers), exploring the range of PHPs that may benefit from expansion by 
similarly creating complementary points of access in the private sector, distinguishing 
between those elements of this multi-pronged approach which are necessary and those 
which are sufficient, as well the implications for access and competition when a product 
such as the Kit Yamoyo is provided through multiple channels, including the public and 
private sectors. There is also scope for the public sector to leverage rural, general 
retailers, who already make the journey from district level centers to rural communities, 
to deliver products for health facilities across ‘the last mile’. Such a model could be an 
innovative way of leveraging an underused asset to improve upon supply chain 
challenges seen in the public sector. This also points to the need to explore public-private 
partnerships at the local, grassroots level, as opposed to being seen solely as ventures 
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involving large corporations or multi-nationals and global NGOs, which tends to be the 
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APPENDIX 1: APPLICATION OF GLOBAL HEALTH DELIVERY FRAMEWORK TO COLALIFE MODEL 
Delivery Framework Component Description of Component Examples of how component was addressed 
 
Use of care delivery value-chains (CDVC) 
 
CDVC lens offers framework for 
understanding, improvement, and 
integration of various activities involved in 
full cycle of care for particular condition 
 
Medical condition = set of interrelated 
patient circumstances involved in full disease 
cycle across time, including common 
complications and co-occurring conditions 
(e.g. pneumonia and diarrhea) 
 
Conceives delivery of care (and the creation 
of patient value) as an overall system, not 
discrete vertical interventions; stresses the 
interconnectedness of different components 
of the care cycle (e.g. prevention; informing 
and engaging; accessing; intervening; 
ongoing management; measurement) 
 
Activities are tailored to reflect 
understanding of the disease; taken together, 
they contribute to patient value and 
improved health outcomes.  
 
 
Taking a health systems perspective, and understanding the bottlenecks to effective access and utilization of ORS and 
zinc, our model took a multi-pronged approach to simultaneously address both supply and demand side factors.  
 
By developing an innovative co-packaged product that helps improve proper utilization of the treatments, as well as 
its end-to-end value chain (bringing treatment closer to home), supplemented by social marketing and health 
promotion, the intervention aimed to address key issues related to access, awareness and use. More on kit-specific 
innovations can be found in Paper 2 (e.g. co-packaging ORS, zinc and soap for hand-washing; zinc provides protection 
against future infection for up to 3 months; etc.) 
 
Future efforts could focus on increasing linkages with upstream activities related to nutrition, water, sanitation and 
hygiene, as well as coordinating approaches for pneumonia and other co-occurring conditions (HIV/AIDS). WASH 
interventions can increase value by improving the ability to forestall diarrhea incidence. Linking with nutritional 
programs could help halt the cycle of malnutrition and diarrhea. Nonetheless the overall system was indeed 
considered resulting in a solution that simultaneously addressed components including prevention (addition od soap 
to Kit), informing and engaging (via social marketing and health promotion activities), accessing and intervening (via 
the private sector), ongoing management and measurement. 
 
Effective treatment delivery has the potential of replacing inappropriate antibiotic prescription and use, curbing 
resistance and contributing to overall value of the system. In addition, by bringing treatment closer to the home, 
caregivers can forgo numerous opportunity costs associated with traveling to a health center to get treatment.  
 
Coordination and partnerships with the public sector, from the MOH level (policy, oversight and procurement) to the 
health facility level compliments private sector access with another value stream. 
 
Monitoring and evaluation a core pillar of work within pilot and resulting scale-up initiatives. 
Shared delivery infrastructure Distributes and integrates care delivery for 
range of conditions across sites of care.  
 
While Kim et al. limit definition of shared 
delivery infrastructure to various common 
components of the health system such as 
health clinics, district hospitals, referral 
hospitals, and community-based care, we 
extend health system concept beyond 
traditional health facilities to include 
alternative options such as commercial 
channels, where appropriate.  
 
Shared delivery infrastructure across 
providers, such as community health 
workers, health clinics, or commercial 
channels can extend reach and access for 
patients, and enable care to occur at most 
Distributed care delivery to community-level, commercial, private sector shops, but for a single condition. Likely 
future scope for capturing synergies in care of related pathologies such as pneumonia, malnutrition, etc. (further 
research required). 
 
Leveraged existing networks and infrastructure of kit manufacturer/assembler (Pharmanova), district level 
wholesalers, Medical Stores Limited (parastatal responsible for transporting medicines for the public sector), and 
community-level retailers to get product to community-level across the last-mile.  
 
Leveraged transport mechanisms including retailers moving product from district centers to community-level via 
bicycle, motorcycle, truck, etc.  
 
Training of retailers coupled with social marketing highlighting issues related to signs of dehydration, when to refer, 





effective (including cost-effective) location. 
 
Shared delivery infrastructure can enable 
better leverage of facilities and personnel 
from different sectors. Task shifting of 
appropriate product provision and advice 
have the potential to reduce pressures on 
already overburdened health facilities and 
clinical staff. Essential to this is ensuring 
quality of care, and improved outcomes, and 
thus value to patients.  
 
Aligning delivery with external contexts Within the framework, contextual factors 
broadly divided into 2 categories: 1) direct 
influences on health (e.g. nutrition) and 2) 
broader economic and social factors that 
underlie direct influences (e.g. poverty, 
education) 
 
Direct contextual influences on health can be 
further categorized: 1) those affecting the 
incidence of diseases and injuries; 2) those 
affecting ability to access health-care services 
(e.g., cost, ease of transportation, stigma); 
and 3) those affecting the effectiveness of care 
delivery itself (e.g. adherence to prescribed 
therapies) 
 
Starting point is an understanding of the 
social circumstances of patients and their 
families 
 
In Zambia contextual factors included:  
- MOH supportive of private sector initiatives and local production;  
- OTC status of Zinc (and ORS) and compatibility with use at the household level; 
- No private sector access in rural areas with access limited to often distant health centers; 
- Existing networks of rural retailers already transporting goods across the last mile; 
- Good level of awareness around ORS amongst caregivers already;  
- Weak public sector supply chain for medicines with regular stock outs (see Paper 1); 
- Diarrhea perceived as major health issue by caregivers. Our survey found that 81% of all respondents at endline 
(n=2477) cited diarrhea as the major health concern amongst children under 5.  
- 41% of these respondents did not have a toilet (used the bush) 
- proportion of rural population with access to improved water source: 49% (World Bank Statistics, 2012) 
- See paper 1 for contextual demand-side factors relating to access 
Leveraging the health-care delivery system 
for economic and social development 
Numerous external contextual factors 
affecting incidence of illness and constraining 
value of care delivery link directly or 
indirectly to economic development   
 
Harnessing positive linkages with economic 
development is an essential component of 
designing value-based systems of global 
health-care delivery 
 
Such systems directly catalyze economic 
development through 4 primary 
mechanisms:  















Bringing treatment closer to the home and improving uptake of ORS and zinc by helping to shape the market for an 
innovative co-packaged kit reduces diarrhea related morbidity and mortality.  
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2) Employment;  
3) Health systems can drive economic 
development thru local procurement 
of goods, services, and equipment  
4) Purposeful development of delivery 
systems in poor communities can be 
a catalyst for improving 
infrastructure (e.g. cell phone 
towers, internet access, 
electrification, clean water access, 
and local transportation systems) 
that will likely have wider economic 
benefits 
 
Health-care organizations that seek out local 
suppliers and build local capacity can hope 
for a double impact, as health system 
procurement can stimulate business and 
cluster development that goes well beyond 
the health sector 
 
Working with our private sector pharmaceutical partner, Pharmanova, we have localized production and supply of 
ORS and zinc in collaboration with the MOH and the Zambian Medicines Authority.  
 
All players involved in the value-chain – manufacturer, wholesaler, and retailer - make profit as the product is pulled 
to the community-level, thereby contributing to livelihoods. 
 
Procuring locally keeps money in the local system and has stimulated development of new products within local 







                     APPENDIX 2: COLALIFE PROJECT LOGIC MODEL 
Impact  
(out of scope) 
Contribution towards MDG 4 – reduced childhood mortality – by reducing incidence (and severity) of diarrhea in 
children 0-59 months in underserved rural communities  
                         
Purpose 
(will measure up to 
this level) 
Mothers and care-givers of children 0-59 months in underserved rural communities increase use of ORS and Zinc in household treatment of diarrhea 
   
Intermediate Outcome Increased Access by mothers/caregivers of [affordable] Kits (anti-diarrhea kit) in underserved rural 
communities 
-Lessons learnt /results disseminated 
-Sustainability / exit strategy implemented 
- multi-sectoral partnership established for last-mile 
delivery and scale-up/sustainability 
                          
Immediate 
Outcome 
(2) Improved availability of [affordable] Kits (anti-diarrhea kit) in 
underserved rural communities via profit-driven supply chains  
(1) Increased awareness of Kits and benefits of 
contents (ORS, Zinc, Soap) among mothers/care-
givers 
-Relevant data effectively collected and 
analysed 
-Where appropriate, new PPPs established 
for Last Mile supply chain model scale-up 
-Sustainability/exit strategies/plans agreed/ 
transferred 
                          
 
Outputs 
1 Kits meet needs at all levels in value chain 
2 Novel leverage of the Coca-Cola supply chain meets demand for 
Kits in under-served communities 
3 Retailers and wholesalers trained in benefits of Kits  
4 IEC/Social marketing program for mothers/care-
givers on benefits of Kits designed and implemented  
-Effective M&E and learning frameworks 
designed and implemented 
-Key learnings related to PPP potential in 
two additional countries identified 








1.    Design Anti-Diarrhea Kit (ADK) to meet all needs in the value chain: 
Procure contents: ORS/Zinc, soap 
Design costing, margins, pricing, subsidy/credit availability, vouchers and tracking 
Test affordability, desirability and attractiveness of product 
Design and test packaging (functionality, fit, robustness/damage, tamper-proofing, attractiveness, messaging) 
 
2.    Design and implement novel supply chain leveraging Coca-Cola Last Mile distribution, to meet demand: 
Implement packing and fulfilment process for the ADK product 
Distribute Kits to wholesaler level 
Leverage last mile distribution via Coca-Cola retailers/entrepreneurs 
 
3.    Design/deliver awareness raising, training and follow-up to convey benefits of Kits to retailers and wholesalers 
 
4.    Design, test and deliver a social marketing campaign to convey to mothers/care-givers the benefits of Kits: 
Design, test and produce IEC materials for inclusion in/on Kits 
Design, test and deliver household-level awareness-raising & training 
Design, test and deliver community level activity and media channels 
5. Design and implement effective M&E 
framework  
 
6. Develop learning framework to capture 
additional learnings outside of formal 
evaluation  
 
7. Formative dissemination of activities and 
issues via use of social media (open 
innovation approach) and other venues 
 
8. Design sustainability or exit strategy 
 
9. Explore last mile distribution chains and 
related Public-Private Partnership (PPPs) 
opportunities in two other African countries 
 Results chain A : Supply Chain       Results Chain B : KAP among Mothers/Care-givers      Knowledge translation      
APPENDIX 3: KIT COSTING BREAKDOWN 
During the trial there was a top end (manufacturer level) subsidy for the cost of the Kit. The subsidy was intentional and derived from donor funding (i.e. the trial budget). Innovative in design 
and in content, the Kit was not at a stage, when the trial commenced, where competitive tenders could be sought, economies of scale could be exploited, or local production sourced. During 
the trial, we were dealing with relatively small production figures, continual innovation, and sourcing from different places (e.g. importing PedZinc from Tanzania, soap from India, packaging 
from the UK). Since the trial, continual refinement based on trial findings (See Appendix 5), a move towards local production, and economies of scale have led to cost reductions and 
elimination of the top end subsidy. The tables below show examples of kit costing during the trial and since.  
Costs in US Dollars  Aug-12   Jan-16   






























(3%)   
0.03  
(6%)   
TOTAL Components Cost: 1.23   0.38   
Packaging 
0.28 
(16%) Original Aidpod Format 0.00 Carton cost = $0.45 (K5); 100 kits per carton 
Labour/Assembly 
0.21 
(12%)   
0.14 
(26%) 
Includes assembly overhead; Flexi-Pack Format 
(flexi-pack=K0.00 (donated), outer polythene 
bag=K0.04) 
TOTAL per Kit 1.72   0.53   
          
Price to wholesaler (delivered) 0.65   0.71 
Introductory ex-factory price including delivery 
(34% margin) 
Price to Retailer 0.77 Wholesaler makes 19% 0.86 Target wholesale price (21% gross margin) 
Price to Customer (RRP) 1.04 Retailer makes 35% 1.16 Target retail price (35% gross margin) 
Subsidy: 1.08   0.00   
Notes: -Percentages are of total kit cost 
-Subsidy is based on Total cost/kit minus cost to wholesaler (e.g. USD 1.72-0.65) 
-In the trial the wholesale and retail prices were fixed. In the scale-up the market determines the wholesale and retail prices. 
-Costings of the scale-up version have been derived during an unprecedented fall in the value of the Zambian Kwacha.Excahnge rate from USD to ZM - 08/12: 1 = 4.8; 01/16: 1 = 11.2 
-In Nov-15 Shoprite (national supermarket) entered the market and are buying at the ex-factory price of K8.00 ($0.67) and selling at K8.19 ($0.69). This will undercut wholesalers.  
-Shoprite have agreed to allow bulk purchases and will act as 'quasi' wholesalers in the towns/communities where they are located. 
-Percentages are of total kit cost





Kit Sales to 30-Sep-13 were calculated in two ways: 
 
1. By adding up the individual sales to retailers recorded on stock sheets maintained at the wholesaler. These stock sheets were 
provided by the project and were an add-on to the standard record systems already maintained at the wholesaler level 
 
2. By subtracting the stock levels at the wholesaler on 30-Sep-13 from the total purchases by the wholesaler from the 
manufacturer 
 
In the case of Katete district, both methods gave the same figure for total sales: 13,590. This was not the case in Kalomo district. 
The first method gave a total of 11,155 and the second 12,640 – a 13.3% difference. The difference can be attributed to 
inaccuracies in the recording of individual sales to retailers by wholesalers in Kalomo. At busy times the recording will have been 
overlooked. The Kalomo wholesaler was equally well run as the wholesaler in Katete but in Kalomo, any one of multiple 
employees kept the stock sheet recording individual sales to retailers. In contrast, the wholesaler in Katete was run by the owner 
and the records of sales to individual retailers were kept by the owner himself.  
 
In order to get a picture of monthly sales for Kalomo the figures recorded on the wholesaler stock sheets were adjusted upwards 
by 13.3%. 
 
The level of insight and accuracy around sales diminished, from a project perspective, as one moved from the top-end of the 
value-chain to the bottom. Monthly sales data was most accurate at the manufacturer and wholesaler levels, but not consistently 
maintained at the retailer level. Thus, there was a limitation in our ability to disaggregate cash-based vs. voucher-based sales on a 
monthly basis. Only at the end of the project were we able to effectively determine, based on the total kits sold to community-
retailers, how many were acquired through vouchers and how many through cash (Total Kit Sales to Retailers – Total Vouchers 
Redeemed = Cash Sales).  Approximately 19% (5000) of sales were cash based, while 81% (21,000) were voucher based.  
APPENDIX 5: THE INNOVATION PROCESS - HOW TRIAL FINDINGS HAVE INFLUENCED NEW KIT 
FORMATS & ONGOING REFINEMENT OF KIT YAMOYO  
Innovation is a dynamic process requiring constant evolution. Despite numerous awards and global recognition 
stemming from the concept of nesting essential medicines in the empty spaces between crated bottles of Coca-Cola, 
the evidence suggested a need to move in a different direction. Analysis of data from the trial suggested ways in which 
our model could be improved and achieve potentially greater impact by reducing costs and maintaining key 
functionalities. While cost is not the only dimension of access, it is indeed an important one. Key findings and 
refinements are summarized below, and have led to two new kit formats that are now being locally produced and used 





 85% of caregivers who used Kit Yamoyo only used 4 or fewer sachets.  
 
 An additional 10% used all 8 sachets 
 Assuming those that used all 8 did so because they thought they had to 
(not because the child was still dehydrated), we can safely assume that 90-
95% needed 4 sachets or less.  
 Reduced number of sachets included from 8 to 4 
 Encourages combination therapy use, and discourages use of ORS (e.g. 
saved for use during a future episode) without zinc.  






 During the trial, the zinc (® PedZinc) used in the Kit was being imported 
from Tanzania, as no locally produced options existed 
 Working with our pharmaceutical partner, Pharmanova, and the Zambian 
Medicines Regulatory Authority (ZAMRA), one of the first locally 
produced zinc products was developed and approved 
 Human-centered design principles have been applied to try and improve 
adherence to the 10-day regimen.  Will be tested thru ongoing research. 
 Because zinc is included in kit, no box/packaging or PIL required for 
blister pack = cost reduction 
 
 




 Small bar of soap was being imported from India as there was no locally 
produced small bar of soap 
 The only local soap manufacturer in Zambia, Trade Kings, did not 
produce a small bar 
 Discussions with Trade Kings has now resulted in plans to produce a 




 Only 30% of Kit users reported using the instructions at endline (higher in 
Kalomo vs. Katete likely due to differing education levels)  
 It was relatively expensive to produce, included instructions in two local 
languages, and included multiple folds 
 Literacy rates of women in rural Zambia are about 54% (DHS, 2014), and 
although someone may speak a local language, they likely do not read it. 
If they do read, it is more likely to be in English.  
 Focus on graphics, reduce text 
 Leaflet also doubles as branding for product (easily changed/adapted for 
different situations e.g. unbranded public sector version) 





 Very few retailers used the empty space between crated bottles of Coca-
Cola to transport kits (4-8%); innovative feature not a benefit 
 Allowed us to refocus on cost and local production while maintaining key 
benefits 
 Worked with PI Global & Amcor to develop two new formats (i.e. flexi-
pack & screw-top) for next phase of work (Kit Yamoyo Transition to 
scale – KYTS) 
 Screw-top is 40% cheaper and can be mad in Zambia now (can retail for 8 
kwacha with no top end subsidy) 
 Flexi-pack is even cheaper and can retail for 5 kwacha (as in the trial) but 
with no top end subsidy required and acceptable margins for each player 
in the value-chain 
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APPENDIX 6: DESCRIPTION OF VARIOUS SOURCES OF PHARMACEUTICALS/PHPs IN ZAMBIA 
Outlet Type  Description 
Public Health Facility   
Third level hospital These are government health facilities 
providing free prescription medicine, 
medical consultations, and diagnosis. 
Health centers serve a catchment area of 
between 10,000 (rural) to 50,000 (urban) 
residents. They are staffed by a nurse or 
clinical officer. First-level hospitals accept 
referrals from local health centers and 
health posts. They serve populations of 
between 80,000 and 200,000 people with 
surgical, obstetric and diagnostic services. 
At the provincial level, second-level 
hospitals typically offer services in internal 
medicine, gynecology, psychiatry and 
intensive care. Third-level hospitals serve a 
catchment of 800,000 people and expand 
upon provincial level services, while also 
serving as training and research 
institutions.  
Second level hospital  
First level hospital  
Hospital affiliated center 
Urban health center 
Rural health center 
Health post 
Part One Pharmacy  
Part one pharmacy Pharmacies that are licensed by the 
Zambian Medicines Regulatory Authority 
(ZAMRA) and sell prescription medicine at 
a commercial rate. Part One pharmacies are 
manned by pharmacists and qualified 
health practitioners. They sell all classes of 
medicines. In addition to being regulated 
by the PRA, they are also required to have 
a trading license from the local council. 
These pharmacies may also sell cosmetics. 
Only found in major centers.  
Drug Shop  
Drug shop Drug shops sells medicines at a 
commercial rate, but differ from 
pharmacies in a number of aspects: 1) Drug 
stores are usually smaller than pharmacies; 
2) they are not regulated by the Zambian 
Medicines Regulatory Authority 
(ZAMRA), and instead are licensed by the 
local government board (however, an 
unknown proportion operate without a 
license); 3) they are only permitted to sell 
over the counter medicines; 4) they are not 
guaranteed to be manned by qualified 
health dispensers/ practitioners, and are 
sometimes manned by relatives of qualified 
health dispensers or someone with only 
basic education or knowledge about 
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medicines. Not typically found in rural 
areas.  
Private Health Facility  
Private hospitals Private hospitals sell medicines at a 
commercial rate and are manned by 
qualified health dispensers/practitioners, 
who are registered with the medical 
council. These facilities are regulated by 
the Zambian Medicines Regulatory 
Authority (ZAMRA). They have a hospital 
license and can admit patients for more 
than 48 hours. 
Private clinic Private clinics sell medicines at a 
commercial rate and are manned by 
qualified health dispensers/practitioners, 
who are registered with the medical 
council. As with private hospitals, they are 
regulated by the Zambian Medicines 
Regulatory Authority (ZAMRA). Private 
clinics have a clinic license, and differ from 
hospitals in that they can admit patients for 
a maximum of 48 hours. 
Surgery Surgeries are also manned by qualified 
health practitioners who are registered with 
the medical council. They have a clinic 
license and offer certain specialized 
services, but they are not allowed to admit 
patients. They are most common in urban 
areas. 
Grocery Store  
Grocery store* Small businesses that sell fast moving 
consumer goods including food, beverages, 
and household products. These outlets 
commonly sell antipyretics, but may have 
the potential to sell other types of PHPs. 
Other  
Kiosk* Small businesses, made from temporary 
wooden structures, which sell fast moving 
consumer goods. They may also sell 
medicines. Kiosks are usually found near 
schools, colleges and universities. 
Kantemba* These are similar to kiosks but have a more 
permanent structure. They are twice the 
size of a phone booth with walls made 
from metal. 
Super/Mini market or petrol station Express stores at filling stations. Small 
businesses which sell general groceries; 
they may stock some medicines such as 
such as antipyretics or cough syrups. 
Container This is a shipment container that has been 
turned into a shop. They have commodities 
that can also be found in grocery stores but 
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may also sell over the counter medicines. 
Containers need to obtain a trading license 
from the local council. These are typically 
found along major roadways near towns.  
Mobile provider These are street hawkers who sell a variety 
of items, which may include medicines. 
They typically operate in residential areas 
and at road junctions. In residential zones, 
hawkers mostly target low income and 
rural areas. In urban zones, they may have 
a hawker’s license under the local council. 
Other Other outlet types not fitting into any of the 
aforementioned outlet types - largely 
market stands and stalls. 
Source: Palafox B, Patouillard E, Tougher S, Goodman C, Hanson K, Mpasela F, O’Connell K and the ACTwatch Study group. 
2012. ACTwatch 2009 Supply Chain Survey Results, Zambia. Nairobi: ACTwatch project, Population Services International. 
 
* Outlet types that form the basis of this study highlighted in green 
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APPENDIX 7: EXAMPLE OF HOUSEHOLD SURVEY 
 
Household Survey - Endline 
 
Please note that further changes were made to this survey upon entry into ODK. This is a near final 




Note: Module response sequences depend on respondent. Each 
respondent wil not have to go through every module: 
 
 
Caregivers with a child who had diarrhea in the 2 weeks preceding survey 








Caregivers without a child who had diarrhea in the 2 weeks preceding survey 








Caregivers who used Kit Yamoyo 
Children w/ diarrhea in past 2 weeks: 1, 2, 3, 4, 6, 5 
 
 
Children w/out diarrhea in past 2 weeks: 1, 2, 4, 7, 6, 5
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COTZ- HOUSEHOLD SURVEY–Endline      QID: _______ 
Interviewer: Ask to speak to head of household. If head of household is not available, 
ask to speak to a household member who can assist. Read the following: 
Good day, I am (insert name). I am representing UNICEF, Keepers Zambia Foundation, and 
RuralNet Associates as part of a research partnership here in Zambia, for a study approved 
by Ministry of Health. I am part of a team interviewing people about health products. The 
information will be used to improve health products and services for people like you. 
Can you please tell me if there any children between 6 and 59 months old who live in this 
household? These are children born on or after 18 August 2008 and before February 17 
2013. 
 
If no, thank the respondent and move to next household. 
 
 
If Yes, How many children in this household are between the ages of 6 and 59 months? 
 
CONTINUE 
Your household has been selected to participate in this study randomly. The information 
gathered here and your details will be kept confidential, and you do not have to answer any 
questions that you do not want to. Your participation in the study is voluntary and you will 
not be affected in any way if you decide not to participate. It is your choice. If you agree to 
help, I will ask you a series of questions related to your access to health products and 
services. We will use this electronic tablet to enter your responses to our questions. The 
interview will take about 1 hour. 
I would first like to ask some questions about your household, and then ask about diarrhea in 
children to the main caregiver of a child within your household. The answers will help us to 
learn more about opinions and experiences concerning diarrhea in children, and will be used 
to improve health products and services for people like you.  
Do you have any questions? You may contact Stephen Tembo of RuralNet Associates [give 
business card if they would like] if you have any further questions or concerns related to this 
work. You may contact the Ethics Committee which approved this study about any problems 
or concerns as well. Would your household like to help by participating in the study? 
If  No , STOP.  
Interviewer: Can I ask why you would not like to participate in this survey? 
Not interested    1  
Busy                  2 
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Other                3  
________________________________________________________ 
Thank the respondent and move to next household. 
If yes, get signature and administer screening matrix in tablet and say: Okay, let s 
begin .  
MOVE TO SURVEY. 
________________________________(Signature of head of household/assistant) 
____________________(Date) 




Please give the 
FIRST NAME 
ONLY of the 
children between 
the ages of 6 and 
59 months who 










Q002. What age is 
(NAME)? 

















































1 Yes  Don t 
know 
01  [__][__]months 
Give legend: 
12 months = 1yr 
 [__][__]   0  1   2 0  1  2 
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24 months = 2 
yrs 
36 months = 3 
yrs 
48 months – 4 yr 
 
02       
03       
04       
05       




 If no caregivers are aged 15 years or older, thank the respondent and move to 
next household.  
 If there is a caregiver aged 15 years or older in the house, select 1 caregiver 
aged 15 years or older to participate based on the sampling strategy below.  
 Caregiver Sampling Order:  
o Caregiver who is present 
o Main caregiver of Child between 6 and 59 months of age with diarrhea in 
the past 2 weeks who is available (verify with caregiver that diarrhea = 3 
or more loose or watery stools in a day) 
o Main caregiver of Child between 6 and 59 months who is available 
o If multiple caregivers with children between 6-59 months who had 
diarrhea, and are available, select alphabetically by first name 
 Reference child sampling order: 
o If the caregiver selected has more than one child between 6-59 months of 
age with diarrhea, select the reference child alphabetically by first name 
 If the caregiver selected is different from the initial person you spoke with, get 
them to sign the informed consent as well.  
 Diarrhea is defined as *3 or more loose or watery stools in one day. Review this 
definition with caregiver to make sure you are talking about the same thing. 
 
 




QUESTIONNAIRE FOR MOTHERS/CARERS - baseline 
 
Module 1: QUESTIONNAIRE IDENTIFICATION DATA & FILTERS 
001 Question for Care givers : Do you agree to participate in this survey ?  
YES  Move on to Questions below. Ensure that Caregiver has signed the consent 
form.  
NO Terminate Interview 
002  Questionnaire Identification Number   (From your assigned block of Ids)
 |___|___|___|___|___| 
003SiteNumber_____________________ 
We would like to start by asking some background questions about your household. 
004 Name of head of household (First and Last Name) ____________________________ 
Q1001.  Enumerator s name    
Q1002.  Supervisor Name    
Q1003.  Province Code 1. Southern    2. Eastern   
Q1004.  District Code 1.  Kalomo                2. Katete                  
3. Monze                   4. Petauke 
 
Q1005.  What is the name of your 
Village/Community? 
   
Q1006.  Time Started:__________    
Q1007.  Respondent’s relationship to 
head of household 
Head of Household   
Spouse   




















Q1009.  How old are you? 
(Interviewer: Record age 
in completed years) 
[_____________] Years   
 
NO Questions & Filters Responses  Skip To 





















Q1011.  What is the highest level of school 





Interviewer, please note the following 
equivalent standards and grades for: 
Sub A to standard 3 = Grades 1 -  5 
Standards 4 to 6      =  Grades 6 - 8 
Form 1 to 3             =  Grades 8-10 
Form 4 to 5             =  Grades 11- 12 
Grade 1 to 4 
Grade 5 to 7 
Grade 8 to 9 
Grade 10 to 12 
Higher learning 
None 
























Q1012.  How old is the head of household? (in 
completed years) 











Q1013.  What is the highest level of school you have 
successfully completed?  
 
Grade 1 to 4 
Grade 5 to 7 
Grade 8 to 9 
Grade 10 to 12 
Higher learning 












 Interviewer, please note the 
following equivalent standards 
and grades for: 
Sub A to standard 3 = Grades 1 -  5 
Standards 4 to 6      =  Grades 6 - 8 
Form 1 to 3             =  Grades 8-10 
Form 4 to 5             =  Grades 11- 12 
   
Q1014.  What was the main activity of the head of 

















Civil servant (government worker) 
Formal private company employee 
Informal small business owner 
Informal Small businessemployee 
Piece worker  
Brick layer/builder 
Teacher 


























Q1015.  What is the nature of this work? That is, is it 
permanent, temporary, or occasional? 
 
Permanent   









Q1016.  How many hectares of farmland does your 
family/household own? 
 
1 Lima or ¼ hectare = half a football 
pitch 
1 hectare = 2 football pitches 
 
1 acre = 0.4 hectares 
1 lima = 0.25 hectares 
[__________________] hectares Don t know  888  
Q1017.  How many of the following animals does 
your household own: 
Goats? Sheep? Cows?chickens?pigs? 
 
(Interviewer: READ LIST AND RECORD 
RESPONSE FOR EACH ITEM. If none, enter 
« 00 ». If 96 or more, enter « 96 ». If 
number is not known, enter « 888»). 
 
 
 Animal #  
A Goats   
B Sheep   
C Cows/oxen   
D Chickens   
E Pigs   
    
    
  
 
Q1018.  Do you own or rent your home? Own  
Rent  
Family/relative 












Q1019.  How many rooms are in your dwelling? 
 
INTERVIEWER: DWELLING IS DEFINED 
AS THE INDIVIDUAL UNIT THAT THE 
CAREGIVER LIVES IN.  
NOTE: THIS IS DIFFERENT FROM A 
FAMILY PROPERTY WITH MULTIPLE 
UNITS 
Number of Rooms [__][__] Don t Know    888  
Q1020.  (INTERVIEWER: OBSERVE AND REPORT. Earth/Sand/ Mud/Dung  1  
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IF UNCLEAR  READ LIST IF NECESSARY) 
 
 
What is the main material of the floor in 
the dwelling where your household lives? 
 
 












Q1021.   
(INTERVIEWER: OBSERVE AND REPORT. 
IF UNCLEAR  READ LIST IF NECESSARY) 
 
 
What is the main material of the roof in the 
dwelling where you household lives? 
 
Concrete/Cement 















Q1022.  Does your household have: 
 
(INTERVIEWER: READ LIST AND 




  Yes No 
A Electricity 1 2 
B Radio 1 2 




Q1023.  Does any member of your 
household own: 
 
(INTERVIEWER: READ LIST AND 




  Yes No 
A Bicycle 1 2 
B Motorcycle/Scooter 1 2 
C Car or Mini-Truck 1 2 
D Mobile Phone 1 2 
  
Q1024.  What is the main source of drinking 





Piped water in residence/house 
Piped water in public tap 
Protected well  
Unprotected well  
Borehole  
River, stream, canal, or surface water  
Rainwater 












Q1025.  What kind of toilet do most 




Own flush toilet  
Shared flush toilet  
Pit latrine with concrete slab 
Pit latrine without slab/open pit 
Ventilated improved pit (VIP) latrine 
Integrated Latrine (toilet and hand-
washing together) 
None/Bush 













Q1026.  What do you use as your main 
source of fuel for cooking in this 
household? 
[SINGLE RESPONSE] 
Kerosene    

















Q1027.  What are the main health issues for 


























Module 2: Child Diarrhea Status Make change of module obvious in tab. 
Ensure Heading shows up. Delete these comments in paper version to be 
printed. 
 Questions/Filters Codes/Responses  Skip 
To 
Q2001.  What is the first name of 
the selected child between 
6 and 59 months of age 
Selected using sampling 
strategy: first precedence 
– child with diarrhea in 
last 2 weeks; 2nd 






















Q2004.  What is your relationship 
with (NAME) ? 
INTERVIEWER: WE ARE 




















Q2005.  Thinking back over the past 
3 months, have you seen or 
Yes    
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heard any messages about 
treatment for diarrhea? 
Q2006.  Where did you hear/see the 
message(s) about treatment 
for diarrhea? 
Interviewer: Multiple 
responses allowed. Note 
all that apply. Do not read 
list.  
Radio   
Television  
Community education 
session/health talk  
Community health worker  





















































2006.a Was the person delivering 
the message wearing a t-
shirt that looked like this? 
SHOW PICTURE OF 
ORANGE PROMOTERS T-
Shirt& RED SHOPKEEPER 
T-SHIRT (Include on tablet 
if possible) 
YES 
NO Don t remember  1 2 3 2007 2007 2007 
2006.b Was it one of these posters? 
Show Picture of Kit 
Yamoyo promotional 
posters (include on tablet 
if possible) 
YES 
NO Don t remember 1 2 3  
Q2007.  Has (NAME) had diarrhea Yes  1 Mod 
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in the last 2 weeks?  
Interviewer: Diarrhea is 
defined as 3 or more 
loose or watery stools in 
one day. Review that 
definition with caregiver. 
 




Module 3: Children under 5 with diarrhea in past 2 weeks  
Q3001.  How many days ago did the 
diarrhea start? 
(Interviewer: If the same 
day, record ’00.’) 
Probe:   try to help them 
remember the exact 
number of days, as 
opposed to saying 1 week 
or 2 weeks. 
 
    [__][__] days 
 






Q3002.  For how many days did the 
child have diarrhea? 
(Interviewer: if the child 
still has diarrhea, ask  
How many days has the 
child had diarrhea ) 
 
[__][__]days   
3002aa When (NAME) had diarrhea 
over the past 2 weeks, on 
average, how many loose or 
watery stools did he/she 
have per day? 
[__][__] loose or watery stools   
3002a Has the child had diarrhea 
on and off for more than 4 
weeks? 
Yes 
No Don t Know 1 2 888  3003 3003 
3002b How long has the child had 
diarrhea on and off for?  
1 Month = 4 weeks 
2 Months = 8 weeks 
3 Months = 12 weeks 
__________________ weeks 
 Don t Know   888  
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4 Months = 16 weeks 
Q3003.  Has (NAME) also had a 
fever in the last 2 weeks? 
Yes   






Q3004.  Did (NAME) have any blood 
in the stool when he or she 
had diarrhea in the last 2 
weeks? 
 
Yes   







Q3005.  How much fluid/liquid was 
(NAME) given to drink 
during the recent episode of 
diarrhea?  Was he or she 
given less than usual to 
drink, about the same 
amount, more than usual to 
drink, or nothing to drink? 
(Interviewer: If less,  
probe: Was (NAME) given 
much less than usual to 
drink or somewhat less?) 
Much less  
Somewhat less   
About the same   
More  










Q3006.  Did (NAME) breastfeed 
during the recent episode of 
diarrhea?  
(Interviewer: If Yes, Probe: 
More? Less? Or about the 
same? 
If No, find out why – see 
responses) 
YES 
Breastfed more  
Breastfed less   




Stopped breastfeeding due to 
diarrhea 
Does not breastfeed 
anymore/weaned/too old 
















Q3007.  When (NAME) had 
diarrhea, was he or she 
given less than usual to eat, 
about the same amount, 
more than usual, or 
nothing? 
Much less  
Somewhat less   
About the same   
More  
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Interviewer: If less,  
probe: Was child given 
much less than usual to 
eat or somewhat less? 
Q3008.  Do you know what ORS is? 
 
 
(Interviewer: refer to it in 
different ways – local 
name (Manzi yamoyo), 
Oral Rehydration Salts, 
and show image of local 
ORS packets on screen 
noting that they 









3008b In the past 3 months have 








Q3009.  Have you ever heard any 












Q3009a Where did you hear/see the 
message(s) about ORS? 
Interviewer: Multiple 
responses allowed. Note 
all that apply. Do not read 
list.  
Radio   
Television  
Community education 
session/health talk  
Community health worker  


























































3009.b Do you remember if the 
person delivering the 
message was wearing a t-
shirt that looked like this? 
SHOW PICTURE OF 
ORANGE PROMOTERS T-
Shirt (Include on tablet if 
possible) 
YES 
NO Don t remember  1 2 3 3010 3010 3010 
3009.c Was it one of these posters? 
Show Picture of Kit Yamoyo 
promotional poster 
(include on tablet if 
possible) 
YES 
NO Don t remember 1 2 3  
Q3010.  Please tell me if you agree 
or disagree with each of 
these statements.  
 
Interviewer: Read this 
list. 
 
                Ag   Dis  DK 
ORS is medicine that  
gives good health                       1    2   
888 
 
ORS is a treatment for  
diarrhea                                      1     2    
888 
 
ORS stops  
Diarrhea                                      1     2   
888 
 
My child does not  
like the taste of  
ORS                                               1     2   
888 
 
ORS prevents  




Q3011.  Can you describe the 
process of how to make 
ORS Solution in as detailed 
a way as possible? 
 
Mix contents of ORS package with 
water 
Ensure water is clean/Purify water 













allowed. check all that are 
mentioned by caregiver. 
Do not read responses. 
Only check boxes that are 
mentioned by respondent) 
Wash hands prior to preparing 
Respondent explains how to use Kit 
Yamoyo 
Sprinkle over food 
Swallow Powder 













Q3012.  Do you think ORS is 
effective in treating 
diarrhea? 
 
Yes    
No 









Q3013.  Why do you think ORS is 
effective in treating 
diarrhea? 
 
(Do not read responses. 
Multiple responses 
allowed. Only check boxes 
that are mentioned by 
respondent) 
Diarrhea stops quickly  
Child recovers quickly  
Child regains appetite  
Prevents dehydration 
 



















Q3014.  Why don t you think ORS is 
effective in treating 
diarrhea? 
 
(Do not read responses.  
Multiple responses 
allowed. Only check boxes 
that are mentioned by 
respondent) 
It only prevents dehydration 
It is only for giving strength 
Diarrhea does not stop 
soon/diarrhea continues Child doesn t like the taste  













Q3015.  Do you plan on using ORS 
the next time your under 5 
child has diarrhea? 
Yes    
No    Don t know     1 2 888  
Q3016.  Was [NAME] given any ORS 
solution to drink since he or 
she started having 
Yes   
No  Don t know  1 2 888 3017  3017A  3017A 
 





examples of ORS – Images 
on tablet and probe:  
These are some local 
examples of ORS, did you 
give any of these? ) 
Q3017.  Which ORS product(s) was 
given to (NAME)? 
 
(Interviewer: Multiple 
responses allowed. If they 
don’t know, you can show 
them the poster with 
samples of local products 
(ORS packets and the 
actual kit yamoyo sachet, 
and ask respondent to 
select any/all used during 
the recent episode of 
diarrhea.) 
 
If more then one answer is 
selected, confirm that they 
used two different types of 
ORS during the most 
recent episode of diarrhea 
 
GRZ (Health Center) 
From Kit Yamoyo 
Other from Private shop (eg. 









3017A Thinking back over the past 
6 months, have you heard a 
message/received 
information about an anti-
diarrheal kit called Kit 
Yamoyo? 
Interviewer: Show Image 


























3017B Did you use the Kit Yamoyo 
to treat [NAME] when 
he/she had diarrhea in the 
past 2 weeks? 
YES 




3017C Have you ever used the Kit 
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children under-5 with 
diarrhea? 




3017C2 If you used the Kit Yamoyo 
previously to treat diarrhea 
in one of your children, but 
not during the most recent 
episode, why did decide not 
to buy one during the most 
recent episode? 
Kit is too expensive 
Kit was not available at my local 
shop 
I prefer to go to the health center 
I did not have a voucher 





























3017D If no, why did you not use 
the Kit Yamoyo to treat your child s diarrhea? 
Interviewer. Do not read 
list. Multiple responses 
allowed. 
Child has not had diarrhea 
Kit is too expensive 
Kit was not available at my local 
shop 
I prefer to go to the health center 
I have not heard about it/Do not 





















3017E How many days after the 
diarrhea began did (NAME) 
first get ORS? 
Interviewer: if same day 
mark   
 
(____) 














Q3018.  How many packets of ORS 
did you prepare for (NAME) 
during the episode of 
diarrhea? 
If they say one, probe: did 
you use the whole packet? 
___________________ 








Q3019.  Did you use ordinary water 
or did you use treated 
water when you prepared 
Ordinary (Non-purified) Water  
Treated Water (chlorine) 















Q3020.  How much of the ORS 
packet/sachet did you use 
each time you prepared the 
ORS? 
(Interviewer: If they don’t 
know how to respond,  you 
may give examples from 
the list) 
Entire contents of packet 
Half of the packet 











Q3021.  What quantity of water did 
you mix the ORS with each 
time you prepared the 
solution? 
 
)nterviewer: )f they don t 
know the particular 
metric measurement, 
probe as to what type of 
container they used to 
measure the amount of 
water. Do not read list of 
responses. 
 
Used1 standard household drinking 
cup/mug/glass 
Used Kit Yamoyo Container 

























Q3022.  How many days did you 
give the child the ORS? 
[__][__]   
Q3023.  How often did you give the 
ORS solution to (NAME)? 
(Interviewer: Read the list 
and ask respondent to 
select one response.) 
 
Frequently   
After each liquid stool  
Morning, mid-day, and night   
Whenever the child wanted it   Don t know   













Q3024.  From where was the ORS 
originally obtained? 
Health center/clinic/hospital   
Community health worker   
Private pharmacy 
Neighbor/friend/family member  
Traditional Healer 
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Don t know  










Q3025.  From which health facility 





3025A How much did you spend 
on transport to get to the 
health center? 
 
If they spent nothing to 
get there, put 0  
[___________]Kwacha 
 Don t know   88
8 
 
3025B How much did you spend 
on food and drinks during 
your trip to the health 
center? 
 
If they spent nothing to 
get there, put 0  
[___________]Kwacha 




3025C What other expenses if any, 
did you have during your 
trip to the health center? 
Medicines 











3025D How much did you spend 
on this? 
[_________________] 
 don t know   88
8 
 
Q3026.  Did you pay for the ORS? Yes 





Q3027.  How much did you pay? 
 
Put currency (Kwacha) 
(______) Kwacha   
Q3028.  What do you think of the 
price of ORS? 
Interviewer: Read options 
and ask respondent to 
select one response. 
 
Not expensive   
Affordable  
Expensive  
Too expensive  
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Q3029.  How far from your 
household was the location 
the ORS was obtained from? 
 
(Interviewer: Ask for 
response in Km) 
 


















Q3030.  How long did it take to walk 
there from your home? 
 
Interviewer: If they say 
they did not walk, ask 
them how long it would 
take to walk there. 
 
Minutes [_______________] Don t know 
 
1 hour = 60 mins 
2 hours = 120 mins 
3 hours = 180 mins 








Q3031.  Was (NAME) given a home-
prepared sugar-salt 
solution (SSS) during 
his/her recent episode of 
diarrhea? 
Inteviewer: Use the local 
term(s) for the sugar-salt 
solution (as distinguished 
from purchased ORS). 
Explain 1 teaspoon of salt 
to 6 teaspoons of sugar in 
a Liter of water.  
 
Yes   









Q3032.  How often did you give the 
home-prepared sugar-salt 
solution to (NAME)? 
Interviewer: Read the list 
and ask the respondent to 
select one response. 
 
Frequently   
After each liquid stool   
Morning, mid-day, and night   











 If Q3016=2 (NO) AND Q3031=2 (NO) then go to Q3033. Otherwise, go to Q3034. 
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Q3033.  Interviewer: If the 
caregiver did not provide 
either ORS or SSS to the 
child, ask  why did you not 
give (NAME) either ORS or 
home-prepared sugar-salt 
solution?  
[Interviewer: Do not read 
list. Multiple responses 
allowed.] 
 
Child not seriously ill   
Could not find ORS/SSS to buy   
Products too costly  
Child/Mother does not like   Didn t know about ORS/SSS 
Health center did not have any 
No nurse/doctor/health staff 
available at clinic 
Gave other medicine Didn t know how to make SSS 
Forgot about ORS/SSS 

















 Now ) d like to ask a few questions about diarrhea treatments. 










Q3035.  Where did you receive the 
main advice? 
 
Health center/clinic/hospital   
Community health worker   
Private pharmacy 
Neighbor/friend/family member  
Traditional Healer 
 NGO/ Faith-based organization/CBO  
Private shop/Community 
Retailer/Intemba 
Kit Yamoyo Promoter Don t know  

















Q3036.  Did you seek treatment 
from someone outside the 









Q3037.  How many days after the 
diarrhea began did you first 
seek treatment? 
Interviewer: If the same 
day, record .  
 
[__][__]   
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treatment for (NAME)? 
(Interviewer: Do not read 
list. Multiple responses 
allowed) 
 
Health center/clinic/hospital   
Community health worker   
Private pharmacy 
Neighbor/friend/family member  
Traditional Healer 
 NGO/ Faith-based organization/CBO  
Private shop/Community 
Retailer/Intemba Don t know  












Q3039.  How many days after the 
diarrhea began did (NAME) 





Q3040.  Was  (NAME) given 
anything other than ORS or 
a home-prepared treatment 
to treat the diarrhea? 
Interviewer: Probe, We 
want to know any other 
treatments which were 
given to treat the child, 
aside fromORS and SSS.  
 
Yes  












Q3041.  Can you tell me or show me 
what treatments were given 
to (NAME)? 
 
Interviewer:  If the 
respondent is not sure 
which products were 
given, show image with 
local options. Multiple 
options allowed. Click all 
that apply.  
Probe: Anything else? 
Kit Yamoyo 
Zinc 
Antibiotic (e.g. flagyl)  
Anti-diarrheal  
Anti-malarial  
Other pill/syrup   




 Don t know  














Q3042.  Have you ever heard about 
















Interviewer: Show images 
of zinc examples to 
respondent (PedZinc, 
blister pack, Health 
Center Zinc) 





Q3043.  Can you tell me what you 
know about zinc? 
 
Interviewer: Multiple 
responses allowed. Do not 
read list.  
 
Probe: anything else? 
 
Treatment for diarrhea  
Needs to be taken with ORS/ORT  
Makes child stronger  
Helps prevent future episodes of 
diarrhea  














Q3044.  Thinking back over the last 
3 months, have you heard 
any messages or received 














3044a Where did you hear/see the 
message(s) about zinc? 
Interviewer: Multiple 
responses allowed. Note 
all that apply. Do not read 
list.  
Radio   
Television  
Community education 
session/health talk  
Community health worker  
Health clinic 




























































Q3045.  Was the person delivering 
the message wearing a t-
shirt that looked like this? 
SHOW PICTURE OF 
ORANGE PROMOTERS T-
Shirt and RED 
SHOPKEEPER T-
SHIRT(Include on tablet if 
possible) 
YES 




Q3046.  Was it one of these posters? 
Show Picture of Kit 
Yamoyo promotional 
posters (include on tablet 
if possible) 
YES 
NO Don t remember 1 2 3  
Q3047.  What information did you 
get from the message(s) 
that you heard? 
 
Interviewer: Multiple 
responses allowed.  
 
Probe: anything else? 
Zinc reduces the duration  of the 
diarrheal episode  
Zinc reduces the severity of 
diarrhea  
The risk of new episode in the 
future is reduced  
Zinc is available in health centers  
Zinc should be taken with 
ORS/ORT  
A complete 10-day dose  should 
be administered  
Zinc is an appropriate  treatment 
for diarrhea 
Zinc is a micronutrient 



















Q3048.  Did anyone recommend you 
use zinc to treat the 
diarrhea? 
Yes    
No    Don t know     1 2 888  Q3050Q30
50 
Q3049.  If yes, who recommended 
zinc? 
(Interviewer: Do not read 
list. Mark only one 
 
Health center/clinic/hospital   
Community health worker   
Private pharmacy 















 NGO/ Faith-based organization/CBO  
Private shop/Community 
Retailer/Intemba 
Kit Yamoyo Promoter Don t know  









Q3050.  Did anyone give (NAME) a 
zinc product? 
Yes 




Q3051.  If NO, can you tell me why 
you did not give your child 
zinc to treat the diarrhea? 
Never heard of zinc  
Did not know where to buy  
Zinc is too expensive 
Used another product I had confidence 
in Don t think it works ) had it, but didn t know ) was supposed 
















Q3052.  Which type of zinc product 
was (NAME) given? 
Interviewer: Show 
examples of any local zinc 
products 
 
Tablets from health center 
Tablets from Kit Yamoyo (PedZinc) 



















Q3053.  How many zinc tablets did 
you receive? 
 
(________) Don t know  888  
3053B How many zinc tablets did 
you give [NAME] per day? 
(________________) 







Q3054.  How many days did you 
give zinc to (NAME)? 
(___________________) 





Q3055.  Interviewer: If less than Child was cured  
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10 tablets ask: 
Was there a reason (NAME) 
took less than 10 tablets? 
Interviewer: Do not read 
list. Multiple responses 
allowed. 
 
Child vomited treatment  
Needed treatment for another person 
Wanted to save remaining treatment for 
future illness  
Did not know child needed to take entire 
treatment  
Thought I needed to give zinc only along 
with ORS  
Child still taking the treatment  












Q3056.  Where did you obtain the 
zinc product? 
 
Interviewer: Mark only one 
answer. 
Health center/clinic/hospital   
Community health worker   
Private pharmacy 
Neighbor/friend/family member  
Traditional Healer 
 NGO/ Faith-based organization/CBO  
Private shop/Community 
Retailer/Intemba Don t know  














Q3057.  How far from your 
household was the location 
the zinc was obtained from? 
 
(Interviewer: Ask for 
response in Km) 
 
 [_______________] km 
 









Q3058.  How long did it take to walk 
there from your home? 
 
Interviewer: If they say 
they did not walk, ask 
them how long it would 
take to walk there. 
 
Minutes [_______________] 
 Don t know  
 
1 hour = 60 mins 
2 hours = 120 mins 
3 hours = 180 mins 








Q3059.  What was your main reason 
for choosing this source of 
supply? 
Interviewer; Mark only 




Easily accessible  
Quality of care  
Most knowledgeable source 









Q3060.  Did you give (NAME) ORS or Yes    1 Q306
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SSS along with the Zinc? No    2 2 
Q3061.  What was the primary 
reason you did not give ORS 
or SSS along with zinc? 
Interviewer: Do not read 
list. Mark only one 
response.  
Did not know it should be given 
together  











Q3062.  What dose of zinc per day 
was given to (NAME)? 
 
Half tablet  
1 whole tablet 
2 whole tablets 










Q3063.  Is (NAME) still taking zinc? Yes    
No Don t know 1 2 888  
Q3064.  Does (NAME) still have 
diarrhea? 
Yes    
No Don t know 1 2 888  
Q3065.  Did you think this zinc 
treatment was effective in 
treating (NAME)? 
 
Yes    




Q3066.  Why do you think it was 
effective? 
Diarrhea stopped quickly  
Child recovered quickly  
Child regained appetite 














Q3067.  Why don t you think it was 
effective? 
 
Diarrhea did not stop soon   Child didn t like the taste  
Too hard to administer 











Q3068.  Do you plan on using zinc 
the next time (NAME) has 
diarrhea? 
Yes    
No    Don t know     1 2 888  
Q3069.  Did you purchase the zinc or 
obtain it free from the 
Purchased 













3069A For those that obtained it 
free: 
How did you obtain the free 
zinc? 
Redeemed voucher for Kit Yamoyo 
Free from health center 










Q3070.  What price did you pay? Price_______________ Don t know  888  Mod
6 
Q3071.  What do you think of the 
price of zinc? 
Interviewer: Read options 
and ask respondent to 
select one response. 
 
Not expensive   
Affordable  
Expensive  
Too expensive  









Q3072.  If the price of zinc exceeded 
what you would be willing 
or able to pay, what would 
you do? 
 
Find cheaper brand 






3073.  Interviewer: If negative 
responses given in Q3016 
AND Q3031 AND Q3042 
AND Q3050 indicating 
that they gave no 
treatments (including no 
ORS/SSS or home 
remedies), ask the 
following. Multiple 
responses allowed.  Do 
not read list.  
 
Can you tell me why you did 
not provide any treatment 
to (NAME) during this 
recent episode of diarrhea? 
Child not very sick  
Could not afford  
Did not know where to get treatment    
Child too young for drugs   
Health center had no treatment 
Child has never had diarrhea Don t know  






















Module 4: For caregivers of children under age 5 years who did not have a child 
with diarrhea within last two weeks. 
Q4001.  When one of your children  
under the age of five has 
diarrhea, where would you 
most frequently seek 
advice? 
 
Health center/clinic/hospital   
Community health worker   
Private pharmacy 
Neighbor/friend/family member  
Traditional Healer 
 NGO/ Faith-based organization/CBO  
Private shop/Community 
Retailer/Intemba 
Kit Yamoyo Promoter 



















Q4002.  When one of your children 
under the age of five has 
diarrhea, where would you 
most frequently seek 
treatment? 
 
Health center/clinic/hospital   
Community health worker   
Private pharmacy 
Neighbor/friend/family member  
Traditional Healer 
 NGO/ Faith-based organization/CBO  
Private shop/Community 
Retailer/Intemba 
Kit Yamoyo Promoter 
Do not seek treatment Don t know  


















Q4003.  When one of your children  
under the age of five has 
diarrhea, what do you most 
often do to treat him or 
her? 
 
Interviewer: do not read 
list. Ask respondent to 
state only ONE answer – 
the most frequently used 
treatment. 
Give more than usual amount of fluids  
Give ORS   
Give homemade sugar salt solution (SSS)  
Give home-based fluids (not ORS or SSS)  
Give antibiotic (e.g. flagyl)   
Give antidiarrheal   
Give more than usual to eat   
Continue breastfeeding   
Take to clinic or hospital 


























Q4004.  Probe: In addition to the 
answer just provided, what 
else (if anything) do you do 
most often to treat him or 
her? 
Interviewer: do not read 
list. Ask respondent to 
choose only ONE answer 
– the second most 
frequently used 
treatment. 
Give more than usual amount of fluids  
Give ORS   
Give SSS  
Give home-based fluids(not ORS or SSS)  
Give antibiotic   
Give antidiarrheal   
Give more than usual to eat   
Continue breastfeeding   
Take to clinic or hospital 





















Q4005.  When one of your children 
under 5 has diarrhea, do 
you give less than usual to 
drink, about the same 
amount, more than usual to 
drink, or nothing to drink? 
(Interviewer: If less,  
probe: would you give 
much less than usual to 
drink or somewhat less?) 
Much less  
Somewhat less   
About the same   
More  










Q4006.  When one of your children 
under 5 has diarrhea, do 
you normally continue to 
breastfeed during the 
episode? 
(Interviewer: Probe: More 
or Less?) 
YES 
Breastfed more  
Breastfed less   




Stopped breastfeeding due to 
diarrhea 
Does not breastfeed 
anymore/weaned/too old 
















Q4007.  When one of your children 
under 5 has diarrhea, do 
you normally give less than 
usual to eat, about the 
Much less  
Somewhat less   
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same amount, more than 
usual, or nothing? 
Interviewer: If less,  
probe: much less than 
usual to eat or somewhat 
less? 





Q4008.  Thinking back over the past 
3 months, have you seen or 
heard any messages about 
treatment for diarrhea? 
Yes    





Q4009.  Where did you hear/see 
the message(s) about 
treatment for diarrhea? 
Interviewer: Multiple 
responses allowed. Note 
all that apply. Do not 
read list.  
Radio   
Television  
Community education 
session/health talk  
Community health worker  













































Q4010.  Was the person delivering 
the message wearing a t-
shirt that looked like this? 
SHOW PICTURE OF 
ORANGE PROMOTERS T-
Shirt and RED Shop Keeper 
Shirt (Include on tablet if 
possible) 
YES 
NO Don t remember  1 2 3 4012 4012 4012 
Q4011.  Was it one of these 
posters? 
Show Picture of Kit Yamoyo 
promotional posters 
(include on tablet if 
possible) 
YES 
NO Don t remember 1 2 3  
Q4012.  Do you know what ORS is? Yes 1  
 





(Interviewer: refer to it 
in different ways – local 
name (Manziyamoyo), 
Oral Rehydration Salts, 
and show image of local 
ORS packets on screen 
noting that they 




Q4013.  In the past 3 months have 












Q4014.  Where did you hear/see 
the message(s) about ORS? 
 
Interviewer: Multiple 
responses allowed. Note 
all that apply. Do not 
read list.  
Radio   
Television  
Community education 
session/health talk  
Community health worker  














































Q4014A Was the person delivering 
the message wearing a t-
shirt that looked like this? 
SHOW PICTURE OF 
ORANGE PROMOTERS T-
Shirt and Red Retailer 
Shirt (Include on tablet if 
possible) 
YES 
NO Don t remember  1 2 3 4015 4015 4015 
Q4014B Was it one of these 
posters? 
Show Picture of Kit 
Yamoyo promotional 
YES 
NO Don t remember 1 2 3  
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posters (include on tablet 
if possible) 
Q4015.  Please tell me if you agree 
or disagree with each of 
these statements.  
 
Interviewer: Read this 
list. 
 
                Ag   Dis  DK 
ORS is medicine that  
gives good health                         1   2  
888 
 
ORS is a treatment for  
diarrhea                                         1   2   
888 
 
ORS stops  
Diarrhea                                        1    2   
888 
 
My child does not  
like the taste of  
ORS                                                 1   2   
888 
 
ORS prevents  




Q4016.  Can you describe the 
process of how to make 
ORS Solution in as detailed 
a way as possible? 
 
(multiple answers 
allowed. check all that are 
mentioned by caregiver. 
Do not read responses. 
Only check boxes that are 
mentioned by respondent) 
Mix contents of ORS package with 
water 
Ensure water is clean/Purify water 
Ensure proper measurement of 
water 
Wash hands prior to preparing 
Respondent explains how to use Kit 
Yamoyo 
Sprinkle over food 
Swallow Powder 



















Q4017.  Do you think ORS 
treatment is effective in 
treating diarrhea? 
 
Yes    





Q4018.  Why do you think ORS is Diarrhea stops quickly  1 4020 
 





(Do not read responses. 
Multiple responses 
allowed. Only check boxes 
that are mentioned by 
respondent) 
Child recovers quickly  
Child regains appetite  
Prevents dehydration 
















Q4019.  Why don t you think ORS is 
effective in treating 
diarrhea? 
 
(Do not read responses.  
Multiple responses 
allowed. Only check boxes 
that are mentioned by 
respondent) 
It only prevents dehydration 
It is only for giving strength 
Diarrhea does not stop 
soon/diarrhea continues Child doesn t like the taste  
Too hard to administer  















Q4020.  Do you plan on using ORS 
the next time your under 5 
child has diarrhea? 
Yes    
No    Don t know     1 2 88
8 
 
Q4020A Thinking back over the past 
6 months, have you heard a 
message/received 
information about an anti-
diarrheal kit called Kit 
Yamoyo? 
Interviewer: Show Image 
of Kit Yamoyo and an 
actual Kit Yamoyo 
YES 
NO Don t Know 1 2 88
8 
 
Q4020B Have you ever used the Kit 
Yamoyo to treat any of 
your children under-5 with 
diarrhea? 
YES 





Q4020C If no, why did you not use 
the Kit Yamoyo to treat your child s diarrhea? 
Multiple responses 
Child has not had diarrhea 
Kit is too expensive 
Kit was not available at my local 
shop 
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allowed. Do not read list. I have not heard about it/Do not 









Q4021.  Have you ever prepared 
ORS solution for your 










Which ORS product(s) was 




responses allowed. If they 
don’t know you can show 
them the poster with 
samples of local products 
(ORS packets), and the 
actual Kit Yamoyo, and 
ask respondent to select 
any/all used during the 
recent episode of 
diarrhea.) 
 
If more then one answer is 
selected, confirm that they 
used two different types of 
ORS during the most 
recent episode of diarrhea 
 
GRZ (Health Center) 
From Kit Yamoyo 
Other from Private shop (eg. 








Q4022.  Do you use ordinary water 
or do you use treated water 
when you prepare ORS? 
 
Ordinary (Non-purified) Water  
Treated Water (chlorine) 
Treated Water (Boiled)  








Q4023.  How much of the ORS 
packet/sachet would you 
typically use each time you 
prepare the ORS solution? 
)nterviewer: )f they don t 
know how to respond, 
you may give examples 
Entire contents of packet 
Half off the packet 
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from the list 
Q4024.  What quantity of water 
would you mix the ORS 
with each time you prepare 
the solution? 
 
)nterviewer: )f they don t 
know the particular 
metric measurement, 
probe as to what type of 
container they would use 
to measure the amount of 
water. Do not read list of 
responses. 
(Show images of each) 
Used1 standard household drinking 
cup/mug/glass 
Used Kit Yamoyo Container 

























Q4025.  From where would you 
typically obtain ORS? 
Health center/clinic/hospital   
Community health worker   
Private pharmacy 
Neighbor/friend, family member  
Traditional Healer 
Private shop/Retailer/Intemba Don t know  





















Q4026.  From which health facility 







How much would you 
spend on transport to get 
to the health center, if 
anything? 
 
If they spent nothing to 
get there, put 0  
[___________]Kwacha 
 Don t know   
Q4026
B 
How much would you 
typically spend on food and 
drinks during your trip to 
the health center, if any? 
 
If they spent nothing, put 
0  
[___________]Kwacha 




Q4026 What other expenses if any, Medicines 1  
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C would you typically have 
during your trip to the 
health center? 











How much would you 
typically spend on this? 
[_________________] 
 don t know   88
8 
 
Q4027.  How far is the location you 
would typically obtain ORS 
from? 
 
(Interviewer: Ask for 
answer in Km) 
 
 [_______________] km 








Q4028.  How long would it take to 
walk there? 
 
Interviewer: If they say 
they do not walk, ask 
them how long it would 
take to walk there 
Minutes (__________________) 
 
1 hour = 60 mins 
2 hours = 120 mins 
3 hours = 180 mins 
4 hours = 240 minutes 
 
  
Q4029.  When your under 5 child 
has had diarrhea in the 
past, have you ever given 
them home-prepared 
sugar-salt solution (SSS)? 
Insert above the local 
term(s) for the sugar-salt 
solution (as 
distinguished from 
purchased ORS – explain 
1 teaspoon of salt to 6 
teaspoons of sugar in a 
liter of water) 
 
Yes   









Q4030.  Interviewer: check responses to Q4021 and Q4029 
If Q4021=2 (NO) AND Q4029=2 (NO) then go to Q4031. Otherwise, go to Q4032. 
Q4031.  Interviewer: If the 
caregiver does not 
provide either ORS or SSS 
to the child, ask  why 
Child not seriously ill   
Normally cannot find ORS/SSS to 
buy   








 | P a g e  
 
235 
have you never given your 
under 5 child either ORS or 
home-prepared sugar-salt 
solution to treat diarrhea?  
[Interviewer: Do not read 
list. Multiple responses 
allowed.] 
Child/Mother does not like   Didn t know about ORS/SSS 
Health centerusually does not have 
any 
No nurse/doctor/health staff 
available at clinic 
Give other medicine Don t know how to make SSS 
Forgot about ORS/SSS 











Q4032.  When one of your children 
under 5 child has diarrhea 
do you ever give anything 
other than ORS or home-














Q4033.  Can you tell me or show me 
what treatments you would 
give to your under 5 child if 




Zinc other than from Kit Yamoyo 
ORS other than from Kit Yamoyo 
Antibiotic (e.g. flagyl)  
Anti-diarrheal  
Anti-malarial  
Other pill/syrup   
Intravenous fluid  
Vitamins 
Herbal/traditional remedy 
 Don t know  















Q4034.  Have you ever heard about 




pictures of Zinc examples 
to verify 
Yes 









Q4035.  Can you tell me what you 
know about zinc? 
 
Interviewer: Multiple 
responses allowed. Do 
Zinc is appropriate medicines for 
diarrhea 
Makes child stronger 
Zinc reduces the duration  of the 
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not read list. 
 
Probe: anything else? 
 
Zinc reduces the severity of 
diarrhea  
The risk of new episode in the 
future is reduced  
Zinc is available in health centers  
Zinc should be taken with 
ORS/ORT  
A complete 10-day course  should 
be administered  
Zinc is a micronutrient 















Q4036.  Thinking back over the last 
3 months, have you heard 
any messages or received 
information about zinc? 
 
Yes 








Q4037.  Where did you hear/see the 
message(s) about zinc? 
Interviewer: Multiple 
responses allowed. Note 
all that apply. Do not read 
list.  
Radio   
Television  
Community education 
session/health talk  
Community health worker  
Health clinic 












































Q4038.  Was the person delivering 
the message wearing a t-
shirt that looked like this? 
SHOW PICTURE OF 
ORANGE PROMOTERS T-
Shirt and Red Retailer 
Shirt (Include on tablet if 
possible) 
YES 
NO Don t remember  1 2 3 4040 4040 4040 
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Q4039.  Was it one of these posters? 
Show Picture of Kit 
Yamoyo promotional 
posters (include on tablet 
if possible) 
YES 
NO Don t remember 1 2 3  
Q4040.  What information did you 
get from the message(s) 
that you heard? 
 
Interviewer: Multiple 
responses allowed.  
 
Probe: anything else? 
 
Zinc reduces the duration of the 
diarrheal episode  
Zinc reduces the severity of 
diarrhea  
The risk of new episode in the 
future is reduced  
Zinc is available in health centers  
Zinc should be taken with 
ORS/ORT  
A complete 10-14 day dose 
should be administered  
Zinc is an appropriate treatment 
for diarrhea 
Zinc is a micronutrient 




















Q4041.  Has anyone ever 
recommended use of zinc to 
treat diarrhea? 
Yes    
No    Don t know     1 2 888  Q4043Q4043 
Q4042.  If yes, who recommended 
zinc? 
(Interviewer: Do not read 




Health center/clinic/hospital   
Community health worker   
Private pharmacy 
Neighbor/friend/family member  
Traditional Healer 
 NGO/ Faith-based organization/CBO  
Private shop/Community 
Retailer/Intemba 
Kit Yamoyo Promoter Don t know  
















Q4043.  Have you ever used zinc to 
treat [NAME] with 
diarrhea? 
Yes 
No Don t know 1 2 888 4045  Mod6 
Q4044.  If NO, can you tell me why 
you have not given your 
Never heard of zinc  
Did not know where to buy  
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child zinc to treat the 
diarrhea? 
Used another product I had confidence 
in Don t think it works ) had it, but didn t know ) was supposed 











Q4045.  Which type of zinc product 
did you use? 
 
 
Tablets from health center 
Tablets from Kit Yamoyo 

















How many zinc tablets did 
you receive? 
 
(________) Don t know  888  
Q4045
b 
How many zinc tablets did you 
give [NAME] per day? 
 
___________________ 



























Interviewer: If less than 
10 tablets ask: 
Was there a reason (NAME) 
took less than 10 tablets? 
Interviewer: Do not read 
list. Multiple responses 
allowed. 
 
Child was cured  
Child would not take zinc treatment   
Child vomited treatment  
Needed treatment for another person 
Wanted to save remaining treatment for 
future illness  
Did not know child needed to take entire 
treatment  
 
Thought I needed to give zinc only along 
with ORS  
Child still taking the treatment  
















Q4046.  If your child had diarrhea, can 
you tell me all the places you 
could get zinc? 
 
Interviewer: Multiple 
responses allowed. Do not read 
responses.  
 
Probe: anywhere else? 
Health center/clinic/hospital   
Community health worker   
Private pharmacy 
Neighbor/friend, family member  
Traditional Healer 
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Q4047.  What is the main reason 
you would choose these 
sources of supply? 
Interviewer; Mark only 




Easily accessible  
Quality of care  








Q4048.  When your child under 5 
has diarrhea, would you 
give ORS or SSS along with 
zinc? 
Yes    




Q4049.  What is the primary reason 
you would not give ORS or 
SSS along with zinc? 
Interviewer: Do not read 
list. Mark only one 
response.  
Did not know it should be given 
together  
Did not have ORS  Don t think ORS is effective   Didn t have ingredients for ORT 











Q4050.  Do you think zinc treatment 
is effective in treating 
diarrhea? 
 
Yes    
No    Don t know    1 2 888 4051 4052 4053 
Q4051.  Why do you think zinc is 
effective for treating 
diarrhea? 
 
(Do not read responses. 
Multiple responses 
allowed. Only check boxes 
that are mentioned by 
respondent) 
Diarrhea stopped quickly  
Child recovered quickly  
Child regained appetite 










Q4052.  Why don t you think zinc is 
effective in treating 
diarrhea? 
(Do not read responses.  
Multiple responses 
allowed. Only check boxes 
 
Diarrhea did not stop soon   Child didn t like the taste  
Too hard to administer 
Diarrhea started again 
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that are mentioned by 
respondent) 
Q4053.  Do you plan on using zinc 
the next time your under 5 
child has diarrhea? 
Yes    
No    Don t know     1 2 888  
Q4054.  When you used zinc, did 
you purchase the zinc or 








Q4055.  What price did you pay? Price_______________ Don t know  888  
Q4056.  What do you think of the 
price of zinc? 
Interviewer: Read 
options and ask 
respondent to select one 
response. 
 
Not expensive   
Affordable  
Expensive  
Too expensive  









Q4057.  If the price of zinc exceeded 
what you were willing or 
able to pay, what would you 
do? 
 
Find cheaper brand 






Q4058.  Interviewer: If negative 
responses given in Q4021 
AND Q4029 AND Q4034 
AND Q4044 indicating 
that they have never 
given any treatments 
(including no ORS/SSS or 
home remedies), ask the 
following. Multiple 
responses allowed.  Do 
not read list.  
 
Can you tell me why you 
have never provided any 
Child not very sick  
Could not afford  
Did not know where to get treatment    
Child too young for drugs   
Health center had no treatment 
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treatment to (NAME) 
during an episode of 
diarrhea? 
I would now like to ask you some questions about hand-washing 
Module 6: Hand-washing (Everyone) 
Q6001.  Do members of your 
household typically wash 
their hands with soap 
before eating a meal? 
Yes, sometimes 
Yes, always 





Q6002.  Please show me where 
members of your household 




Not in dwelling/plot/yard 


















Q6003.  Observe Presence of Water 
at the specific place for 
hand-washing.  
Verify by checking the 
tap/pump, or basin. 
Bucket, water container 
or similar objects for 
presence of water.  
 
Water is available 
 








Q6004.  Record if soap or detergent 
is present at the specific 
place for hand-washing. 
 
Circle all that apply  
Include image of Kit 
Yamoyo bar of soap so 
interviewer can identify 
Other Bar Soap 
Detergent (Powder/Liquid/Paste)  
Liquid Soap 
Ash/Mud/Sand 
















Q6005.  Do you have any soap or 
detergent (or other locally 















We would now like to ask you some questions about the Kit Yamoyo and your experience 
with it. 
your household for washing 
hands?  
5 
Q6006.  Can you please show it to 
me?  
Record observation. Circle 
all that apply.  
Bar Soap 
Detergent (Powder/Liquid/Paste)  
Liquid Soap 
Ash/Mud/Sand 
Kit Yamoyo Bar of Soap 
None 






















Did (Name) use the 
Kit Yamoyo anti-
diarrhea Kit when 
he or she had 
diarrhea last? 
Yes 
No Don t Know 1 2 888 3017 3017 
Q7000X
1 
When you used the 
Kit Yamoyo, was it: 
Newly acquired and 
unopened 
Newly acquired but 
open 
Previously acquired 
but unopened; OR 
Previously acquired 
and previously used 
some of the contents 
Newly acquired and unopened 
Newly acquired but open 
Previously acquired but 
unopened 
Previously acquired and 
previously used some of the 
contents 














Q7000 Have you yourself, 
or any other people 
in your household 
over the age of 5 
Yes 
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ever used the Kit 
Yamoyo? 
Q7001.  Have you ever 
attended an 
education/promotio
n event for the Kit 
Yamoyo? 
Yes 
No Don t know 1 2 888 7002a  7002a 
Q7002.  If no, where did you 




allowed. Do not 
read list. 
Radio   
Television  
Community education 
session/health talk  
Community health worker  
Health clinic 
































Q7002a Did the promotion 
event have an 
influence on your 
decision to obtain a 
Kit Yamoyo? 
Yes 
No Don t Know 1 2 888  
Q7003.  What are the key 
messages you have 
received with 




all that are 
mentioned. Do not 
read list.  
Probe: Any 
Use ORS & Zinc together to 
treat diarrhea 
Can buy Kit Yamoyo at the 
local shop 
Mix 1 sachet with Kit Yamoyo 
container full of water 
Give 1 tablet of zinc per day 
Finish all ten pills of zinc 
Give ORS after each liquid 
stool/loose motion 
Wash hands with soap 
Give antibiotic (e.g. Flagyl)  
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messages at all? Continue breastfeeding 
Take to clinic/health 
center/hospital when danger 
signs (i.e. blood in stool, 
severely dehydrated, vomiting) 







Q7004.  How many Kit Yamoyo s have you 
ever obtained? 
________________ 







Q7005.  From where did you 
obtain your most 
recent Kit Yamoyo? 
Private shop/Community 
Retailer/Intemba 
Health center/clinic/hospital   




 NGO/ Faith-based organization/CBO  Don t know  


































Q7006.  From which health 
facility did you 





Q7007.  From which retailer 
did you obtain the 
Kit Yamoyo? 
Interviewer: Name 
of shop or shop 






Q7007a Did you find the 
retailer to be helpful 
with regard to the 
Yes 
No  Don t know 1 2 888  
 




Q7008.  Did the 
retailer/shop owner 
give any advice, 
instructions, or 
guidance when you 
got the Kit Yamoyo? 
Yes 
No Don t know 1 2 888  7010 7010 
Q7009.  What advice, 
instructions, or 




all that are 
mentioned. Do not 
read list.  
Probe: Any 
guidance at all? 
Use ORS & Zinc together to 
treat diarrhea 
Can buy Kit Yamoyo at the 
local shop 
Mix 1 sachet with Kit Yamoyo 
container full of water 
Give 1 tablet of zinc per day 
Finish all ten pills of zinc 
Give ORS after each liquid 
stool/loose motion 
Wash hands with soap 
Give antibiotic (e.g. Flagyl)  
Give more than usual amount 
of fluid 
Continue breastfeeding 
Take to clinic/health 
center/hospital when danger 
signs (i.e. blood in stool, 
severely dehydrated, vomiting) 






















Q7010.  Did you pay for the 
Kit Yamoyo or use a 
voucher the last 
time you obtained 
one? 
Paid 
Voucher Don t know 1 2 888  7012 7013 
Q7011.  How much did you 
pay? 
(______)  7013 
Q7012.  From where did you 
acquire the 
voucher? 
Kit Yamoyo Promoter 
Health center/clinic/hospital   
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Other   
(specify)_____________ 
 
Q7012a Would you have 
tried the Kit Yamoyo 
if you did not 
receive a voucher? 
Yes 
No Don t Know 1 2 888  
Q7013.  What do you think 
of the retail price of 
the Kit Yamoyo 
(5000 Kwacha or 
5KR)? 
Interviewer: Read 





Not expensive   
Affordable  
Expensive  
Too expensive  









Q7014.  How far from your 
household was the 





for response in 
Km) 
 
 [_______________] km 
 








Q7015.  How long did it take 




they say they did 
not walk, ask them 
how long it would 
take to walk there. 
 
Minutes [_______________] Don t Know  
 
1 hour = 60 mins 
2 hours = 120 mins 
3 hours = 180 mins 







Q7015a Is this the closest 
retail shop to your 
home? 
Yes 
No Don t Know 1 2 888  
Q7015b What was your main 
reason for choosing 
Price  
Easily accessible  
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this source of 
supply? 
Interviewer; Mark 
only one answer. 
Do not read list. 
 
Most knowledgeable source 





Q7016.  Does a local shop 
always have Kit 
Yamoyo in stock and 
available? 
Interviewer: you 










Q7017.  How many days 
after the diarrhea 
began did you first 
seek out the Kit 
Yamoyo? 
Interviewer: If the 
same day, record 
;  
If Child did not 
have diarrhea 





Child did not have diarrhea 
when I acquired Kit Yamoyo 













Q7018.  How many days 
after the diarrhea 
began did your child 
first use the Kit 
Yamoyo? 
Interviewer: if 
same day mark 
  
If the Kit Yamoyo 
has not been used 
yet record 222. 
(____) 








Can you name all of 
the items found in 
the Kit Yamoyo? 
Interviewer: 
Multiple answers 
allowed. Click all 
that are 
mentioned. Do not 












Did you use the 
instructions found 
in the Kit Yamoyo? 
Yes 
No Don t Know 1 2 888  7024 7024 
Q7021.  
Did you find the 
instructions useful? 
Yes 
No Don t Know 1 2 888  
Q7022.  
What did you like 
most about the 
instructions? 
Multiple responses 
allowed. Mark all 
that are 
mentioned. Do not 
read list.  
Probe: Anything 
else? 
Instructions were clear 
Diagrams/pictures 
Instruction are in my language 












What, if anything, 
did you find unclear 
in the instructions? 
 
Multiple responses 
allowed. Do not 
read list.  
 
If necessary, 
probe: Can you be 
more specific? 
Container to be used as 
measure for water 
 
One packet of ORS to be mixed 
with 1 container full of water 
 
How many packets of ORS to 
use 
 
How often to give ORS 
 
How many zinc tablets to give 
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What is the soap for 
 
Nothing was unclear 
 





Q7023a Can you describe 
the process of how 




allowed. check all 
that are mentioned 
by caregiver. Do 
not read responses. 
Only check boxes 
that are mentioned 
by respondent) 
Wash hands prior to preparing 
 
Remove seal  
 
Mix contents of 1 sachet of ORS 
with Kit Yamoyo container full 
of water 
 
 Ensure water is clean/Purify 
water/Boil water 
 
Let boiled water cool before 
pouring into Kit Yamoyo 
container 
 
Shake Kit Yamoyo container 
with lid on to mix the ORS and 
water together  
 
Give ORS after each watery 
stool 
 
Take 1 tablet of zinc per day 
 
Take full course of zinc tablets 
until finished (10 days) 
 


































How many packets 
of ORS from the Kit 
Yamoyo did you 
prepare for your 
child during the 
episode of diarrhea? 
 
____________ 












Did you use 
ordinary water or 
did you use treated 
water when you 
prepared the Kit 
Yamoyo ORS? 
 
Ordinary (Non-purified) Water  
Treated Water (chlorine) 
Treated Water (Boiled)  








How much of the 
ORS packet/sachet 
did you use each 
time you prepared 
the ORS? 
(Interviewer: If 
they don’t know 
how to respond, 
you may give 
examples from the 
list) 
Entire contents of packet 
Half of the packet 










What quantity of 
water did you mix 
the ORS with each 
time you prepared 
the solution? 
 
Used1 standard household 
drinking cup/mug/glass 
Used Kit Yamoyo Container 





































Till what level did 
you fill the Kit 
Yamoyo container 
with water to mix 
the solution? 
Filled to top 
Filled to line marked on 
container 









For how many days 
did you give the 
child the ORS from 
Kit Yamoyo? 
[__][__]   
 




How often did you 
give the ORS 









Frequently   
After each liquid stool  
Morning, mid-day, and night   
Whenever the child wanted it   Don t know   












Did you use each of 
the items in the Kit 
Yamoyo when your 
child had diarrhea – 
the ORS, zinc, and 
soap? 
Yes 
No Don t know 1 2 888   
Q7031A Did you use the 
ORS? 
Yes 
No Don t know 1 2 888  7032A 
Q7031B Did you use the Zinc 
tablets? 
Yes 
No Don t know 1 2 888  7032A 
Q7031C Did you use the bar 
of soap? 
Yes 
No Don t know 1 2 888 7032B 7032A 
Q7032.  
Which items did you 
not use? 
Multiple answers 
















Q7032a Why did you not use 
the item(s)? 
Child did not have diarrhea Don t think it works 
Child did not like it 
Did not know how to use it 











Q7032b What did you use 


















Had you ever heard 
about zinc as a 
medicine for 
diarrhea prior to 
learning about the 
Kit Yamoyo? 
Yes 








Was the zinc from 
the Kit Yamoyo the 
first time your child 
has ever had zinc as 
a treatment for 
diarrhea? 
Yes 
No Don t Know 1 2 888 If NO to 7031B Skip this 
question 
Q7035.  
Can you tell me 





allowed. Do not 






Zinc is appropriate medicines 
for diarrhea 
 
Makes child stronger 
 
Zinc reduces the duration  of 
the diarrheal episode 
 
Zinc reduces the severity of 
diarrhea 
 
The risk of new episode in the 
future is reduced 
 
Zinc is available in health 
centers  
 
Zinc should be taken with 
ORS/ORT  
 
A complete 10-day 
course  should be 
administered  
 
Zinc is a micronutrient 
 
Zinc is used for malnutrition  






































What dose of zinc 
per day was given to 
your child? 
 
Probe: How many 
tablets? 
Half tablet  
1 whole tablet 
2 whole tablets 














How many days did 












than 9, go 
to 7039  
Q7038.  
Interviewer: If less 
than 10 tablets 
ask: 
Was there a reason 
your child took less 
than 10 tablets? 
Interviewer: Do 




Child was cured  
Child would not take zinc treatment   
Child vomited treatment  
Needed treatment for another person 
Wanted to save remaining treatment 
for future illness  
Did not know child needed to take 
entire treatment  
No one told me to give all the 
treatment  
Thought I needed to give zinc only 
along with ORS  
Child still taking the treatment  




















Is your child still 
taking zinc? 
Yes    
No Don t know 1 2 888 If NO to 7031B Skip this 
question 
Q7040.  
Does your child still 
have diarrhea? 
Yes    





Did you thinkthe Kit 
Yamoyo was 
effective in treating 
your child s 
diarrhea? 
 
Yes    
No    Don t know    1 2 888  7043  
7044 
 




Why do you think 
the Kit Yamoyo was 
effective? 
 
(Do not read 
responses.  
Multiple responses 
allowed. Only check 
boxes that are 
mentioned by 
respondent) 
Diarrhea stopped quickly  
Child recovered quickly  
Child regained appetite 
Child has not had diarrhea again 















Why don t you think 
the Kit Yamoyowas 
effective? 
(Do not read 
responses.  
Multiple responses 
allowed. Only check 




Diarrhea did not stop soon   Child didn t like the taste  
Too hard to administer 












Was it easy to find 
Kit Yamoyo in a 









Did you keep the Kit 
Yamoyo container 
after you were 












Have you used the 
Kit Yamoyo 
container for any 
other purpose? 
Storage of salt 
Storage of sugar 
Storage for buttons 









Do you plan on 
using the Kit 
Yamoyo the next 
time your child has 
diarrhea? 
Yes    
No    Don t know     1 2 888  
 




What was the one 
thing you liked best 
about the Kit 
Yamoyo? 
 
Only one response 
allowed. Do not 
read list. Looking 
for the top thing 






Easy to access 
Good value/Affordable )t worked/Stopped child s diarrhea 


















What did you like 




allowed. Do not 
read list. 
Had to pay for it 
Too expensive 
Not easy to find 
Not in stock when I needed it 
No antibiotic included 











Do you currently 
have a Kit Yamoyo 








Can you show it to 
me? 
Yes, Observed 








Newly acquired and 
unopened 





and previously used 
some of the contents 
 
Newly acquired and unopened 
Newly acquired but open 
Previously acquired but 
unopened 
Previously acquired and 






















Module 5: Awareness/likert scales. Should be answered by all 
respondents. (Everyone) 
This section asks your opinion on certain issues.  
 
Please tell me if you believe that the following statements are true or false. 
(Everyone) 
Ability: Knowledge 
  True  False Don t Know 
Q5002.  Diarrhea can be associated with lack of 
cleanliness 
1 0 888 
Q5003.  Diarrhea can be caused by drinking unsafe 
water 
1 0 888 
Q5004.  Diarrhea can be caused by eating unhygienic 
foods 
1 0 888 
Q5005.  Only those diarrheal episodes that have blood 
in the stool require antibiotics 
1 0 888 
Q5006.  Most diarrhea can be managed at home 
without drugs 
1 0 888 
 
Please tell me if you agree or disagree with these statements. Probe: Read out 
responses (Strongly agree, agree somewhat, disagree somewhat, strongly 
disagree) (everyone) 
 MOTIVATION: THREAT SUSCEPTIBILITY (CHILDREN 
UNDER 5) 
  










Q5001 Children die of diarrhea 
mainly because of 
dehydration. Can you tell 








Very thirsty/drinks eagerly 
Dark coloured urine 
Skin is less elastic (goes back slowly 
when pinched) 
Limp/unconscious Don t know 
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Q5007.  If my child gets 
diarrhea it is best to 
do nothing and it 
will pass in time 
4 3 2 1 888 
Q5008.  The children (child) 
under 5 in my 
household are (is) 
healthy so their 
(his/her) bodies 
could fight off 
diarrhea without 
doing anything 
4 3 2 1 888 
Q5009.  Children under 5 





4 3 2 1 888 
Q5010.  I am not worried 
about the children 
(child) under 5 in 
my household 
getting diarrhea 
4 3 2 1 888 
Q5011.  Children are more 
likely to get 
diarrhea than adults 
4 3 2 1 888 
 Everyone accept those that said NO to /  i.e. don t know ORS  or /  i.e. don t know zinc . All who answered Mod  should answer these as 
well.  
 Opportunity: Availability 
Skip if have not heard about ORS or ZINC or DTK in Mod 3 and Mod 4 
No.       










Q5012.  Shops near here always have 
ORS for sale 
4 3 2 1 888 
5012A Shops near here always have 
Zinc for sale 
4 3 2 1 888 
Q5013.  ORS treatments are difficult 
to get around here 
4 3 2 1 888 
5012B Zinc treatments are difficult 
to get around here 
4 3 2 1 888 
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Q5014.  There is a place nearby 
where I can get zinc and ORS 
when my child needs it 
4 3 2 1 888 
Q5015.  ) don t know where to get 
zinc  
4 3 2 1 888 
Q5016.  Zinc and ORS treatment 
products are available 
within walking distance 
from my home 




GENERAL AWARENESS OF ORS: Skip only if NO to 8 or  i.e. don t know ORS  
 Motivation: Outcome 
Expectations 
     
No.       










Q5017.  ORS is effective for treatment of 
diarrhea 
4 3 2 1 888 
Q5018.  ORS does not help prevent 
dehydration 
4 3 2 1 888 
Q5019.  There is no need to take a child to 
the health facility if there is blood 
in the stool 
4 3 2 1 888 
Q5020.  The amount of water mixed with 
the ORS does not matter 
4 3 2 1 888 
Q5021.  Children should continue eating 
and drinking if they have 
diarrhea 
4 3 2 1 888 
 
GENERAL AWARENESS OF ZINC: Skip only if NO to  or  i.e. don t know ZINC) 
 Motivation: Outcome 
Expectations 
     
No.       










Q5022.  Zinc is effective for treatment of 
diarrhea 
4 3 2 1 888 
Q5023.  Zinc reduces the duration of a 
diarrheal episode 
4 3 2 1 888 
Q5024.  Zinc should always be given with 
ORS for optimal diarrhea 
treatment 
4 3 2 1 888 
Q5025.  Use of zinc reduces the risk of 
dehydration in children 
4 3 2 1 888 
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Q5026.  Zinc reduces the risk of a new 
diarrheal episode in the following 
2 to 3 months 
4 3 2 1 888 
Q5027.  Zinc does not help in reducing the 
severity of a diarrheal episode 
4 3 2 1 888 
Q5028.  What is the minimum number of 
days that ZINC tablets should be 
taken? 
 
(Record figure in the space 
provided) 
[___________] days 





General awareness of soap (Everyone) 
Q5029.  What are the best ways to prevent 
germs that cause diarrhea? 
 
Multiple Responses Allowed. Do 
not read list 
Purify/boil water 
Wash hands (with soap) 
Wash utensils 
Peel raw fruit 






























Q5030.  Germs that cause diarrhea can be passed by people s hands e.g. 
handshake) 
4 3 2 1 888 
Q5031.  Washing our hands with soap 
protects us better than with just plain 
water 
4 3 2 1 888 
Q5032.  Soap is too expensive so we don t use 
it 
4 3 2 1 888 
Q5033.  When should one wash their hands? 
 
INTERVIEWER: Multiple response 
possible. Probe for additional 
responses and mark all that apply) 
After using the latrine/toilet 
Before preparing food and drink 
Before eating 
Before feeding children 
After Working Don t know 











 Capacity/Ability: Use of Products 
Skip if NO to 3042 or 4034 or 3017A or 4020A. Everyone from Mod 7 should answer these 
questions.  
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No.       










Q5034. Zinc is an appropriate treatment 
for diarrhea in children 
4 3 2 1 888 
Q5035. Zinc with ORS should be used for 
every type of diarrhea in children 
4 3 2 1 888 
Q5036. Diarrhea in children should be 
treated with an antibiotic 
4 3 2 1 888 
Q5037. Zinc has too many side efects, so 
) dont feel safe giving zinc to my 
smal child 
4 3 2 1 888 
Q5038. Zinc tastes bad so my child wont 
take it 
4 3 2 1 888 
Q5039. Zinc is only a nutritional 
supplement, not an efective 
treatment for diarrhea in children 
4 3 2 1 888 
Q5040. Zinc should be given along with 
ORS to be most efective 
4 3 2 1 888 
Q5041. It is dificult to remember to give 
a child zinc when the diarrhea 
has stopped 
4 3 2 1 888 
Q5042. I would purchase and use zinc or 
the Kit Yamoyo the next time my 
child has diarrhea 




Is there anything I did not ask that you think I should know? Is there anything you 
want to go back to? Is there anything you would like to ask me about the topics we 
have discussed today? 
ENUMERATORS, PLEASE ENTER ANY ADDITIONAL NOTES, ADDITIONAL 








Q 5044.   Acquire GPS Location ________________________ _____________________ 
 




Dr. Rohit Ramchandani, DrPH, MPH, B.Sc. 
 
328 La Rocca Ave  • Vaughan, ON • Canada •L ( L  






Johns Hopkins Bloomberg School of Public Health Baltimore, MD 
Doctor of Public Health (DrPH) Aug 2010 – December 2015 






Antara Global Health Advisors Toronto, Ontario/Global 
Founder and CEO May 2012 – Present 
 Providing consulting services and technical expertise to organizations (NGOs, Governments, donors, 
foundations, innovators, private sector, universities, etc.) in global health and development, including 
services in: M&E; research design, implementation and analysis; health markets; global health delivery 
and implementation sciences; multi-sectoral partnership development (e.g. public-private partnerships); 
program management and development; innovation for development & human-centered design; global 
health strategy; proposal development & assessment; child health; etc. 
 Advising on a strategy to improve prevention of HIV in adolescent girls in sub-Saharan Africa; Client: 
Janssen/Johnson & Johnson 
 Developing multi-sectoral partnership and funding strategy to improve health of garment factory 
workers in Southeast Asia; Client: Janssen/Johnson & Johnson 
 Selected as Senior (ealth Evaluation Specialist for Aga Khan Foundation s multi-country Central Asia 
Health Systems Strengthening Project mid-term evaluation; Client: Aga Khan Foundation Canada/DFATD 
 Leading evaluation of the national scale-up of the globally recognized ColaLife model (across rural and 
urban, public and private sector markets); Client: ColaLife/CARE.  
 Conducted large-scale global interview process with leaders in international health to evaluate emerging 
opportunities in health markets; Client: Rockefeller Foundation and Future Health Systems Consortium.  
 Providing advice as member of an expert panel on the development of a blue print for a Backpack PLUS 
for Community Health Workers; Client: MDG Health Alliance and UNICEF 
 Member of the UN Innovation Working Group under the Every Woman, Every Child Initiative; Client: UN 
 Developing report on rural, private sector retailers and health market opportunities in emerging 
economies; Client: GlaxoSmithKline/Barclay s Partnership  
 
Boston University School of Public Health Boston, MA 
Master Of Public Health (MPH) Sept 2004- Jan 2006 
 International Health & Epidemiology  
 Dean s (onor List; .  GPA 
 
University of Waterloo Waterloo, ON 
Honors Bachelor of Science (B.Sc.) Sept 2000 – Apr 2004 
 Honors Health Studies & Gerontology, Faculty of Applied Health Sciences 
 National Laureate of the Canada Millennium Excellence Scholarship 
 Young Alumni Award, October 2009 
 






University of Waterloo School of Public Health Waterloo, Ontario 
Adjunct Lecturer Dec 2012 – Present 
 Delivering guest lectures and keynotes at special events on topics relating to global health and 




ColaLife Canada/United Kingdom/Zambia 
Public Health Advisor & Principal Investigator Jul 2010 – Present 
 Established globally renowned, innovative, social enterprise movement as one of three executive 
members  
 Developed an innovative public-private-partnership model in order to test to what extent leveraging the 
Coca-Cola supply-chain will improve access and utilization of oral rehydration salts and zinc in rural 
areas of developing countries  
 Providing leadership and technical services relating to trial design, monitoring and evaluation, training, 
product innovation, partnership development, data analysis, donor reporting, fundraising and advocacy 
 Worked, and gathered both quantitative and qualitative evaluation data, across diverse groups of 
stakeholders at multiple levels (national, provincial, district, community), including via in-depth 
interviews, focus group discussions, household surveys, retailer surveys, health center impact 
assessments, direct observation, project management meetings, documentation/records review and 
other methodologies 
 Scaling up successful model nationally in partnership with the Ministry of Health, International NGOs, 
local NGOs and private sector partners. 
 
 
 Canadian International Development Agency (CIDA), 
Strategic Policy and Performance Branch 
 Ottawa, Ontario / Global 
 Apr 2010 – Aug 2010 
 Senior Policy Analyst/Special Advisor – G8 Maternal and 
Child Health Initiative  
  
 Provided key insights and public health advise relating to Canada s G8 Maternal and Child Health 
Initiative (a.k.a. Muskoka Initiative). 
 Led C)DA s involvement on the UN Secretary General s Joint Action Plan for Women s and Children s 
Health Working Groups on Innovation and Finance as a CIDA health expert. 
 Developed white paper on Innovations in Service Delivery as part of the Joint Action Plan – posted on The Partnership for Maternal, Newborn, and Child (ealth s website. 
 
 
Canadian International Development Agency (CIDA), 
Multilateral and Global Programs Branch, Global 
Initiatives Directorate (GID) 
 
Ottawa, Ontario / Global  
Dec 2007- Apr 2010 
 
Senior Health Advisor   
 Developed Treasury Board Submission and co-developed innovative financing concept for a multilateral 
tuberculosis program (TB REACH Facility) that resulted in Government of Canada commitment of 
$120M in new funding for tuberculosis detection and control; Partner: Stop TB Partnership  
 





LV Prasad Eye Institute / World Health Organization (WHO) Hyderabad, India 
Project Manager / Intern Jun-Aug 2004 
 Managed a team of three while on W(O internship through the LV Prasad Eye )nstitute s International 
Center for the Advancement of Rural Eye Care.  
 Gained a deep understanding of and helped execute community eye screening programs to improve 
access to healthcare for under-serviced populations in remote rural villages and urban slums.  
 Shadowed hospital administration and clinical staff at rural eye hospital; recommended potential 
improvements and cost-saving mechanisms.  




 Managed and led Canadian participation on the Affordable Medicines Facility – malaria (AMFm); 
represented Global Fund constituency of Canada, Germany and Switzerland; advocated for reaching the 
poor in high-level inter-governmental negotiations with numerous multilateral agencies, foundations, 
academics, governments and NGOs; resulted in increased emphasis and focus on reaching the poor and 
ensuring equity issues were incorporated into the fabric of the technical design for the pilot phase of this 
multi-million dollar, global  initiative; Partner: Global Fund for AIDS, TB and Malaria 
 Represented C)DA interests on the Government of Canada s Global Health Research Initiative (GHRI) 
Steering Committee; helped develop strategic directions for this global health research funding 
partnership; represented GHRI in G8 discussions relating to global health research collaboration; 
Partner: GHRI 
 Provided evidence-based advice to senior management relating to global health funding decisions; 
managed multilateral tuberculosis and other health programs in order to maximize program 
effectiveness and efficiency; oversight and management of large-scale multilateral evaluations; analyzed 
program results and lessons learned for application to future policy and programming; worked with 
partners to ensure collaboration and harmonization. 
 
  
Accenture Inc., Healthcare and Life Sciences Practice Canada 
Management Consultant  Jan 2006 - Nov 2007 
 Developed core strategic and technical management consulting skills including change management, 
performance/program evaluation, requirements gathering, business process design, project 
management, staff supervision and proposal development.  
 Provided industry specific strategic advice and support to senior management teams from a diverse 
range of health-related organizations. 
 Evaluated, measured and analyzed public sector value and productivity within the Ontario Health System 
and coordinated a policy development process for a Director-level working group; Client: Ontario 
Ministry of Health.   
 Worked with large hospital network to help develop provincial strategy for reducing wait times in 5 key 
surgical areas; Client: University Health Network 
 Managed project financials, key deliverables, and vendor relations for a large scale Provincial Laboratory 
Information System that allows for e-sharing of laboratory results throughout Ontario; Client: Ontario 
Ministry of Health  
 Conducted project management activities for Enterprise Resource Planning (ERP) implementation at 
large global pharmaceutical company; Client: Pfizer 
 Played key leadership role in RFP response processes resulting in contracts ranging from $750K - 
$9Million. 
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Government of Canada, Health Canada, International Affairs 
Directorate, International Health Policy and Communications Division 
Ottawa, ON  
May-Aug 2003 
Jr. Policy Analyst  
 Conducted literature reviews and created analytical reports to educate Canadian policy makers about 
innovative health practices in other countries; contributed international perspectives for analysis and 
development of new health policies and practices.  
 Prepared report for Pakistani Minister of Health on Canadian health insurance system to aid Pakistan 
with health insurance plan development.  
 Consulted with representatives from various Health Canada branches to develop report that streamlined 
all international initiatives, improving access to information and potential for collaboration.  
 
University Health Network, Toronto Western 
Hospital, Department of Ophthalmology 
      Toronto, ON 
                                May-Sept 2001-2002 
Vision Science Researcher   
 
 Gained valuable analytical research and lab skills while assisting in the investigation of the Role of 
Lamina Cribrosa Biomechanics and Ischemia in Glaucomatous Optic Neuropathy.  
 Simulated glaucoma in post-mortem human eye to determine and record the first physiological changes 
that take place within the eye using retinal tomography.  
 Initiated a clinical research database system for glaucoma unit of largest Department of Ophthalmology 





Jane Goodall Institute of Canada Canada/Africa 
Board of Directors March 2015-Ongoing 
 Providing strategic oversight and development of JGI Canada to maximize impact in the area of 
human/community development as well as environmental and chimpanzee conservation. 
 Elected to jointly govern this international NGO through the establishment of broad policies and 
objectives; support and review performance of the Chief Executive Officer; help ensure availability of 
adequate resources; approve annual budgets; provide guidance on staffing and human resources; 
represent the organization to stakeholders 
 
 
Unite For Sight Canada/Global 
Regional Director of Canada May 2005-Jan 2008 
 Appointed to the Unite for Sight executive team to improve and expand operations in Canada.  
 Managed all Canadian operations, human and financial resources for this international 501(C)(3) non-
profit organization focused on improving eye health and preventing blindness.  
 Significantly increased Canadian volunteer participation; developed new Canadian chapters; attracted 
significant media attention; implemented Canadian arm of Ghana-based micro-credit program; 
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UW International Health Development Association (UWIHDA) Waterloo, ON 
Founder, Past Executive Director, and External Advisor Sept 2002 – 2011 
 Created university-based non-governmental organization to raise Canadian awareness of international 
health disparities and development issues. 
 Designed and implemented diverse international public health and development projects providing 
students with an annual opportunity to volunteer in a developing area. 
 Managed human and financial resources, established partnerships with leading international 
organizations, raised substantial programming funds, and led the development of this organization to 
become a leading student-run non-profit. 
 
 
Youth Challenge International Guyana, South America 
Community Health Educator July – Aug 2002 
 Developed and led health promotion workshops while living in three interior Amerindian 
communities focusing on issues including: malaria, HIV/AIDS, waterborne diseases, and nutrition. 
 Helped establish first community health center in village of Malali.  
 Assisted with study that introduced innovative, low-cost, bacterial replication technology utilized to 
reduce malaria vector populations; introduced insecticide treated bed-net programs.   
 
 
QUALIFICATIONS & SKILLS 
 
 Languages – English (fluent), French (competent), and Hindi (competent). 
 Overseas experience working with international organizations in global health; substantive experience 
and skills in program and project management, research & evaluation; excellent organizational, oral, 
and written communication skills; Strong analytical and presentation skills; ability to establish working 
relationships with diverse groups; demonstrated reliability, judgment, and initiative; proven leadership 
excellence and management skills; tri-sector experience 
 On-the-ground experience working in Africa, Asia, South America, North America and Europe 
 Strong background in public health, health services delivery/implementation science, health markets, 
program development and evaluation, epidemiology, infectious and chronic diseases, health policy, 
tuberculosis, maternal and child health, childhood diarrhea, malaria and vision/ocular sciences.   
 Substantial experience managing small and large teams of people 
 Computer Skills – Microsoft Professional/Office Suite, SharePoint administration, e-mail systems, blogs, 
social media, web 2.0 applications, Open Data Kit + Commcare, EpiInfo, Lives Saved Tool (LiST), STATA 
 
 
SELECTED AWARDS AND HONOURS 
 
 INDEX Award 2015: Design to Improve Life, Finalist (top 4%), June 2015 
 GlaxoSmithKline (GSK) – Save the Children Healthcare Innovation Award ( Oscars of Healthcare Innovation ), 
February 2015 
 Financial Times/International Finance Corporation Transformational Business Award – Health Category, May 
2014 
 Highlighted as a Best Buy in Global Health . Impact Magazine. Retrieved from 
http://www.redorbit.com/news/health/1112958787/innovations-save-lives-of-mothers-and-children/ 
 Highlighted at the UN General Assembly for selection as one of 10 Breakthrough Innovations in Child Health (for 
the Kit Yamoyo anti-diarrhea kit) – PATH and the Every Woman, Every Child Initiative, September 2013 
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 Obeserver (UK Newspaper) Ethical Product of the Year Award (for the Kit Yamoyo anti-diarrhea 
kit), June 2013 
 Winner of the Diamond Award (Top Award) and the Food Security Award at the 25th Dupont 
Packaging Innovation Awards (for the Kit Yamoyo anti-diarrhea kit), May 2013 
 International Product Design of the Year (for the Kit Yamoyo anti-diarrhea kit) - London Design 
Museum, April 2013 
 Top 5% Most Viewed LinkedIn Profiles of 2012  
 DFID Grant Recipient for the ColaLife Operational Trial Zambia- USD$ 1.35M, 2012 
 Grand Challenges Canada s Rising Stars in Global Health Grant Recipient (as PI for the ColaLife 
Operational Trial Zambia)- CAD$ 100,000, 2012 
 Alumni of the Governor General s Canadian Leadership Conference GGCLC  for Top Canadian 
Leaders in various sectors, June 2012 
 Georgeda Buchbinder Research Award, Johns Hopkins School of Public Health, June 2011 
 Young Alumni Award, Faculty of Applied Health Sciences, University of Waterloo, October 2009 
 Featured Alumni Profile, Boston University School of Public Health, February 2009 
 Celebrating Performance Award, Accenture Health and Life Sciences, July 2007 
 Profiled as Alumni Success Story for the Faculty of Applied Health Sciences, University of Waterloo, 
March 2007  
 Volunteer of the Year, Unite For Sight, December 2005 
 University of Waterloo John McBain Award for International Entrepreneurship, 2004 
 Canada Millennium Excellence Award (National Laureate) – academic achievement, contribution to 
the community, dedication to leadership and innovation, 2000-2004 
 Vedic Cultural Scholarship - outstanding contribution to the South Asian Community (1st prize), 2000 
 University of British Columbia Shad Valley Program Alumnus – international program based on 
science, entrepreneurship, and technology for top 200 students in Canada, 1999 






 Delegate, Canada 150 Social Impact Research and Development (R&D) Retreat, Wasan Island, July 2015 
 Member of the Global Diarrhea and Pneumonia Working Group, 2014-present  
 Member of the UN Every Woman, Every Child Innovation Working Group (IWG), 2010-present 
 Member of the Canadian Association of International Development Professionals (CAIDP), 2013-
present 
 Advisory Board Member, Raising the Village, 2012 – present 
 Member of the UN Secretary General s Joint Action Plan for Women s and Children s (ealth, 2010-
present 
 Member of the Canadian Society for International Health, 2009-present 
 Global Fund for A)DS, Tuberculosis and Malaria s Ad-Hoc Committee for the Affordable Medicines 
Facility – Malaria (AMFm), June 2008 – April 2009 
 Roll Back Malaria AMFm Task Force, December 2007 – February 2009 
 Co-Chair (with DFID) of the Roll Back Malaria AMFm Task Force Sub-Group on Reaching the Poor, June 
2008 – November 2008 
 Permanent Secretariat of the CIDA Health Programming Division Results-Based Management (RBM) 
Committee, April 2008 – 2010 
 Organizer of the CIDA Health Innovations Series, July 2008 
 Represented Canada on the Stop TB Coordinating Board, Rio de Janeiro, Brazil, March 2009 
 Represented Canada at a high level Ministerial Meeting on Tuberculosis Control During the Global 
Financial Crisis, Rio de Janeiro, Brazil, March 2009 
 Member of the International AIDS Society (IAS), 2006-2007 
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 Member of the Organizing Committee for the AIDS 2006 Conference, Toronto, ON, August 2006 
 Member of the Delta Omega Public Health Honor Society – Alpha Beta Chapter, 2006 inductee 
 Student Trustee, York Region District School Board, 1999 
 
SELECTED PRESENTATIONS/CONFERENCES  
 
 Panelist/Speaker, Ubering Global Health: Sustainable Business Models for Healthcare Delivery, 
Canadian Conference for Global Health & McGill University, November 2015 
 Keynote Speaker, Public Private Partnerships & Innovation in Global Health, Dalhousie University, 
April 2015, March 2015 
 Speaker, Revolutionizing Big Pharma for Global Health, University of Toronto, February 2015 
 Guest Lecturer, Social Entrepreneurship & Global Health, Harvard School of Public Health, February 
2015  
 Keynote Speaker, Community Partnerships Plenary – Canadian Conference for Global Health, 
November 2014  
 Invited Panel Moderator for Health and Social Entrepreneurship, Greenhouse, University of 
Waterloo, October 2014 
 Keynote Public Lecture - Gates Foundation, Seattle, United States, May 2014 
 Invited panelist - Pegasus Conference, Toronto, Canada, May 2014 
 Invited Presentation - Integrated Community Case Management (ICCM) Evidence Review Symposium, 
Accra, March 2014 
 Keynote speaker – Social Innovation. Center for International Policy Studies, University of Ottawa, 
January 2014 
 Invited Presentation and Panelist - Shifting Behaviours: Tools for Better Health Practices. Aga Khan 
Foundation Canada, Ottawa, November 2013 
 Guest Lecturer – Design and Health, Alpert Medical School at Brown University & Rhode Island 
School of Design, Providence, December 2013 
 Invited Speaker – Public, Private Partnerships and Health. Stanford University Graduate School of Business  Center for African Studies and the School of Medicine s Center for )nnovation in Global 
Health, Stanford, October 2013 
 UN General Assembly – high-level private presentation to Prime Minister Stoltenberg of Norway, 
Princess Sara Zeid, Bill Gates, and PATH CEO Steve Davis, New York, September 2013 
 )nvited Presentation - Rising Stars in Global Health Symposium, rd )nterscience Conference on Antimicrobial Agents and Chemotherapy )CAAC  , an American Society for Microbiology ASM  meeting, Colorado, September  
 Invited Speaker – Revolutionizing Global Health with Cola, TEDx Toronto, November 2012. Accessible 
at: http://tedxtalks.ted.com/video/Revolutionizing-Global-Health-
w;search%3Atag%3A%22tedxyouth-toronto%22 
 Speaker - 3rd Annual Global Health Innovation Conference. A Vision of Possibilities: Merging Clinical 
and Public Health Perspectives in Ocular Health . Yale University. New Haven, April, 2006. 
 Speaker - 2nd Annual International Unite for Sight Conference. A Successful Model for Comprehensive 
Eye Care Coverage in the Developing World: The Case of LV Prasad Eye Institute". Harvard University. 












 Berry S., Berry J., Ramchandani R. (2015). Should We Welcome Multinational Companies’ Involvement in 
Programmes to Improve Child Health?  British Medical Journal (BMJ), 350:h3046. Available at: 
http://www.bmj.com/content/350/bmj.h3046/rapid-responses 
 Ramchandani, R.  Impact of Emulating Commercial, Private-Sector Value-Chains on Uptake of ORS and 
Zinc for Childhood Diarrhea in Rural Zambia: Evaluation of the ColaLife Trial. (In progress), 2015.  
 Ramchandani R.  Product Innovation and Human-Centered Design for Global Health Delivery: Improving 
Effective Use of Oral Rehydration Salts Through the Introduction of an Innovative Diarrhea Treatment Kit. 
(In Progress), 2015.  
 Ramchandani R.  Serving the Underserved: A Description of Rural, Commercial General Stores as 
Community-Level Providers of Public Health Commodities in Zambia. (In progress), 2015. 
 Ramchandani R. Putting the Live  Back in Delivery. Retrieved December 12, 2014 from: 
https://www.devex.com/news/putting-the-live-back-in-delivery-84917 
 Ramchandani R, Berry S, Berry J. Diarrhea, Seasonality and Climate Change. Retrieved October.30, 2014 
from: http://www.colalife.org/2014/10/21/some-thoughts-on-diarrhea-incidence-and-
seasonalityclimate-change/ 




 Berry S, Berry J, Ramchandani R. Top 10 Achievements in 2013.  Retrieved January 14, 2014, from 
http://www.colalife.org/2013/12/30/top-10-achievements-in-2013/ 
 Ramchandani R. Final Survey Kicks Off – Feeling of Slight Relief. Retrieved January 14, 2014, from 
http://www.colalife.org/2013/08/22/final-survey-kicks-off-feelings-of-slight-relief/ 
 Ramchandani R. Rohit reports on our trip to Katete on 3 December. Retrieved January 14, 2014, from 
http://www.colalife.org/2012/12/14/rohit-reports-on-our-trip-to-katete-on-3-december/ 
 Berry S, Ramchandani R. Is it right to sell ORS to poor people when they can make their own? Retrieved 
January 14, 2014, from http://www.colalife.org/2013/06/15/is-it-right-to-sell-ors-to-poor-people-
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